Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp251

Request ID: cder_mpl1r_wp251_nsdp_v01

Request Description: In this report we characterized dispensing and administration of 34 New Molecular Entities (NMEs) approved from August 1, 2018 to December 31, 2018, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module, version 12.1.2

Data Source: We distributed this request to 13 Sentinel Data Partners on September 20, 2023. We included aggregate results from all 13 data partners in this report. The study period included data from January 1, 2018 to most recent data available. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 34 NMEs drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between August 1, 2018 and December 31, 2018, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24 ,25-40, 41-64, and 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse[1] (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request and Appendix E for a list of non-proprietary and proprietary names of medical products, used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1]Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

	Table of Contents

Table of Contents

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

> **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

> **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

> **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

> **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

> **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Mogamulizumab-Kpkc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	816	N/A[2]
Demographic Characteristics		
Age (years)	69.9	11.0
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	171	21.0%
≥ 65 years	616	75.5%
Sex		
Female	348	42.6%
Male	468	57.4%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	174	21.3%
White	516	63.2%
Hispanic origin		
Yes	13	1.6%
No	595	72.9%
Unknown	208	25.5%
Year		
2018	*****	*****
2019	278	34.1%
2020	183	22.4%
2021	164	20.1%
2022	172	21.1%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	11	1.3%
Alzheimer's Disease and related conditions	38	4.7%
Atrial Fibrillation	97	11.9%
Diabetes Mellitus	187	22.9%

cder_mpl1r_wp251

Table 1a. Aggregated Characteristics of Mogamulizumab-Kpkc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	118	14.5%
Hyperlipidemia	387	47.4%
Hypertension	459	56.3%
Depression	171	21.0%
Ischemic Heart Disease	193	23.7%
Rheumatoid Arthritis/Osteoarthritis	107	13.1%
Stroke/TIA[4]	16	2.0%
Breast Cancer	29	3.6%
Colorectal Cancer	15	1.8%
Prostate Cancer	45	5.5%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	202	24.8%
Anemia	325	39.8%
Asthma	47	5.8%
Benign Prostatic Hyperplasia	68	8.3%
Chronic Kidney Disease	160	19.6%
COPD[5] and Bronchiectasis	75	9.2%
Glaucoma	32	3.9%
Osteoporosis	32	3.9%
Obesity: diagnosed or identified by weight management procedures	128	15.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	92	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	252	30.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	13	1.6%
Drug Abuse or Dependence	27	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	62	7.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.7	17.4
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.5	1.0
Mean number of non-acute institutional encounters	0.1	0.3

Table 1a. Aggregated Characteristics of Mogamulizumab-Kpkc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of other ambulatory encounters	7.9	12.9
Mean number of filled prescriptions	27.9	19.8
Mean number of generics dispensed	12.0	6.7
Mean number of unique drug classes dispensed	10.8	5.8

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1b. Aggregated Characteristics of Patisiran in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	570	N/A[2]
Demographic Characteristics		
Age (years)	68.8	9.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	12	2.1%
41-64 years	122	21.4%
≥ 65 years	436	76.5%
Sex		
Female	209	36.7%
Male	361	63.3%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	172	30.2%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	138	24.2%
White	245	43.0%
Hispanic origin		
Yes	*****	*****
No	403	70.7%
Unknown	*****	*****
Year		
2018	*****	*****
2019	187	32.8%
2020	109	19.1%
2021	140	24.6%
2022	121	21.2%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	11	1.9%
Alzheimer's Disease and related conditions	11	1.9%
Atrial Fibrillation	130	22.8%
Diabetes Mellitus	112	19.6%
Heart Failure	367	64.4%

cder_mpl1r_wp251

Table 1b. Aggregated Characteristics of Patisiran in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	219	38.4%
Hypertension	300	52.6%
Depression	94	16.5%
Ischemic Heart Disease	186	32.6%
Rheumatoid Arthritis/Osteoarthritis	113	19.8%
Stroke/TIA[4]	30	5.3%
Breast Cancer	15	2.6%
Colorectal Cancer	*****	*****
Prostate Cancer	36	6.3%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	74	13.0%
Anemia	162	28.4%
Asthma	26	4.6%
Benign Prostatic Hyperplasia	54	9.5%
Chronic Kidney Disease	162	28.4%
COPD[5] and Bronchiectasis	47	8.2%
Glaucoma	44	7.7%
Osteoporosis	25	4.4%
Obesity: diagnosed or identified by weight management procedures	68	11.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	47	8.2%
Smoking: diagnosed or identified by smoking cessation procedures	136	23.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	24	4.2%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	38	6.7%

cder_mpl1r_wp251

Table 1b. Aggregated Characteristics of Patisiran in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	13.9
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.6	12.4
Mean number of filled prescriptions	19.7	15.4
Mean number of generics dispensed	8.4	5.1
Mean number of unique drug classes dispensed	8.0	4.7

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1c. Aggregated Characteristics of Ethinyl Estradiol and Segesterone Acetate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	12,072	N/A[2]
Demographic Characteristics		
Age (years)	29.3	7.9
Age		
0-17 years	*****	*****
18-24 years	3,833	31.8%
25-40 years	6,682	55.4%
41-64 years	1,107	9.2%
≥ 65 years	*****	*****
Sex		
Female	12,043	99.8%
Male	29	0.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	119	1.0%
Black or African American	272	2.3%
Multi-racial	255	2.1%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	9,891	81.9%
White	1,515	12.5%
Hispanic origin		
Yes	434	3.6%
No	780	6.5%
Unknown	10,858	89.9%
Year		
2018	0	0.0%
2019	185	1.5%
2020	3,457	28.6%
2021	3,977	32.9%
2022	4,031	33.4%
2023	422	3.5%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	103	0.9%

Table 1c. Aggregated Characteristics of Ethinyl Estradiol and Segesterone Acetate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	*****	*****
Hyperlipidemia	172	1.4%
Hypertension	135	1.1%
Depression	2,161	17.9%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	129	1.1%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	228	1.9%
Anemia	534	4.4%
Asthma	237	2.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	36	0.3%
COPD[5] and Bronchiectasis	14	0.1%
Glaucoma	18	0.1%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	984	8.2%
Obesity: identified by weight management-related prescriptions	66	0.5%
Overweight	442	3.7%
Smoking: diagnosed or identified by smoking cessation procedures	345	2.9%
Smoking: identified by smoking-related prescriptions	23	0.2%
Alcohol Abuse or Dependence	98	0.8%
Drug Abuse or Dependence	194	1.6%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.1	7.8
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.7	4.0
Mean number of filled prescriptions	7.0	8.4

cder_mpl1r_wp251

Table 1c. Aggregated Characteristics of Ethinyl Estradiol and Segesterone Acetate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	3.5	3.4
Mean number of unique drug classes dispensed	3.4	3.1

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1d. Aggregated Characteristics of Migalastat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	170	N/A[2]
Demographic Characteristics		
Age (years)	49.4	13.8
Age		
0-17 years	0	0.0%
18-24 years	12	7.1%
25-40 years	44	25.9%
41-64 years	74	43.5%
≥ 65 years	40	23.5%
Sex		
Female	86	50.6%
Male	84	49.4%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	81	47.6%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	93	54.7%
Year		
2018	27	15.9%
2019	48	28.2%
2020	43	25.3%
2021	27	15.9%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	14	8.2%
Diabetes Mellitus	13	7.6%
Heart Failure	23	13.5%

Table 1d. Aggregated Characteristics of Migalastat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	27	15.9%
Hypertension	44	25.9%
Depression	41	24.1%
Ischemic Heart Disease	22	12.9%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	12	7.1%
Anemia	18	10.6%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	28	16.5%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	31	18.2%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	11	6.5%
Smoking: diagnosed or identified by smoking cessation procedures	20	11.8%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1d. Aggregated Characteristics of Migalastat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.4	11.1
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	6.4	14.7
Mean number of filled prescriptions	18.3	16.1
Mean number of generics dispensed	7.0	5.4
Mean number of unique drug classes dispensed	6.6	4.9

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1e. Aggregated Characteristics of Stiripentol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	402	N/A[2]
Demographic Characteristics		
Age (years)	12.6	6.9
Age		
0-17 years	303	75.4%
18-24 years	79	19.7%
25-40 years	20	5.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	211	52.5%
Male	191	47.5%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	23	5.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	183	45.5%
White	178	44.3%
Hispanic origin		
Yes	30	7.5%
No	216	53.7%
Unknown	156	38.8%
Year		
2018	0	0.0%
2019	199	49.5%
2020	158	39.3%
2021	21	5.2%
2022	24	6.0%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	*****	*****

Table 1e. Aggregated Characteristics of Stiripentol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA[4]	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	18	4.5%
Asthma	16	4.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1e. Aggregated Characteristics of Stiripentol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.3	21.5
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	52.4	57.2
Mean number of filled prescriptions	24.7	17.1
Mean number of generics dispensed	6.9	4.5
Mean number of unique drug classes dispensed	6.5	4.1

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1f. Aggregated Characteristics of Cenegermin-Bkbj in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	5,521	N/A[2]
Demographic Characteristics		
Age (years)	71.0	12.7
Age		
0-17 years	43	0.8%
18-24 years	27	0.5%
25-40 years	199	3.6%
41-64 years	1,025	18.6%
≥ 65 years	4,227	76.6%
Sex		
Female	3,544	64.2%
Male	1,977	35.8%
Race[3]		
American Indian or Alaska Native	22	0.4%
Asian	123	2.2%
Black or African American	218	3.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,112	20.1%
White	4,032	73.0%
Hispanic origin		
Yes	116	2.1%
No	4,170	75.5%
Unknown	1,235	22.4%
Year		
2018	0	0.0%
2019	998	18.1%
2020	1,380	25.0%
2021	1,413	25.6%
2022	1,654	30.0%
2023	76	1.4%
Health Characteristics		
Acute Myocardial Infarction	29	0.5%
Alzheimer's Disease and related conditions	254	4.6%
Atrial Fibrillation	640	11.6%
Diabetes Mellitus	1,542	27.9%

Table 1f. Aggregated Characteristics of Cenegermin-Bkbj in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	781	14.1%
Hyperlipidemia	2,092	37.9%
Hypertension	2,786	50.5%
Depression	1,153	20.9%
Ischemic Heart Disease	1,271	23.0%
Rheumatoid Arthritis/Osteoarthritis	1,231	22.3%
Stroke/TIA[4]	239	4.3%
Breast Cancer	172	3.1%
Colorectal Cancer	58	1.1%
Prostate Cancer	109	2.0%
Lung Cancer	57	1.0%
Endometrial Cancer	16	0.3%
Acquired Hypothyroidism	938	17.0%
Anemia	1,356	24.6%
Asthma	243	4.4%
Benign Prostatic Hyperplasia	243	4.4%
Chronic Kidney Disease	1,084	19.6%
COPD[5] and Bronchiectasis	491	8.9%
Glaucoma	1,485	26.9%
Osteoporosis	421	7.6%
Obesity: diagnosed or identified by weight management procedures	914	16.6%
Obesity: identified by weight management-related prescriptions	33	0.6%
Overweight	497	9.0%
Smoking: diagnosed or identified by smoking cessation procedures	967	17.5%
Smoking: identified by smoking-related prescriptions	47	0.9%
Alcohol Abuse or Dependence	87	1.6%
Drug Abuse or Dependence	183	3.3%
History of Cardiac Arrest	12	0.2%
History of Coronary Angioplasty or Bypass	383	6.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	17.9
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.6	11.8
Mean number of filled prescriptions	27.7	20.3

Table 1f. Aggregated Characteristics of Cenegermin-Bkbj in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	11.7	6.2
Mean number of unique drug classes dispensed	10.7	5.4

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1g. Aggregated Characteristics of Lanadelumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,109	N/A[2]
Demographic Characteristics		
Age (years)	44.2	14.8
Age		
0-17 years	102	9.2%
18-24 years	103	9.3%
25-40 years	303	27.3%
41-64 years	404	36.4%
≥ 65 years	197	17.8%
Sex		
Female	754	68.0%
Male	355	32.0%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	69	6.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	527	47.5%
White	490	44.2%
Hispanic origin		
Yes	58	5.2%
No	526	47.4%
Unknown	525	47.3%
Year		
2018	178	16.1%
2019	388	35.0%
2020	245	22.1%
2021	125	11.3%
2022	155	14.0%
2023	18	1.6%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	20	1.8%
Diabetes Mellitus	87	7.8%
Heart Failure	33	3.0%

Table 1g. Aggregated Characteristics of Lanadelumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	152	13.7%
Hypertension	233	21.0%
Depression	236	21.3%
Ischemic Heart Disease	68	6.1%
Rheumatoid Arthritis/Osteoarthritis	114	10.3%
Stroke/TIA[4]	11	1.0%
Breast Cancer	11	1.0%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	89	8.0%
Anemia	124	11.2%
Asthma	126	11.4%
Benign Prostatic Hyperplasia	13	1.2%
Chronic Kidney Disease	53	4.8%
COPD[5] and Bronchiectasis	57	5.1%
Glaucoma	11	1.0%
Osteoporosis	21	1.9%
Obesity: diagnosed or identified by weight management procedures	204	18.4%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	57	5.1%
Smoking: diagnosed or identified by smoking cessation procedures	180	16.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	11	1.0%
Drug Abuse or Dependence	55	5.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	11	1.0%

Table 1g. Aggregated Characteristics of Lanadelumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.7	12.8
Mean number of emergency room encounters	1.2	3.4
Mean number of inpatient hospital encounters	0.3	1.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.3	14.3
Mean number of filled prescriptions	19.0	20.2
Mean number of generics dispensed	7.1	6.1
Mean number of unique drug classes dispensed	6.7	5.6

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1h. Aggregated Characteristics of Eravacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	723	N/A[2]
Demographic Characteristics		
Age (years)	63.3	13.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	60	8.3%
41-64 years	274	37.9%
≥ 65 years	377	52.1%
Sex		
Female	378	52.3%
Male	345	47.7%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	71	9.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	208	28.8%
White	429	59.3%
Hispanic origin		
Yes	25	3.5%
No	482	66.7%
Unknown	216	29.9%
Year		
2018	*****	*****
2019	93	12.9%
2020	165	22.8%
2021	205	28.4%
2022	246	34.0%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	26	3.6%
Alzheimer's Disease and related conditions	88	12.2%
Atrial Fibrillation	153	21.2%
Diabetes Mellitus	311	43.0%
Heart Failure	208	28.8%

cder_mpl1r_wp251

Table 1h. Aggregated Characteristics of Eravacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	381	52.7%
Hypertension	547	75.7%
Depression	252	34.9%
Ischemic Heart Disease	252	34.9%
Rheumatoid Arthritis/Osteoarthritis	223	30.8%
Stroke/TIA[4]	58	8.0%
Breast Cancer	24	3.3%
Colorectal Cancer	20	2.8%
Prostate Cancer	23	3.2%
Lung Cancer	13	1.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	171	23.7%
Anemia	450	62.2%
Asthma	94	13.0%
Benign Prostatic Hyperplasia	69	9.5%
Chronic Kidney Disease	378	52.3%
COPD[5] and Bronchiectasis	208	28.8%
Glaucoma	14	1.9%
Osteoporosis	52	7.2%
Obesity: diagnosed or identified by weight management procedures	274	37.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	80	11.1%
Smoking: diagnosed or identified by smoking cessation procedures	289	40.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	39	5.4%
Drug Abuse or Dependence	76	10.5%
History of Cardiac Arrest	13	1.8%
History of Coronary Angioplasty or Bypass	88	12.2%

Table 1h. Aggregated Characteristics of Eravacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.0	29.7
Mean number of emergency room encounters	1.5	3.0
Mean number of inpatient hospital encounters	1.8	1.8
Mean number of non-acute institutional encounters	0.4	0.9
Mean number of other ambulatory encounters	34.3	41.5
Mean number of filled prescriptions	31.7	26.2
Mean number of generics dispensed	13.6	7.6
Mean number of unique drug classes dispensed	12.3	6.7

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1i. Aggregated Characteristics of Doravirine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	4,812	N/A[2]
Demographic Characteristics		
Age (years)	55.6	10.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	601	12.5%
41-64 years	3,111	64.7%
≥ 65 years	1,061	22.0%
Sex		
Female	1,176	24.4%
Male	3,636	75.6%
Race[3]		
American Indian or Alaska Native	29	0.6%
Asian	58	1.2%
Black or African American	1,677	34.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,170	24.3%
White	1,867	38.8%
Hispanic origin		
Yes	353	7.3%
No	3,487	72.5%
Unknown	972	20.2%
Year		
2018	207	4.3%
2019	1,689	35.1%
2020	1,407	29.2%
2021	808	16.8%
2022	660	13.7%
2023	41	0.9%
Health Characteristics		
Acute Myocardial Infarction	85	1.8%
Alzheimer's Disease and related conditions	133	2.8%
Atrial Fibrillation	160	3.3%
Diabetes Mellitus	944	19.6%
Heart Failure	529	11.0%

cder_mpl1r_wp251

Table 1i. Aggregated Characteristics of Doravirine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	1,469	30.5%
Hypertension	1,969	40.9%
Depression	1,477	30.7%
Ischemic Heart Disease	824	17.1%
Rheumatoid Arthritis/Osteoarthritis	469	9.7%
Stroke/TIA[4]	136	2.8%
Breast Cancer	20	0.4%
Colorectal Cancer	84	1.7%
Prostate Cancer	78	1.6%
Lung Cancer	28	0.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	258	5.4%
Anemia	1,189	24.7%
Asthma	320	6.7%
Benign Prostatic Hyperplasia	266	5.5%
Chronic Kidney Disease	1,322	27.5%
COPD[5] and Bronchiectasis	466	9.7%
Glaucoma	108	2.2%
Osteoporosis	123	2.6%
Obesity: diagnosed or identified by weight management procedures	648	13.5%
Obesity: identified by weight management-related prescriptions	31	0.6%
Overweight	332	6.9%
Smoking: diagnosed or identified by smoking cessation procedures	1,340	27.8%
Smoking: identified by smoking-related prescriptions	149	3.1%
Alcohol Abuse or Dependence	271	5.6%
Drug Abuse or Dependence	637	13.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	259	5.4%

Table 1i. Aggregated Characteristics of Doravirine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.6	24.2
Mean number of emergency room encounters	0.7	2.0
Mean number of inpatient hospital encounters	0.4	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.5	20.1
Mean number of filled prescriptions	38.9	28.7
Mean number of generics dispensed	11.7	6.7
Mean number of unique drug classes dispensed	9.7	5.8

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1j. Aggregated Characteristics of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	995	N/A[2]
Demographic Characteristics		
Age (years)	49.6	11.4
Age		
0-17 years	0	0.0%
18-24 years	27	2.7%
25-40 years	241	24.2%
41-64 years	616	61.9%
≥ 65 years	111	11.2%
Sex		
Female	311	31.3%
Male	684	68.7%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	297	29.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	371	37.3%
White	311	31.3%
Hispanic origin		
Yes	97	9.7%
No	584	58.7%
Unknown	314	31.6%
Year		
2018	21	2.1%
2019	295	29.6%
2020	317	31.9%
2021	149	15.0%
2022	192	19.3%
2023	21	2.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	12	1.2%
Atrial Fibrillation	16	1.6%
Diabetes Mellitus	144	14.5%

Table 1j. Aggregated Characteristics of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	41	4.1%
Hyperlipidemia	195	19.6%
Hypertension	258	25.9%
Depression	260	26.1%
Ischemic Heart Disease	83	8.3%
Rheumatoid Arthritis/Osteoarthritis	90	9.0%
Stroke/TIA[4]	12	1.2%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	23	2.3%
Anemia	107	10.8%
Asthma	63	6.3%
Benign Prostatic Hyperplasia	29	2.9%
Chronic Kidney Disease	54	5.4%
COPD[5] and Bronchiectasis	72	7.2%
Glaucoma	12	1.2%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	198	19.9%
Obesity: identified by weight management-related prescriptions	16	1.6%
Overweight	65	6.5%
Smoking: diagnosed or identified by smoking cessation procedures	210	21.1%
Smoking: identified by smoking-related prescriptions	26	2.6%
Alcohol Abuse or Dependence	44	4.4%
Drug Abuse or Dependence	125	12.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	24	2.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.0	14.0
Mean number of emergency room encounters	0.5	1.7
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.9	19.0
Mean number of filled prescriptions	27.7	24.0

cder_mpl1r_wp251

Table 1j. Aggregated Characteristics of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	8.9	6.2
Mean number of unique drug classes dispensed	7.9	5.3

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1k. Aggregated Characteristics of Moxetumomab Pasudotox-Tdfk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	49	N/A[2]
Demographic Characteristics		
Age (years)	69.6	10.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	34	69.4%
Hispanic origin		
Yes	*****	*****
No	33	67.3%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	20	40.8%
2020	11	22.4%
2021	*****	*****
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****

cder_mpl1r_wp251

Table 1k. Aggregated Characteristics of Moxetumomab Pasudotox-Tdfk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	16	32.7%
Hypertension	20	40.8%
Depression	*****	*****
Ischemic Heart Disease	12	24.5%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	32	65.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	12	24.5%
Smoking: diagnosed or identified by smoking cessation procedures	18	36.7%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1k. Aggregated Characteristics of Moxetumomab Pasudotox-Tdfk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.3	16.6
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	7.5	9.6
Mean number of filled prescriptions	16.4	12.0
Mean number of generics dispensed	8.1	5.0
Mean number of unique drug classes dispensed	7.5	4.4

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1l. Aggregated Characteristics of Fremanezumab-Vfrm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	59,590	N/A[2]
Demographic Characteristics		
Age (years)	47.4	13.0
Age		
0-17 years	338	0.6%
18-24 years	3,605	6.0%
25-40 years	16,253	27.3%
41-64 years	31,745	53.3%
≥ 65 years	7,649	12.8%
Sex		
Female	51,464	86.4%
Male	8,126	13.6%
Race[3]		
American Indian or Alaska Native	174	0.3%
Asian	447	0.8%
Black or African American	2,425	4.1%
Multi-racial	807	1.4%
Native Hawaiian or Other Pacific Islander	64	0.1%
Unknown	30,507	51.2%
White	25,166	42.2%
Hispanic origin		
Yes	1,874	3.1%
No	22,992	38.6%
Unknown	34,724	58.3%
Year		
2018	2,477	4.2%
2019	15,538	26.1%
2020	14,227	23.9%
2021	11,552	19.4%
2022	14,110	23.7%
2023	1,686	2.8%
Health Characteristics		
Acute Myocardial Infarction	59	0.1%
Alzheimer's Disease and related conditions	706	1.2%
Atrial Fibrillation	897	1.5%
Diabetes Mellitus	5,579	9.4%

Table 1l. Aggregated Characteristics of Fremanezumab-Vfrm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	1,451	2.4%
Hyperlipidemia	9,363	15.7%
Hypertension	12,164	20.4%
Depression	22,051	37.0%
Ischemic Heart Disease	3,212	5.4%
Rheumatoid Arthritis/Osteoarthritis	10,547	17.7%
Stroke/TIA[4]	1,274	2.1%
Breast Cancer	774	1.3%
Colorectal Cancer	94	0.2%
Prostate Cancer	119	0.2%
Lung Cancer	90	0.2%
Endometrial Cancer	48	0.1%
Acquired Hypothyroidism	5,772	9.7%
Anemia	6,797	11.4%
Asthma	4,560	7.7%
Benign Prostatic Hyperplasia	407	0.7%
Chronic Kidney Disease	2,566	4.3%
COPD[5] and Bronchiectasis	2,368	4.0%
Glaucoma	786	1.3%
Osteoporosis	1,456	2.4%
Obesity: diagnosed or identified by weight management procedures	12,977	21.8%
Obesity: identified by weight management-related prescriptions	915	1.5%
Overweight	4,519	7.6%
Smoking: diagnosed or identified by smoking cessation procedures	7,812	13.1%
Smoking: identified by smoking-related prescriptions	801	1.3%
Alcohol Abuse or Dependence	819	1.4%
Drug Abuse or Dependence	2,937	4.9%
History of Cardiac Arrest	37	0.1%
History of Coronary Angioplasty or Bypass	557	0.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.6	12.9
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	10.9
Mean number of filled prescriptions	30.2	24.0

cder_mpl1r_wp251

Table 1l. Aggregated Characteristics of Fremanezumab-Vfrm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	11.2	6.8
Mean number of unique drug classes dispensed	10.4	6.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

Table 1m. Aggregated Characteristics of Duvelisib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	483	N/A[2]
Demographic Characteristics		
Age (years)	71.0	9.7
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	90	18.6%
≥ 65 years	381	78.9%
Sex		
Female	212	43.9%
Male	271	56.1%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	44	9.1%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	102	21.1%
White	323	66.9%
Hispanic origin		
Yes	16	3.3%
No	369	76.4%
Unknown	98	20.3%
Year		
2018	*****	*****
2019	126	26.1%
2020	124	25.7%
2021	97	20.1%
2022	105	21.7%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	20	4.1%
Atrial Fibrillation	85	17.6%
Diabetes Mellitus	112	23.2%
Heart Failure	89	18.4%

cder_mpl1r_wp251

Table 1m. Aggregated Characteristics of Duvelisib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	185	38.3%
Hypertension	245	50.7%
Depression	84	17.4%
Ischemic Heart Disease	121	25.1%
Rheumatoid Arthritis/Osteoarthritis	68	14.1%
Stroke/TIA[4]	25	5.2%
Breast Cancer	11	2.3%
Colorectal Cancer	11	2.3%
Prostate Cancer	22	4.6%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	81	16.8%
Anemia	325	67.3%
Asthma	23	4.8%
Benign Prostatic Hyperplasia	62	12.8%
Chronic Kidney Disease	156	32.3%
COPD[5] and Bronchiectasis	70	14.5%
Glaucoma	21	4.3%
Osteoporosis	19	3.9%
Obesity: diagnosed or identified by weight management procedures	78	16.1%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	65	13.5%
Smoking: diagnosed or identified by smoking cessation procedures	151	31.3%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	20	4.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	36	7.5%

Table 1m. Aggregated Characteristics of Duvelisib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.3	15.9
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	1.0	1.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	12.6	18.8
Mean number of filled prescriptions	25.6	17.1
Mean number of generics dispensed	11.7	6.3
Mean number of unique drug classes dispensed	10.9	5.5

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1n. Aggregated Characteristics of Galcanezumab-Gnlm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	145,444	N/A[2]
Demographic Characteristics		
Age (years)	47.2	12.8
Age		
0-17 years	720	0.5%
18-24 years	8,573	5.9%
25-40 years	41,582	28.6%
41-64 years	75,850	52.2%
≥ 65 years	18,719	12.9%
Sex		
Female	123,311	84.8%
Male	22,133	15.2%
Race[3]		
American Indian or Alaska Native	540	0.4%
Asian	836	0.6%
Black or African American	6,468	4.4%
Multi-racial	1,167	0.8%
Native Hawaiian or Other Pacific Islander	124	0.1%
Unknown	74,905	51.5%
White	61,404	42.2%
Hispanic origin		
Yes	4,111	2.8%
No	60,821	41.8%
Unknown	80,512	55.4%
Year		
2018	1,551	1.1%
2019	38,279	26.3%
2020	49,877	34.3%
2021	25,526	17.6%
2022	27,460	18.9%
2023	2,751	1.9%
Health Characteristics		
Acute Myocardial Infarction	176	0.1%
Alzheimer's Disease and related conditions	1,617	1.1%
Atrial Fibrillation	2,247	1.5%
Diabetes Mellitus	14,386	9.9%

cder_mpl1r_wp251

Table 1n. Aggregated Characteristics of Galcanezumab-Gnlm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	3,923	2.7%
Hyperlipidemia	23,191	15.9%
Hypertension	30,561	21.0%
Depression	54,466	37.4%
Ischemic Heart Disease	8,467	5.8%
Rheumatoid Arthritis/Osteoarthritis	24,885	17.1%
Stroke/TIA[4]	3,108	2.1%
Breast Cancer	1,766	1.2%
Colorectal Cancer	260	0.2%
Prostate Cancer	369	0.3%
Lung Cancer	242	0.2%
Endometrial Cancer	115	0.1%
Acquired Hypothyroidism	14,284	9.8%
Anemia	16,424	11.3%
Asthma	10,691	7.4%
Benign Prostatic Hyperplasia	1,138	0.8%
Chronic Kidney Disease	6,624	4.6%
COPD[5] and Bronchiectasis	6,510	4.5%
Glaucoma	1,887	1.3%
Osteoporosis	3,216	2.2%
Obesity: diagnosed or identified by weight management procedures	31,829	21.9%
Obesity: identified by weight management-related prescriptions	2,155	1.5%
Overweight	10,822	7.4%
Smoking: diagnosed or identified by smoking cessation procedures	20,952	14.4%
Smoking: identified by smoking-related prescriptions	2,356	1.6%
Alcohol Abuse or Dependence	2,127	1.5%
Drug Abuse or Dependence	7,725	5.3%
History of Cardiac Arrest	85	0.1%
History of Coronary Angioplasty or Bypass	1,616	1.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.4	12.7
Mean number of emergency room encounters	0.6	1.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.4	12.4
Mean number of filled prescriptions	30.3	24.6

Table 1n. Aggregated Characteristics of Galcanezumab-Gnlm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	11.2	6.8
Mean number of unique drug classes dispensed	10.4	6.1

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

Table 1o. Aggregated Characteristics of Dacomitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	70	N/A[2]
Demographic Characteristics		
Age (years)	69.5	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	20	28.6%
≥ 65 years	50	71.4%
Sex		
Female	44	62.9%
Male	26	37.1%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	26	37.1%
White	27	38.6%
Hispanic origin		
Yes	*****	*****
No	41	58.6%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	24	34.3%
2020	*****	*****
2021	19	27.1%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	16	22.9%
Heart Failure	13	18.6%

Table 1o. Aggregated Characteristics of Dacomitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	30	42.9%
Hypertension	35	50.0%
Depression	12	17.1%
Ischemic Heart Disease	18	25.7%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	70	100.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	12	17.1%
Anemia	26	37.1%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	17	24.3%
COPD[5] and Bronchiectasis	12	17.1%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	18	25.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1o. Aggregated Characteristics of Dacomitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.3	18.9
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.0	0.4
Mean number of other ambulatory encounters	10.0	12.3
Mean number of filled prescriptions	26.7	19.4
Mean number of generics dispensed	11.2	7.0
Mean number of unique drug classes dispensed	10.0	6.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1p. Aggregated Characteristics of Cemiplimab-Rwlc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	6,645	N/A[2]
Demographic Characteristics		
Age (years)	77.9	9.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	556	8.4%
≥ 65 years	6,060	91.2%
Sex		
Female	1,786	26.9%
Male	4,859	73.1%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	29	0.4%
Black or African American	85	1.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	892	13.4%
White	5,619	84.6%
Hispanic origin		
Yes	36	0.5%
No	5,446	82.0%
Unknown	1,163	17.5%
Year		
2018	23	0.3%
2019	1,311	19.7%
2020	1,548	23.3%
2021	1,609	24.2%
2022	2,028	30.5%
2023	126	1.9%
Health Characteristics		
Acute Myocardial Infarction	70	1.1%
Alzheimer's Disease and related conditions	626	9.4%
Atrial Fibrillation	1,394	21.0%
Diabetes Mellitus	1,701	25.6%

Table 1p. Aggregated Characteristics of Cemiplimab-Rwlc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	1,244	18.7%
Hyperlipidemia	3,091	46.5%
Hypertension	4,407	66.3%
Depression	1,162	17.5%
Ischemic Heart Disease	2,388	35.9%
Rheumatoid Arthritis/Osteoarthritis	1,185	17.8%
Stroke/TIA[4]	287	4.3%
Breast Cancer	211	3.2%
Colorectal Cancer	191	2.9%
Prostate Cancer	488	7.3%
Lung Cancer	607	9.1%
Endometrial Cancer	22	0.3%
Acquired Hypothyroidism	1,062	16.0%
Anemia	2,558	38.5%
Asthma	229	3.4%
Benign Prostatic Hyperplasia	839	12.6%
Chronic Kidney Disease	1,746	26.3%
COPD[5] and Bronchiectasis	1,034	15.6%
Glaucoma	283	4.3%
Osteoporosis	279	4.2%
Obesity: diagnosed or identified by weight management procedures	911	13.7%
Obesity: identified by weight management-related prescriptions	25	0.4%
Overweight	795	12.0%
Smoking: diagnosed or identified by smoking cessation procedures	2,584	38.9%
Smoking: identified by smoking-related prescriptions	31	0.5%
Alcohol Abuse or Dependence	189	2.8%
Drug Abuse or Dependence	189	2.8%
History of Cardiac Arrest	21	0.3%
History of Coronary Angioplasty or Bypass	865	13.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.8	18.8
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.8	13.2
Mean number of filled prescriptions	21.1	17.6

Table 1p. Aggregated Characteristics of Cemiplimab-Rwlc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	9.5	5.5
Mean number of unique drug classes dispensed	8.8	4.9

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1q. Aggregated Characteristics of Sarecycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	14,322	N/A[2]
Demographic Characteristics		
Age (years)	23.4	10.9
Age		
0-17 years	6,312	44.1%
18-24 years	3,945	27.5%
25-40 years	2,704	18.9%
41-64 years	1,258	8.8%
≥ 65 years	103	0.7%
Sex		
Female	8,946	62.5%
Male	5,376	37.5%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	120	0.8%
Multi-racial	191	1.3%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	12,995	90.7%
White	903	6.3%
Hispanic origin		
Yes	143	1.0%
No	177	1.2%
Unknown	14,002	97.8%
Year		
2018	0	0.0%
2019	3,608	25.2%
2020	3,244	22.7%
2021	3,551	24.8%
2022	3,554	24.8%
2023	365	2.5%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	11	0.1%
Atrial Fibrillation	15	0.1%
Diabetes Mellitus	150	1.0%
Heart Failure	25	0.2%

cder_mpl1r_wp251

Table 1q. Aggregated Characteristics of Sarecycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	257	1.8%
Hypertension	282	2.0%
Depression	1,506	10.5%
Ischemic Heart Disease	41	0.3%
Rheumatoid Arthritis/Osteoarthritis	179	1.2%
Stroke/TIA[4]	*****	*****
Breast Cancer	19	0.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	202	1.4%
Anemia	366	2.6%
Asthma	230	1.6%
Benign Prostatic Hyperplasia	15	0.1%
Chronic Kidney Disease	53	0.4%
COPD[5] and Bronchiectasis	19	0.1%
Glaucoma	28	0.2%
Osteoporosis	15	0.1%
Obesity: diagnosed or identified by weight management procedures	503	3.5%
Obesity: identified by weight management-related prescriptions	43	0.3%
Overweight	329	2.3%
Smoking: diagnosed or identified by smoking cessation procedures	183	1.3%
Smoking: identified by smoking-related prescriptions	21	0.1%
Alcohol Abuse or Dependence	86	0.6%
Drug Abuse or Dependence	109	0.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1q. Aggregated Characteristics of Sarecycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.6	8.0
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.1	2.7
Mean number of filled prescriptions	6.9	8.3
Mean number of generics dispensed	3.7	3.3
Mean number of unique drug classes dispensed	3.3	3.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1r. Aggregated Characteristics of Omadacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	3,970	N/A[2]
Demographic Characteristics		
Age (years)	62.1	14.1
Age		
0-17 years	31	0.8%
18-24 years	75	1.9%
25-40 years	319	8.0%
41-64 years	1,610	40.6%
≥ 65 years	1,935	48.7%
Sex		
Female	2,059	51.9%
Male	1,911	48.1%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	47	1.2%
Black or African American	397	10.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,345	33.9%
White	2,161	54.4%
Hispanic origin		
Yes	124	3.1%
No	2,383	60.0%
Unknown	1,463	36.9%
Year		
2018	0	0.0%
2019	227	5.7%
2020	777	19.6%
2021	1,159	29.2%
2022	1,689	42.5%
2023	118	3.0%
Health Characteristics		
Acute Myocardial Infarction	62	1.6%
Alzheimer's Disease and related conditions	238	6.0%
Atrial Fibrillation	591	14.9%
Diabetes Mellitus	1,811	45.6%
Heart Failure	889	22.4%

cder_mpl1r_wp251

Table 1r. Aggregated Characteristics of Omadacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	1,873	47.2%
Hypertension	2,507	63.1%
Depression	1,083	27.3%
Ischemic Heart Disease	1,113	28.0%
Rheumatoid Arthritis/Osteoarthritis	1,113	28.0%
Stroke/TIA[4]	160	4.0%
Breast Cancer	116	2.9%
Colorectal Cancer	50	1.3%
Prostate Cancer	89	2.2%
Lung Cancer	73	1.8%
Endometrial Cancer	14	0.4%
Acquired Hypothyroidism	664	16.7%
Anemia	1,598	40.3%
Asthma	399	10.1%
Benign Prostatic Hyperplasia	272	6.9%
Chronic Kidney Disease	1,295	32.6%
COPD[5] and Bronchiectasis	982	24.7%
Glaucoma	150	3.8%
Osteoporosis	233	5.9%
Obesity: diagnosed or identified by weight management procedures	1,453	36.6%
Obesity: identified by weight management-related prescriptions	63	1.6%
Overweight	444	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	1,325	33.4%
Smoking: identified by smoking-related prescriptions	33	0.8%
Alcohol Abuse or Dependence	113	2.8%
Drug Abuse or Dependence	307	7.7%
History of Cardiac Arrest	15	0.4%
History of Coronary Angioplasty or Bypass	390	9.8%

Table 1r. Aggregated Characteristics of Omadacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	26.4	23.8
Mean number of emergency room encounters	0.9	1.8
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	14.8	22.8
Mean number of filled prescriptions	32.5	23.8
Mean number of generics dispensed	13.2	6.8
Mean number of unique drug classes dispensed	12.0	6.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1s. Aggregated Characteristics of Elapegademase-Lvlr in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	32	N/A[2]
Demographic Characteristics		
Age (years)	19.1	9.8
Age		
0-17 years	13	40.6%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	14	43.8%
Male	18	56.3%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	13	40.6%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	18	56.3%
Unknown	*****	*****
Year		
2018	*****	*****
2019	19	59.4%
2020	*****	*****
2021	*****	*****
2022	0	0.0%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****

cder_mpl1r_wp251

Table 1s. Aggregated Characteristics of Elapegademase-Lvlr in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA[4]	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.0	6.4
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	9.8	10.1
Mean number of filled prescriptions	17.9	16.9

Table 1s. Aggregated Characteristics of Elapegademase-Lvlr in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	6.6	5.3
Mean number of unique drug classes dispensed	6.3	4.9

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1t. Aggregated Characteristics of Inotersen in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	115	N/A[2]
Demographic Characteristics		
Age (years)	69.0	8.7
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	88	76.5%
Sex		
Female	54	47.0%
Male	61	53.0%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	39	33.9%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	23	20.0%
White	53	46.1%
Hispanic origin		
Yes	0	0.0%
No	85	73.9%
Unknown	30	26.1%
Year		
2018	*****	*****
2019	70	60.9%
2020	16	13.9%
2021	13	11.3%
2022	*****	*****
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	27	23.5%
Diabetes Mellitus	25	21.7%
Heart Failure	75	65.2%

cder_mpl1r_wp251

Table 1t. Aggregated Characteristics of Inotersen in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	51	44.3%
Hypertension	71	61.7%
Depression	17	14.8%
Ischemic Heart Disease	38	33.0%
Rheumatoid Arthritis/Osteoarthritis	23	20.0%
Stroke/TIA[4]	11	9.6%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	15.7%
Anemia	36	31.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	31	27.0%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	18	15.7%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	13	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	26	22.6%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1t. Aggregated Characteristics of Inotersen in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	14.1
Mean number of emergency room encounters	0.4	0.7
Mean number of inpatient hospital encounters	0.5	1.1
Mean number of non-acute institutional encounters	0.1	0.6
Mean number of other ambulatory encounters	8.9	14.5
Mean number of filled prescriptions	21.1	15.2
Mean number of generics dispensed	9.0	5.6
Mean number of unique drug classes dispensed	8.5	5.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1u. Aggregated Characteristics of Talazoparib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	372	N/A[2]
Demographic Characteristics		
Age (years)	57.7	11.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	190	51.1%
≥ 65 years	133	35.8%
Sex		
Female	344	92.5%
Male	28	7.5%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	146	39.2%
White	177	47.6%
Hispanic origin		
Yes	24	6.5%
No	215	57.8%
Unknown	133	35.8%
Year		
2018	11	3.0%
2019	137	36.8%
2020	136	36.6%
2021	54	14.5%
2022	34	9.1%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	15	4.0%
Diabetes Mellitus	66	17.7%
Heart Failure	34	9.1%

cder_mpl1r_wp251

Table 1u. Aggregated Characteristics of Talazoparib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	81	21.8%
Hypertension	124	33.3%
Depression	96	25.8%
Ischemic Heart Disease	38	10.2%
Rheumatoid Arthritis/Osteoarthritis	43	11.6%
Stroke/TIA[4]	*****	*****
Breast Cancer	350	94.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	16	4.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	49	13.2%
Anemia	155	41.7%
Asthma	17	4.6%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	38	10.2%
COPD[5] and Bronchiectasis	27	7.3%
Glaucoma	*****	*****
Osteoporosis	22	5.9%
Obesity: diagnosed or identified by weight management procedures	62	16.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	27	7.3%
Smoking: diagnosed or identified by smoking cessation procedures	89	23.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	13	3.5%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	13	3.5%

Table 1u. Aggregated Characteristics of Talazoparib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.7	15.9
Mean number of emergency room encounters	0.6	1.0
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	9.5	14.9
Mean number of filled prescriptions	23.2	18.2
Mean number of generics dispensed	9.8	6.1
Mean number of unique drug classes dispensed	8.9	5.3

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1v. Aggregated Characteristics of Baloxavir Marboxil in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	110,106	N/A[2]
Demographic Characteristics		
Age (years)	41.6	16.1
Age		
0-17 years	19,064	17.3%
18-24 years	11,454	10.4%
25-40 years	26,040	23.6%
41-64 years	34,588	31.4%
≥ 65 years	18,960	17.2%
Sex		
Female	60,027	54.5%
Male	50,079	45.5%
Race[3]		
American Indian or Alaska Native	142	0.1%
Asian	730	0.7%
Black or African American	1,844	1.7%
Multi-racial	377	0.3%
Native Hawaiian or Other Pacific Islander	59	0.1%
Unknown	85,067	77.3%
White	21,887	19.9%
Hispanic origin		
Yes	2,036	1.8%
No	22,310	20.3%
Unknown	85,760	77.9%
Year		
2018	801	0.7%
2019	25,056	22.8%
2020	44,741	40.6%
2021	7,441	6.8%
2022	31,379	28.5%
2023	688	0.6%
Health Characteristics		
Acute Myocardial Infarction	122	0.1%
Alzheimer's Disease and related conditions	1,342	1.2%
Atrial Fibrillation	2,335	2.1%
Diabetes Mellitus	7,617	6.9%

Table 1v. Aggregated Characteristics of Baloxavir Marboxil in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	2,584	2.3%
Hyperlipidemia	13,114	11.9%
Hypertension	16,440	14.9%
Depression	12,026	10.9%
Ischemic Heart Disease	6,298	5.7%
Rheumatoid Arthritis/Osteoarthritis	7,466	6.8%
Stroke/TIA[4]	661	0.6%
Breast Cancer	980	0.9%
Colorectal Cancer	224	0.2%
Prostate Cancer	617	0.6%
Lung Cancer	188	0.2%
Endometrial Cancer	55	0.0%
Acquired Hypothyroidism	5,331	4.8%
Anemia	7,060	6.4%
Asthma	2,950	2.7%
Benign Prostatic Hyperplasia	1,400	1.3%
Chronic Kidney Disease	3,177	2.9%
COPD[5] and Bronchiectasis	2,668	2.4%
Glaucoma	1,084	1.0%
Osteoporosis	1,350	1.2%
Obesity: diagnosed or identified by weight management procedures	12,892	11.7%
Obesity: identified by weight management-related prescriptions	755	0.7%
Overweight	6,292	5.7%
Smoking: diagnosed or identified by smoking cessation procedures	6,736	6.1%
Smoking: identified by smoking-related prescriptions	394	0.4%
Alcohol Abuse or Dependence	768	0.7%
Drug Abuse or Dependence	1,291	1.2%
History of Cardiac Arrest	29	0.0%
History of Coronary Angioplasty or Bypass	1,597	1.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.6	8.6
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.7	6.4
Mean number of filled prescriptions	10.5	13.3

Table 1v. Aggregated Characteristics of Baloxavir Marboxil in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	4.8	4.5
Mean number of unique drug classes dispensed	4.5	4.1

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

Table 1w. Aggregated Characteristics of Lorlatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,055	N/A[2]
Demographic Characteristics		
Age (years)	59.4	14.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	80	7.6%
41-64 years	448	42.5%
≥ 65 years	475	45.0%
Sex		
Female	587	55.6%
Male	468	44.4%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	81	7.7%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	400	37.9%
White	495	46.9%
Hispanic origin		
Yes	44	4.2%
No	609	57.7%
Unknown	402	38.1%
Year		
2018	53	5.0%
2019	283	26.8%
2020	280	26.5%
2021	184	17.4%
2022	233	22.1%
2023	22	2.1%
Health Characteristics		
Acute Myocardial Infarction	13	1.2%
Alzheimer's Disease and related conditions	27	2.6%
Atrial Fibrillation	68	6.4%
Diabetes Mellitus	158	15.0%
Heart Failure	96	9.1%

Table 1w. Aggregated Characteristics of Lorlatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	308	29.2%
Hypertension	376	35.6%
Depression	202	19.1%
Ischemic Heart Disease	152	14.4%
Rheumatoid Arthritis/Osteoarthritis	102	9.7%
Stroke/TIA[4]	70	6.6%
Breast Cancer	39	3.7%
Colorectal Cancer	*****	*****
Prostate Cancer	27	2.6%
Lung Cancer	984	93.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	143	13.6%
Anemia	393	37.3%
Asthma	65	6.2%
Benign Prostatic Hyperplasia	58	5.5%
Chronic Kidney Disease	187	17.7%
COPD[5] and Bronchiectasis	108	10.2%
Glaucoma	31	2.9%
Osteoporosis	31	2.9%
Obesity: diagnosed or identified by weight management procedures	144	13.6%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	84	8.0%
Smoking: diagnosed or identified by smoking cessation procedures	270	25.6%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	16	1.5%
Drug Abuse or Dependence	33	3.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	29	2.7%

Table 1w. Aggregated Characteristics of Lorlatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.1	13.2
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.6	16.4
Mean number of filled prescriptions	22.7	16.8
Mean number of generics dispensed	9.2	5.6
Mean number of unique drug classes dispensed	8.5	4.9

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1x. Aggregated Characteristics of Revefenacin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	8,196	N/A[2]
Demographic Characteristics		
Age (years)	70.5	10.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	111	1.4%
41-64 years	2,438	29.7%
≥ 65 years	5,627	68.7%
Sex		
Female	4,743	57.9%
Male	3,453	42.1%
Race[3]		
American Indian or Alaska Native	35	0.4%
Asian	39	0.5%
Black or African American	651	7.9%
Multi-racial	14	0.2%
Native Hawaiian or Other Pacific Islander	21	0.3%
Unknown	3,087	37.7%
White	4,349	53.1%
Hispanic origin		
Yes	87	1.1%
No	4,261	52.0%
Unknown	3,848	46.9%
Year		
2018	*****	*****
2019	1,464	17.9%
2020	2,062	25.2%
2021	1,962	23.9%
2022	2,361	28.8%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	185	2.3%
Alzheimer's Disease and related conditions	796	9.7%
Atrial Fibrillation	1,514	18.5%
Diabetes Mellitus	2,346	28.6%
Heart Failure	2,861	34.9%

cder_mpl1r_wp251

Table 1x. Aggregated Characteristics of Revefenacin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	3,671	44.8%
Hypertension	5,403	65.9%
Depression	2,810	34.3%
Ischemic Heart Disease	3,186	38.9%
Rheumatoid Arthritis/Osteoarthritis	1,937	23.6%
Stroke/TIA[4]	345	4.2%
Breast Cancer	231	2.8%
Colorectal Cancer	98	1.2%
Prostate Cancer	176	2.1%
Lung Cancer	587	7.2%
Endometrial Cancer	21	0.3%
Acquired Hypothyroidism	1,305	15.9%
Anemia	2,493	30.4%
Asthma	1,403	17.1%
Benign Prostatic Hyperplasia	632	7.7%
Chronic Kidney Disease	1,981	24.2%
COPD[5] and Bronchiectasis	7,191	87.7%
Glaucoma	230	2.8%
Osteoporosis	620	7.6%
Obesity: diagnosed or identified by weight management procedures	2,281	27.8%
Obesity: identified by weight management-related prescriptions	53	0.6%
Overweight	734	9.0%
Smoking: diagnosed or identified by smoking cessation procedures	4,912	59.9%
Smoking: identified by smoking-related prescriptions	346	4.2%
Alcohol Abuse or Dependence	413	5.0%
Drug Abuse or Dependence	558	6.8%
History of Cardiac Arrest	46	0.6%
History of Coronary Angioplasty or Bypass	859	10.5%

cder_mpl1r_wp251

Table 1x. Aggregated Characteristics of Revefenacin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.0	14.9
Mean number of emergency room encounters	1.3	2.4
Mean number of inpatient hospital encounters	0.6	1.1
Mean number of non-acute institutional encounters	0.2	0.5
Mean number of other ambulatory encounters	14.6	21.8
Mean number of filled prescriptions	38.6	29.5
Mean number of generics dispensed	13.8	7.3
Mean number of unique drug classes dispensed	12.6	6.5

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1y. Aggregated Characteristics of Rifamycin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	68	N/A[2]
Demographic Characteristics		
Age (years)	49.8	12.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	33	48.5%
≥ 65 years	15	22.1%
Sex		
Female	39	57.4%
Male	29	42.6%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	47	69.1%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	18	26.5%
Unknown	50	73.5%
Year		
2018	0	0.0%
2019	*****	*****
2020	41	60.3%
2021	12	17.6%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****

cder_mpl1r_wp251

Table 1y. Aggregated Characteristics of Rifamycin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	*****	*****
Hypertension	11	16.2%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	12	17.6%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1y. Aggregated Characteristics of Rifamycin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.0	15.0
Mean number of emergency room encounters	0.5	2.8
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.9	4.6
Mean number of filled prescriptions	17.4	26.2
Mean number of generics dispensed	7.1	6.3
Mean number of unique drug classes dispensed	6.7	5.7

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1z. Aggregated Characteristics of Emapalumab-Lzsg in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	37	N/A[2]
Demographic Characteristics		
Age (years)	26.1	19.2
Age		
0-17 years	20	54.1%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	20	54.1%
Male	17	45.9%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	18	48.6%
Hispanic origin		
Yes	*****	*****
No	15	40.5%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	*****	*****
2020	17	45.9%
2021	*****	*****
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****

cder_mpl1r_wp251

Table 1z. Aggregated Characteristics of Emapalumab-Lzsg in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	12	32.4%
Hypertension	19	51.4%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	27	73.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	15	40.5%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1z. Aggregated Characteristics of Emapalumab-Lzsg in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	13.8
Mean number of emergency room encounters	1.7	1.9
Mean number of inpatient hospital encounters	2.0	1.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	34.5	26.6
Mean number of filled prescriptions	25.2	21.1
Mean number of generics dispensed	11.6	7.1
Mean number of unique drug classes dispensed	10.5	6.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1aa. Aggregated Characteristics of Glasdegib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	325	N/A[2]
Demographic Characteristics		
Age (years)	74.4	8.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	286	88.0%
Sex		
Female	139	42.8%
Male	186	57.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	51	15.7%
White	239	73.5%
Hispanic origin		
Yes	*****	*****
No	262	80.6%
Unknown	*****	*****
Year		
2018	*****	*****
2019	102	31.4%
2020	101	31.1%
2021	61	18.8%
2022	*****	*****
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	21	6.5%
Atrial Fibrillation	66	20.3%
Diabetes Mellitus	90	27.7%

cder_mpl1r_wp251

Table 1aa. Aggregated Characteristics of Glasdegib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	82	25.2%
Hyperlipidemia	162	49.8%
Hypertension	216	66.5%
Depression	79	24.3%
Ischemic Heart Disease	105	32.3%
Rheumatoid Arthritis/Osteoarthritis	65	20.0%
Stroke/TIA[4]	35	10.8%
Breast Cancer	19	5.8%
Colorectal Cancer	*****	*****
Prostate Cancer	28	8.6%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	56	17.2%
Anemia	321	98.8%
Asthma	12	3.7%
Benign Prostatic Hyperplasia	51	15.7%
Chronic Kidney Disease	126	38.8%
COPD[5] and Bronchiectasis	53	16.3%
Glaucoma	15	4.6%
Osteoporosis	17	5.2%
Obesity: diagnosed or identified by weight management procedures	58	17.8%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	45	13.8%
Smoking: diagnosed or identified by smoking cessation procedures	143	44.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	42	12.9%

Table 1aa. Aggregated Characteristics of Glasdegib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	55.1	21.0
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	1.6	1.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	24.1	23.7
Mean number of filled prescriptions	30.8	25.1
Mean number of generics dispensed	13.2	6.3
Mean number of unique drug classes dispensed	12.2	5.4

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ab. Aggregated Characteristics of Larotrectinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	340	N/A[2]
Demographic Characteristics		
Age (years)	55.8	18.2
Age		
0-17 years	48	14.1%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	101	29.7%
≥ 65 years	163	47.9%
Sex		
Female	200	58.8%
Male	140	41.2%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	29	8.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	122	35.9%
White	177	52.1%
Hispanic origin		
Yes	17	5.0%
No	208	61.2%
Unknown	115	33.8%
Year		
2018	*****	*****
2019	108	31.8%
2020	89	26.2%
2021	71	20.9%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	12	3.5%
Atrial Fibrillation	38	11.2%
Diabetes Mellitus	56	16.5%

cder_mpl1r_wp251

Table 1ab. Aggregated Characteristics of Larotrectinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	33	9.7%
Hyperlipidemia	87	25.6%
Hypertension	146	42.9%
Depression	60	17.6%
Ischemic Heart Disease	55	16.2%
Rheumatoid Arthritis/Osteoarthritis	35	10.3%
Stroke/TIA[4]	18	5.3%
Breast Cancer	48	14.1%
Colorectal Cancer	26	7.6%
Prostate Cancer	14	4.1%
Lung Cancer	79	23.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	69	20.3%
Anemia	141	41.5%
Asthma	25	7.4%
Benign Prostatic Hyperplasia	21	6.2%
Chronic Kidney Disease	55	16.2%
COPD[5] and Bronchiectasis	37	10.9%
Glaucoma	*****	*****
Osteoporosis	11	3.2%
Obesity: diagnosed or identified by weight management procedures	52	15.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	21	6.2%
Smoking: diagnosed or identified by smoking cessation procedures	89	26.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	14	4.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	4.1%

Table 1ab. Aggregated Characteristics of Larotrectinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.1	15.5
Mean number of emergency room encounters	0.5	1.0
Mean number of inpatient hospital encounters	0.8	1.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.8	20.6
Mean number of filled prescriptions	20.7	16.3
Mean number of generics dispensed	9.5	5.9
Mean number of unique drug classes dispensed	8.8	5.2

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ac. Aggregated Characteristics of Amifampridine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	402	N/A[2]
Demographic Characteristics		
Age (years)	62.1	13.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	31	7.7%
41-64 years	128	31.8%
≥ 65 years	223	55.5%
Sex		
Female	226	56.2%
Male	176	43.8%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	22	5.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	107	26.6%
White	261	64.9%
Hispanic origin		
Yes	16	4.0%
No	278	69.2%
Unknown	108	26.9%
Year		
2018	0	0.0%
2019	210	52.2%
2020	69	17.2%
2021	62	15.4%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	33	8.2%
Diabetes Mellitus	72	17.9%
Heart Failure	40	10.0%

cder_mpl1r_wp251

Table 1ac. Aggregated Characteristics of Amifampridine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	111	27.6%
Hypertension	154	38.3%
Depression	84	20.9%
Ischemic Heart Disease	83	20.6%
Rheumatoid Arthritis/Osteoarthritis	67	16.7%
Stroke/TIA[4]	17	4.2%
Breast Cancer	18	4.5%
Colorectal Cancer	*****	*****
Prostate Cancer	13	3.2%
Lung Cancer	56	13.9%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	57	14.2%
Anemia	93	23.1%
Asthma	20	5.0%
Benign Prostatic Hyperplasia	18	4.5%
Chronic Kidney Disease	43	10.7%
COPD[5] and Bronchiectasis	72	17.9%
Glaucoma	14	3.5%
Osteoporosis	20	5.0%
Obesity: diagnosed or identified by weight management procedures	64	15.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	42	10.4%
Smoking: diagnosed or identified by smoking cessation procedures	116	28.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	11	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	21	5.2%

Table 1ac. Aggregated Characteristics of Amifampridine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.8	13.6
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.3	18.0
Mean number of filled prescriptions	21.2	17.9
Mean number of generics dispensed	8.4	5.8
Mean number of unique drug classes dispensed	7.9	5.3

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ad. Aggregated Characteristics of Gilteritinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,788	N/A[2]
Demographic Characteristics		
Age (years)	65.4	12.1
Age		
0-17 years	24	1.3%
18-24 years	30	1.7%
25-40 years	117	6.5%
41-64 years	453	25.3%
≥ 65 years	1,164	65.1%
Sex		
Female	860	48.1%
Male	928	51.9%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	97	5.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	472	26.4%
White	1,169	65.4%
Hispanic origin		
Yes	48	2.7%
No	1,232	68.9%
Unknown	508	28.4%
Year		
2018	35	2.0%
2019	416	23.3%
2020	516	28.9%
2021	389	21.8%
2022	403	22.5%
2023	29	1.6%
Health Characteristics		
Acute Myocardial Infarction	55	3.1%
Alzheimer's Disease and related conditions	107	6.0%
Atrial Fibrillation	282	15.8%
Diabetes Mellitus	411	23.0%
Heart Failure	392	21.9%

cder_mpl1r_wp251

Table 1ad. Aggregated Characteristics of Gilteritinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	746	41.7%
Hypertension	1,078	60.3%
Depression	461	25.8%
Ischemic Heart Disease	528	29.5%
Rheumatoid Arthritis/Osteoarthritis	305	17.1%
Stroke/TIA[4]	146	8.2%
Breast Cancer	72	4.0%
Colorectal Cancer	20	1.1%
Prostate Cancer	77	4.3%
Lung Cancer	29	1.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	304	17.0%
Anemia	1,624	90.8%
Asthma	136	7.6%
Benign Prostatic Hyperplasia	207	11.6%
Chronic Kidney Disease	658	36.8%
COPD[5] and Bronchiectasis	237	13.3%
Glaucoma	54	3.0%
Osteoporosis	79	4.4%
Obesity: diagnosed or identified by weight management procedures	394	22.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	230	12.9%
Smoking: diagnosed or identified by smoking cessation procedures	705	39.4%
Smoking: identified by smoking-related prescriptions	15	0.8%
Alcohol Abuse or Dependence	49	2.7%
Drug Abuse or Dependence	75	4.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	160	8.9%

Table 1ad. Aggregated Characteristics of Gilteritinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	37.0	21.8
Mean number of emergency room encounters	0.9	1.4
Mean number of inpatient hospital encounters	1.7	1.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	25.3	24.3
Mean number of filled prescriptions	28.4	20.3
Mean number of generics dispensed	13.2	6.7
Mean number of unique drug classes dispensed	12.3	6.0

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ae. Aggregated Characteristics of Prucalopride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	33,124	N/A[2]
Demographic Characteristics		
Age (years)	55.5	15.0
Age		
0-17 years	440	1.3%
18-24 years	1,763	5.3%
25-40 years	5,304	16.0%
41-64 years	13,804	41.7%
≥ 65 years	11,813	35.7%
Sex		
Female	26,134	78.9%
Male	6,990	21.1%
Race[3]		
American Indian or Alaska Native	85	0.3%
Asian	472	1.4%
Black or African American	2,013	6.1%
Multi-racial	165	0.5%
Native Hawaiian or Other Pacific Islander	20	0.1%
Unknown	13,891	41.9%
White	16,478	49.7%
Hispanic origin		
Yes	839	2.5%
No	17,588	53.1%
Unknown	14,697	44.4%
Year		
2018	0	0.0%
2019	6,236	18.8%
2020	10,233	30.9%
2021	7,622	23.0%
2022	8,535	25.8%
2023	498	1.5%
Health Characteristics		
Acute Myocardial Infarction	123	0.4%
Alzheimer's Disease and related conditions	970	2.9%
Atrial Fibrillation	1,602	4.8%
Diabetes Mellitus	6,822	20.6%
Heart Failure	2,498	7.5%

cder_mpl1r_wp251

Table 1ae. Aggregated Characteristics of Prucalopride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	9,743	29.4%
Hypertension	11,346	34.3%
Depression	12,380	37.4%
Ischemic Heart Disease	4,873	14.7%
Rheumatoid Arthritis/Osteoarthritis	7,697	23.2%
Stroke/TIA[4]	774	2.3%
Breast Cancer	855	2.6%
Colorectal Cancer	244	0.7%
Prostate Cancer	330	1.0%
Lung Cancer	222	0.7%
Endometrial Cancer	72	0.2%
Acquired Hypothyroidism	5,368	16.2%
Anemia	7,859	23.7%
Asthma	3,168	9.6%
Benign Prostatic Hyperplasia	1,239	3.7%
Chronic Kidney Disease	3,533	10.7%
COPD[5] and Bronchiectasis	2,759	8.3%
Glaucoma	986	3.0%
Osteoporosis	2,249	6.8%
Obesity: diagnosed or identified by weight management procedures	6,083	18.4%
Obesity: identified by weight management-related prescriptions	492	1.5%
Overweight	2,973	9.0%
Smoking: diagnosed or identified by smoking cessation procedures	6,184	18.7%
Smoking: identified by smoking-related prescriptions	384	1.2%
Alcohol Abuse or Dependence	631	1.9%
Drug Abuse or Dependence	2,154	6.5%
History of Cardiac Arrest	48	0.1%
History of Coronary Angioplasty or Bypass	1,213	3.7%

Table 1ae. Aggregated Characteristics of Prucalopride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.3	16.7
Mean number of emergency room encounters	0.7	2.0
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.8	18.3
Mean number of filled prescriptions	33.8	27.6
Mean number of generics dispensed	12.8	7.5
Mean number of unique drug classes dispensed	11.9	6.6

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

Table 1af. Aggregated Characteristics of Calaspargase Pegol-Mknl in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	32	N/A[2]
Demographic Characteristics		
Age (years)	11.6	5.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	*****	*****
Sex		
Female	11	34.4%
Male	21	65.6%
Race[3]		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2018	0	0.0%
2019	*****	*****
2020	0	0.0%
2021	0	0.0%
2022	*****	*****
2023	21	65.6%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%

cder_mpl1r_wp251

Table 1af. Aggregated Characteristics of Calaspargase Pegol-Mknl in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	0	0.0%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA[4]	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	31	96.9%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1af. Aggregated Characteristics of Calaspargase Pegol-Mknl in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	13.0
Mean number of emergency room encounters	1.1	1.0
Mean number of inpatient hospital encounters	2.6	2.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.3	5.0
Mean number of filled prescriptions	15.8	7.9
Mean number of generics dispensed	9.7	4.2
Mean number of unique drug classes dispensed	9.2	3.9

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*NaN: Not a number

  *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ag. Aggregated Characteristics of Tagraxofusp-Erzs in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	88	N/A[2]
Demographic Characteristics		
Age (years)	67.6	12.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	71	80.7%
Sex		
Female	13	14.8%
Male	75	85.2%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	61	69.3%
Hispanic origin		
Yes	*****	*****
No	63	71.6%
Unknown	*****	*****
Year		
2018	0	0.0%
2019	21	23.9%
2020	26	29.5%
2021	24	27.3%
2022	17	19.3%
2023	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	15	17.0%
Diabetes Mellitus	12	13.6%

Table 1ag. Aggregated Characteristics of Tagraxofusp-Erzs in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	12	13.6%
Hyperlipidemia	40	45.5%
Hypertension	50	56.8%
Depression	11	12.5%
Ischemic Heart Disease	19	21.6%
Rheumatoid Arthritis/Osteoarthritis	12	13.6%
Stroke/TIA[4]	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	65	73.9%
Asthma	*****	*****
Benign Prostatic Hyperplasia	16	18.2%
Chronic Kidney Disease	30	34.1%
COPD[5] and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	12	13.6%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	13	14.8%
Smoking: diagnosed or identified by smoking cessation procedures	40	45.5%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.3	16.1
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	1.0	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	13.5	16.4
Mean number of filled prescriptions	14.3	12.2

cder_mpl1r_wp251

Table 1ag. Aggregated Characteristics of Tagraxofusp-Erzs in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Mean number of generics dispensed	7.7	5.0
Mean number of unique drug classes dispensed	7.3	4.6

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 1ah. Aggregated Characteristics of Ravulizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Unique patients	1,859	N/A[2]
Demographic Characteristics		
Age (years)	53.8	17.7
Age		
0-17 years	119	6.4%
18-24 years	94	5.1%
25-40 years	361	19.4%
41-64 years	508	27.3%
≥ 65 years	777	41.8%
Sex		
Female	1,002	53.9%
Male	857	46.1%
Race[3]		
American Indian or Alaska Native	*****	*****
Asian	52	2.8%
Black or African American	196	10.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	651	35.0%
White	936	50.3%
Hispanic origin		
Yes	86	4.6%
No	1,120	60.2%
Unknown	653	35.1%
Year		
2018	0	0.0%
2019	315	16.9%
2020	512	27.5%
2021	271	14.6%
2022	714	38.4%
2023	47	2.5%
Health Characteristics		
Acute Myocardial Infarction	23	1.2%
Alzheimer's Disease and related conditions	38	2.0%
Atrial Fibrillation	139	7.5%
Diabetes Mellitus	347	18.7%

cder_mpl1r_wp251

Table 1ah. Aggregated Characteristics of Ravulizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Heart Failure	228	12.3%
Hyperlipidemia	491	26.4%
Hypertension	907	48.8%
Depression	336	18.1%
Ischemic Heart Disease	283	15.2%
Rheumatoid Arthritis/Osteoarthritis	225	12.1%
Stroke/TIA[4]	65	3.5%
Breast Cancer	30	1.6%
Colorectal Cancer	17	0.9%
Prostate Cancer	40	2.2%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	223	12.0%
Anemia	1,469	79.0%
Asthma	90	4.8%
Benign Prostatic Hyperplasia	97	5.2%
Chronic Kidney Disease	844	45.4%
COPD[5] and Bronchiectasis	111	6.0%
Glaucoma	39	2.1%
Osteoporosis	84	4.5%
Obesity: diagnosed or identified by weight management procedures	369	19.8%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	179	9.6%
Smoking: diagnosed or identified by smoking cessation procedures	364	19.6%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	29	1.6%
Drug Abuse or Dependence	65	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	81	4.4%

Table 1ah. Aggregated Characteristics of Ravulizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation[1]
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	26.1	26.2
Mean number of emergency room encounters	0.5	1.5
Mean number of inpatient hospital encounters	0.5	1.0
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	9.0	15.7
Mean number of filled prescriptions	20.0	17.5
Mean number of generics dispensed	8.2	5.8
Mean number of unique drug classes dispensed	7.7	5.3

[1]Value represents standard deviation where no % follows the value.

[2]N/A: Not Applicable

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]TIA: Transient Ischemic Attack

[5]COPD: Chronic Obstructive Pulmonary Disease

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
mogamulizumab-kpkc	12,446	12,446	100.0%	0	0.0%	0	0.0%	0	0.0%
patisiran	12,700	*****	*****	*****	*****	0	0.0%	0	0.0%
acetate	15,936	7,178	45.0%	1,027	6.4%	2,431	15.3%	5,300	33.3%
migalastat	3,089	3,061	99.1%	*****	*****	*****	*****	*****	*****
stiripentol	4,710	4,330	91.9%	287	6.1%	79	1.7%	14	0.3%
cenegermin-bkbj	27,321	*****	*****	*****	*****	0	0.0%	0	0.0%
lanadelumab	17,975	17,863	99.4%	72	0.4%	40	0.2%	0	0.0%
eravacycline	7,109	*****	*****	*****	*****	0	0.0%	0	0.0%
doravirine	65,449	63,609	97.2%	274	0.4%	1,553	2.4%	13	0.0%
doravirine/lamivudine/tenofovir disoproxil fumarate	9,742	9,467	97.2%	*****	*****	198	2.0%	*****	*****
moxetumomab pasudotox-tdfk	421	421	100.0%	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	444,324	404,544	91.0%	4,950	1.1%	34,728	7.8%	102	0.0%
duvelisib	3,006	2,989	99.4%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	1,201,355	1,145,569	95.4%	10,361	0.9%	45,259	3.8%	166	0.0%
dacomitinib	429	*****	*****	*****	*****	*****	*****	0	0.0%
cemiplimab-rwlc	61,923	61,923	100.0%	0	0.0%	0	0.0%	0	0.0%
sarecycline	44,895	44,539	99.2%	*****	*****	256	0.6%	*****	*****
omadacycline	21,814	21,663	99.3%	62	0.3%	89	0.4%	0	0.0%
elapegademase-lvlr	596	585	98.2%	11	1.8%	0	0.0%	0	0.0%
inotersen	1,584	1,584	100.0%	0	0.0%	0	0.0%	0	0.0%
talazoparib	2,447	2,431	99.3%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	116,976	116,902	99.9%	49	0.0%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
lorlatinib	9,251	9,165	99.1%	58	0.6%	*****	*****	*****	*****
revefenacin	37,270	36,367	97.6%	*****	*****	768	*****	*****	*****
rifamycin	111	*****	*****	*****	*****	0	0.0%	0	0.0%
emapalumab-lzsg	517	517	100.0%	0	0.0%	0	0.0%	0	0.0%
glasdegib	760	*****	*****	*****	*****	0	0.0%	0	0.0%
larotrectinib	2,000	1,949	97.5%	*****	*****	*****	*****	0	0.0%
amifampridine	7,716	7,478	96.9%	36	0.5%	202	2.6%	0	0.0%
gilteritinib	9,808	9,691	98.8%	96	1.0%	*****	*****	*****	*****
prucalopride	184,840	157,658	85.3%	3,532	1.9%	23,600	12.8%	50	0.0%
calaspargase pegol-mknl	51	51	100.0%	0	0.0%	0	0.0%	0	0.0%
tagraxofusp-erzs	1,132	1,132	100.0%	0	0.0%	0	0.0%	0	0.0%
ravulizumab	13,413	12,917	96.3%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	12,446	1	1	1	1	30	1.3	2.6
patisiran	12,700	1	1	1	1	42	2.1	4.5
ethinyl estradiol and segesterone acetate	15,936	1	28	50	127	615	108.3	116.5
migalastat	3,089	1	28	28	28	168	28.0	7.0
stiripentol	4,710	1	24	30	30	180	29.5	12.6
cenegermin-bkbj	27,321	1	14	14	14	34	12.6	3.3
lanadelumab	17,975	1	28	28	28	84	27.0	5.6
eravacycline	7,109	1	1	1	1	41	1.7	1.9
doravirine	65,449	1	30	30	30	210	30.4	10.5
doravirine/lamivudine/tenofovir disoproxil fumarate	9,742	1	30	30	30	180	30.6	10.0
moxetumomab pasudotox-tdfk	421	1	1	1	1	28	1.1	1.9
fremanezumab-vfrm	444,324	1	30	30	30	360	33.6	16.8
duvelisib	3,006	1	28	28	28	84	27.5	3.9
galcanezumab-gnlm	1,201,355	1	28	30	30	651	31.0	12.4
dacomitinib	429	1	30	30	30	90	29.1	5.5
cemiplimab-rwlc	61,923	1	1	1	1	21	1.2	1.8
sarecycline	44,895	1	30	30	30	180	29.9	5.8
omadacycline	21,814	1	1	1	14	90	7.9	11.4
elapegademase-lvlr	596	2	28	28	28	56	27.1	5.8
inotersen	1,584	2	28	28	28	30	27.8	2.2
talazoparib	2,447	1	30	30	30	90	28.2	5.7
baloxavir marboxil	116,976	1	1	1	1	180	2.1	5.6
lorlatinib	9,251	1	30	30	30	213	28.4	7.0
revefenacin	37,270	1	1	30	30	120	19.2	17.3
rifamycin	111	2	3	3	7	36	7.1	7.8

cder_mpl1r_wp251

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
				Distribution of Days Supplied by Dispensing				
emapalumab-lzsg	517	1	1	1	1	7	1.3	1.1
glasdegib	760	1	28	30	30	32	27.2	6.1
larotrectinib	2,000	1	30	30	30	90	28.0	6.4
amifampridine	7,716	1	30	30	30	90	31.1	10.2
gilteritinib	9,808	1	30	30	30	149	27.6	8.4
prucalopride	184,840	1	30	30	30	180	36.8	20.9
calaspargase pegol-mknl	51	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	1,132	1	1	1	1	1	1.0	0.0
ravulizumab	13,413	1	1	1	1	112	3.5	10.7

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Mogamulizumab-Kpkc	**12,446**	**12,446**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	5,465	5,465	43.9%	0	NaN	0	NaN	0	NaN
Male	6,981	6,981	56.1%	0	NaN	0	NaN	0	NaN
patisiran	**12,700**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	4,408	*****	*****	*****	*****	0	NaN	0	NaN
Male	8,292	8,292	65.3%	0	0.0%	0	NaN	0	NaN
ethinyl estradiol and segesterone acetate	**15,936**	**7,178**	**100.0%**	**1,027**	**100.0%**	**2,431**	**100.0%**	**5,300**	**100.0%**
Female	15,906	*****	*****	*****	*****	*****	*****	5,286	99.7%
Male	30	*****	*****	*****	*****	*****	*****	14	0.3%
migalastat	**3,089**	**3,061**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	1,544	*****	*****	*****	*****	18	85.7%	0	0.0%
Male	1,545	*****	*****	0	0.0%	*****	*****	*****	*****
stiripentol	**4,710**	**4,330**	**100.0%**	**287**	**100.0%**	**79**	**100.0%**	**14**	**100.0%**
Female	2,699	2,511	58.0%	147	51.2%	*****	*****	*****	*****
Male	2,011	1,819	42.0%	140	48.8%	*****	*****	*****	*****
cenegermin-bkbj	**27,321**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	17,574	17,574	64.3%	0	0.0%	0	NaN	0	NaN
Male	9,747	*****	*****	*****	*****	0	NaN	0	NaN
lanadelumab	**17,975**	**17,863**	**100.0%**	**72**	**100.0%**	**40**	**100.0%**	**0**	**NaN**
Female	12,404	12,348	69.1%	42	58.3%	14	35.0%	0	NaN
Male	5,571	5,515	30.9%	30	41.7%	26	65.0%	0	NaN
eravacycline	**7,109**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	3,601	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,508	3,508	49.4%	0	0.0%	0	NaN	0	NaN
doravirine	**65,449**	**63,609**	**100.0%**	**274**	**100.0%**	**1,553**	**100.0%**	**13**	**100.0%**
Female	13,743	13,471	21.2%	*****	*****	197	12.7%	*****	*****
Male	51,706	50,138	78.8%	*****	*****	1,356	87.3%	*****	*****

cder_mpl1r_wp251

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
doravirine/lamivudine/tenofovir disoproxil fumarate	9,742	9,467	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	2,633	2,592	27.4%	*****	*****	*****	*****	*****	*****
Male	7,109	6,875	72.6%	*****	*****	167	84.3%	*****	*****
moxetumomab pasudotox-tdfk	421	421	100.0%	0	NaN	0	NaN	0	NaN
Female	66	66	15.7%	0	NaN	0	NaN	0	NaN
Male	355	355	84.3%	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	444,324	404,544	100.0%	4,950	100.0%	34,728	100.0%	102	100.0%
Female	383,821	349,694	86.4%	4,293	86.7%	29,745	85.7%	89	87.3%
Male	60,503	54,850	13.6%	657	13.3%	4,983	14.3%	13	12.7%
duvelisib	3,006	2,989	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,339	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,667	*****	*****	*****	*****	0	0.0%	0	NaN
galcanezumab-gnlm	1,201,355	1,145,569	100.0%	10,361	100.0%	45,259	100.0%	166	100.0%
Female	1,022,838	975,575	85.2%	8,837	85.3%	38,290	84.6%	136	81.9%
Male	178,517	169,994	14.8%	1,524	14.7%	6,969	15.4%	30	18.1%
dacomitinib	429	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	254	254	59.5%	0	0.0%	0	0.0%	0	NaN
Male	175	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	61,923	61,923	100.0%	0	NaN	0	NaN	0	NaN
Female	15,112	15,112	24.4%	0	NaN	0	NaN	0	NaN
Male	46,811	46,811	75.6%	0	NaN	0	NaN	0	NaN
sarecycline	44,895	44,539	100.0%	*****	100.0%	256	100.0%	*****	100.0%
Female	27,315	27,111	60.9%	*****	*****	141	55.1%	*****	*****
Male	17,580	17,428	39.1%	*****	*****	115	44.9%	*****	*****
omadacycline	21,814	21,663	100.0%	62	100.0%	89	100.0%	0	NaN
Female	11,127	11,038	51.0%	33	53.2%	56	62.9%	0	NaN
Male	10,687	10,625	49.0%	29	46.8%	33	37.1%	0	NaN
elapegademase-lvlr	596	585	100.0%	11	100.0%	0	NaN	0	NaN
Female	265	*****	*****	*****	*****	0	NaN	0	NaN

cder_mpl1r_wp251

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed

	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
		Number of Dispensings by Days Supplied							
		1-30 Days		**31-60 Days**		**61-90 Days**		**91+ Days**	
Male	331	*****	*****	*****	*****	0	NaN	0	NaN
inotersen	**1,584**	**1,584**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	852	852	53.8%	0	NaN	0	NaN	0	NaN
Male	732	732	46.2%	0	NaN	0	NaN	0	NaN
talazoparib	**2,447**	**2,431**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	2,331	2,315	95.2%	*****	*****	*****	*****	0	NaN
Male	116	116	4.8%	0	0.0%	0	0.0%	0	NaN
baloxavir marboxil	**116,976**	**116,902**	**100.0%**	**49**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	63,777	63,741	54.5%	23	46.9%	*****	*****	*****	*****
Male	53,199	53,161	45.5%	26	53.1%	*****	*****	*****	*****
lorlatinib	**9,251**	**9,165**	**100.0%**	*****	*****	*****	**100.0%**	*****	**100.0%**
Female	4,964	4,918	53.7%	25	43.1%	21	77.8%	0	0.0%
Male	4,287	4,247	46.3%	*****	*****	*****	*****	*****	*****
revefenacin	**37,270**	**36,367**	**100.0%**	*****	**100.0%**	**768**	**100.0%**	*****	**100.0%**
Female	21,746	21,180	58.2%	*****	*****	492	64.1%	*****	*****
Male	15,524	15,187	41.8%	*****	*****	276	35.9%	*****	*****
rifamycin	**111**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	59	*****	*****	*****	*****	0	NaN	0	NaN
Male	52	*****	*****	*****	*****	0	NaN	0	NaN
emapalumab-lzsg	**517**	**517**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	395	395	76.4%	0	NaN	0	NaN	0	NaN
Male	122	122	23.6%	0	NaN	0	NaN	0	NaN
glasdegib	**760**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	321	321	42.3%	0	0.0%	0	NaN	0	NaN
Male	439	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	**2,000**	**1,949**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	1,012	982	50.4%	*****	*****	*****	*****	0	NaN
Male	988	967	49.6%	21	44.7%	0	0.0%	0	NaN
amifampridine	**7,716**	**7,478**	**100.0%**	**36**	**100.0%**	**202**	**100.0%**	**0**	**NaN**
Female	4,625	4,485	60.0%	25	69.4%	115	56.9%	0	NaN

cder_mpl1r_wp251

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	3,091	2,993	40.0%	11	30.6%	87	43.1%	0	NaN
gilteritinib	**9,808**	**9,691**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	4,880	4,806	49.6%	*****	*****	*****	*****	0	0.0%
Male	4,928	4,885	50.4%	32	33.3%	*****	*****	*****	*****
prucalopride	**184,840**	**157,658**	**100.0%**	*****	**100.0%**	**23,600**	**100.0%**	*****	**100.0%**
Female	144,942	123,426	78.3%	2,622	74.2%	18,851	79.9%	43	86.0%
Male	39,898	34,232	21.7%	*****	*****	4,749	20.1%	*****	*****
calaspargase pegol-mknl	**51**	**51**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	12	12	23.5%	0	NaN	0	NaN	0	NaN
Male	39	39	76.5%	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**1,132**	**1,132**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	185	185	16.3%	0	NaN	0	NaN	0	NaN
Male	947	947	83.7%	0	NaN	0	NaN	0	NaN
ravulizumab	**13,413**	**12,917**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	7,681	7,378	57.1%	*****	*****	*****	*****	*****	*****
Male	5,732	5,539	42.9%	*****	*****	*****	*****	*****	*****

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**12,446**	**1**	**1**	**1**	**1**	**30**	**1.3**	**2.6**
Female	5,465	1	1	1	1	30	1.4	3.3
Male	6,981	1	1	1	1	28	1.2	1.8
patisiran	**12,700**	**1**	**1**	**1**	**1**	**42**	**2.1**	**4.5**
Female	4,408	1	1	1	1	42	2.6	5.4
Male	8,292	1	1	1	1	28	1.8	3.9
ethinyl estradiol and segesterone acetate	**15,936**	**1**	**28**	**50**	**127**	**615**	**108.3**	**116.5**
Female	15,906	1	28	50	127	615	108.3	116.5
Male	30	1	30	90	170	365	131.6	122.6
migalastat	**3,089**	**1**	**28**	**28**	**28**	**168**	**28.0**	**7.0**
Female	1,544	1	28	28	28	84	28.1	6.9
Male	1,545	2	28	28	28	168	27.9	7.2
stiripentol	**4,710**	**1**	**24**	**30**	**30**	**180**	**29.5**	**12.6**
Female	2,699	1	24	30	30	144	28.9	11.1
Male	2,011	1	24	30	30	180	30.3	14.3
cenegermin-bkbj	**27,321**	**1**	**14**	**14**	**14**	**34**	**12.6**	**3.3**
Female	17,574	1	14	14	14	30	12.6	3.3
Male	9,747	1	14	14	14	34	12.5	3.2
lanadelumab	**17,975**	**1**	**28**	**28**	**28**	**84**	**27.0**	**5.6**
Female	12,404	1	28	28	28	84	27.0	5.1
Male	5,571	1	28	28	28	84	27.1	6.6
eravacycline	**7,109**	**1**	**1**	**1**	**1**	**41**	**1.7**	**1.9**
Female	3,601	1	1	1	1	41	1.6	1.9
Male	3,508	1	1	1	1	26	1.8	2.0
doravirine	**65,449**	**1**	**30**	**30**	**30**	**210**	**30.4**	**10.5**
Female	13,743	1	30	30	30	180	29.7	9.1
Male	51,706	1	30	30	30	210	30.6	10.8
doravirine/lamivudine/tenofovir disoproxil fumarate	**9,742**	**1**	**30**	**30**	**30**	**180**	**30.6**	**10.0**
Female	2,633	2	30	30	30	180	30.0	8.8
Male	7,109	1	30	30	30	180	30.8	10.4

cder_mpl1r_wp251

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
moxetumomab pasudotox-tdfk	**421**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.9**
Female	66	1	1	1	1	1	1.0	0.0
Male	355	1	1	1	1	28	1.2	2.0
fremanezumab-vfrm	**444,324**	**1**	**30**	**30**	**30**	**360**	**33.6**	**16.8**
Female	383,821	1	30	30	30	360	33.6	16.7
Male	60,503	1	30	30	30	174	33.9	17.1
duvelisib	**3,006**	**1**	**28**	**28**	**28**	**84**	**27.5**	**3.9**
Female	1,339	1	28	28	28	84	27.6	4.2
Male	1,667	1	28	28	28	56	27.4	3.7
galcanezumab-gnlm	**1,201,355**	**1**	**28**	**30**	**30**	**651**	**31.0**	**12.4**
Female	1,022,838	1	28	30	30	651	31.0	12.4
Male	178,517	1	28	30	30	360	31.1	12.6
dacomitinib	**429**	**1**	**30**	**30**	**30**	**90**	**29.1**	**5.5**
Female	254	1	30	30	30	30	29.2	3.8
Male	175	2	30	30	30	90	28.9	7.2
cemiplimab-rwlc	**61,923**	**1**	**1**	**1**	**1**	**21**	**1.2**	**1.8**
Female	15,112	1	1	1	1	21	1.2	2.2
Male	46,811	1	1	1	1	21	1.1	1.7
sarecycline	**44,895**	**1**	**30**	**30**	**30**	**180**	**29.9**	**5.8**
Female	27,315	1	30	30	30	150	29.9	5.6
Male	17,580	1	30	30	30	180	29.9	6.1
omadacycline	**21,814**	**1**	**1**	**1**	**14**	**90**	**7.9**	**11.4**
Female	11,127	1	1	1	14	90	8.6	12.0
Male	10,687	1	1	1	12	90	7.1	10.7
elapegademase-lvlr	**596**	**2**	**28**	**28**	**28**	**56**	**27.1**	**5.8**
Female	265	5	28	28	28	56	27.2	4.3
Male	331	2	28	28	28	56	27.1	6.8
inotersen	**1,584**	**2**	**28**	**28**	**28**	**30**	**27.8**	**2.2**
Female	852	2	28	28	28	30	27.7	2.2
Male	732	2	28	28	28	30	27.8	2.2

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
talazoparib	**2,447**	**1**	**30**	**30**	**30**	**90**	**28.2**	**5.7**
Female	2,331	1	30	30	30	90	28.2	5.7
Male	116	10	28	30	30	30	27.9	4.8
baloxavir marboxil	**116,976**	**1**	**1**	**1**	**1**	**180**	**2.1**	**5.6**
Female	63,777	1	1	1	1	120	2.2	5.7
Male	53,199	1	1	1	1	180	2.1	5.5
lorlatinib	**9,251**	**1**	**30**	**30**	**30**	**213**	**28.4**	**7.0**
Female	4,964	1	30	30	30	90	28.5	6.9
Male	4,287	1	30	30	30	213	28.2	7.3
revefenacin	**37,270**	**1**	**1**	**30**	**30**	**120**	**19.2**	**17.3**
Female	21,746	1	1	30	30	120	19.7	17.5
Male	15,524	1	1	30	30	120	18.5	17.0
rifamycin	**111**	**2**	**3**	**3**	**7**	**36**	**7.1**	**7.8**
Female	59	2	3	3	12	36	7.5	7.7
Male	52	2	3	3	6	31	6.8	8.0
emapalumab-lzsg	**517**	**1**	**1**	**1**	**1**	**7**	**1.3**	**1.1**
Female	395	1	1	1	1	7	1.1	0.5
Male	122	1	1	1	1	7	1.8	1.8
glasdegib	**760**	**1**	**28**	**30**	**30**	**32**	**27.2**	**6.1**
Female	321	4	28	30	30	30	27.2	6.0
Male	439	1	28	30	30	32	27.2	6.1
larotrectinib	**2,000**	**1**	**30**	**30**	**30**	**90**	**28.0**	**6.4**
Female	1,012	1	30	30	30	90	28.3	7.1
Male	988	1	30	30	30	60	27.8	5.7
amifampridine	**7,716**	**1**	**30**	**30**	**30**	**90**	**31.1**	**10.2**
Female	4,625	1	30	30	30	90	31.1	10.0
Male	3,091	1	30	30	30	90	31.1	10.6
gilteritinib	**9,808**	**1**	**30**	**30**	**30**	**149**	**27.6**	**8.4**
Female	4,880	1	30	30	30	90	27.7	8.2
Male	4,928	1	30	30	30	149	27.4	8.5

cder_mpl1r_wp251

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
prucalopride	**184,840**	**1**	**30**	**30**	**30**	**180**	**36.8**	**20.9**
Female	144,942	1	30	30	30	180	37.0	21.0
Male	39,898	1	30	30	30	120	36.1	20.5
calaspargase pegol-mknl	**51**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	12	1	1	1	1	1	1.0	0.0
Male	39	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	**1,132**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	185	1	1	1	1	1	1.0	0.0
Male	947	1	1	1	1	1	1.0	0.0
ravulizumab	**13,413**	**1**	**1**	**1**	**1**	**112**	**3.5**	**10.7**
Female	7,681	1	1	1	1	102	3.5	10.9
Male	5,732	1	1	1	1	112	3.4	10.6

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
mogamulizumab-kpkc	**12,446**	**12,446**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	19	19	0.2%	0	NaN	0	NaN	0	NaN
18-24 years	18	18	0.1%	0	NaN	0	NaN	0	NaN
25-40 years	291	291	2.3%	0	NaN	0	NaN	0	NaN
41-64 years	2,119	2,119	17.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	9,999	9,999	80.3%	0	NaN	0	NaN	0	NaN
patisiran	**12,700**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	119	119	0.9%	0	0.0%	0	NaN	0	NaN
41-64 years	2,109	2,109	16.6%	0	0.0%	0	NaN	0	NaN
≥ 65 years	10,472	*****	*****	*****	*****	0	NaN	0	NaN
ethinyl estradiol and segesterone acetate	**15,936**	**7,178**	**100.0%**	**1,027**	**100.0%**	**2,431**	**100.0%**	**5,300**	**100.0%**
0-17 years	*****	*****	*****	46	4.5%	108	4.4%	176	3.3%
18-24 years	5,043	2,113	29.4%	331	32.2%	767	31.6%	1,832	34.6%
25-40 years	8,791	4,075	56.8%	576	56.1%	1,333	54.8%	2,807	53.0%
41-64 years	1,507	725	10.1%	74	7.2%	223	9.2%	485	9.2%
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
migalastat	**3,089**	**3,061**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	181	181	5.9%	0	0.0%	0	0.0%	0	0.0%
25-40 years	643	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	1,417	1,406	45.9%	0	0.0%	*****	*****	*****	*****
≥ 65 years	848	*****	*****	*****	*****	*****	52.4%	0	0.0%
stiripentol	**4,710**	**4,330**	**100.0%**	**287**	**100.0%**	**79**	**100.0%**	**14**	**100.0%**
0-17 years	3,466	3,211	74.2%	198	69.0%	*****	*****	*****	*****
18-24 years	965	883	20.4%	60	20.9%	*****	*****	*****	*****
25-40 years	279	236	5.5%	29	10.1%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Number of Dispensings (1-30 Days)	Percent of Total Dispensings (1-30 Days)	Number of Dispensings (31-60 Days)	Percent of Total Dispensings (31-60 Days)	Number of Dispensings (61-90 Days)	Percent of Total Dispensings (61-90 Days)	Number of Dispensings (91+ Days)	Percent of Total Dispensings (91+ Days)
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	**27,321**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	228	228	0.8%	0	0.0%	0	NaN	0	NaN
18-24 years	126	126	0.5%	0	0.0%	0	NaN	0	NaN
25-40 years	1,123	1,123	4.1%	0	0.0%	0	NaN	0	NaN
41-64 years	5,505	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	20,339	20,339	74.5%	0	0.0%	0	NaN	0	NaN
lanadelumab	**17,975**	**17,863**	**100.0%**	**72**	**100.0%**	**40**	**100.0%**	**0**	**NaN**
0-17 years	1,322	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	1,228	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	3,770	3,749	21.0%	*****	*****	*****	*****	0	NaN
41-64 years	7,167	7,141	40.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	4,488	4,425	24.8%	35	48.6%	28	70.0%	0	NaN
eravacycline	**7,109**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	22	22	0.3%	0	0.0%	0	NaN	0	NaN
18-24 years	81	81	1.1%	0	0.0%	0	NaN	0	NaN
25-40 years	383	383	5.4%	0	0.0%	0	NaN	0	NaN
41-64 years	2,641	2,641	37.2%	0	0.0%	0	NaN	0	NaN
≥ 65 years	3,982	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**65,449**	**63,609**	**100.0%**	**274**	**100.0%**	**1,553**	**100.0%**	**13**	**100.0%**
0-17 years	40	40	0.1%	0	0.0%	0	0.0%	0	0.0%
18-24 years	239	239	0.4%	0	0.0%	0	0.0%	0	0.0%
25-40 years	5,364	5,181	8.1%	*****	*****	136	8.8%	*****	*****
41-64 years	42,935	41,841	65.8%	*****	*****	894	57.6%	*****	*****
≥ 65 years	16,871	16,308	25.6%	*****	*****	523	33.7%	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Dispensings by Days Supplied							
		1-30 Days		**31-60 Days**		**61-90 Days**		**91+ Days**	
	Total Number of Dispensings	**Number of Dispensings**	**Percent of Total Dispensings**	**Number of Dispensings**	**Percent of Total Dispensings**	**Number of Dispensings**	**Percent of Total Dispensings**	**Number of Dispensings**	**Percent of Total Dispensings**
doravirine/lamivudine/tenofovir disoproxil fumarate	**9,742**	**9,467**	**100.0%**	*****	**100.0%**	**198**	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	205	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,703	1,621	17.1%	*****	*****	56	28.3%	*****	*****
41-64 years	6,434	6,271	66.2%	*****	*****	116	58.6%	*****	*****
≥ 65 years	1,400	*****	*****	*****	*****	26	13.1%	0	0.0%
moxetumomab pasudotox-tdfk	**421**	**421**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	306	306	72.7%	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**444,324**	**404,544**	**100.0%**	**4,950**	**100.0%**	**34,728**	**100.0%**	**102**	**100.0%**
0-17 years	2,016	1,849	0.5%	*****	*****	148	0.4%	*****	*****
18-24 years	22,342	20,489	5.1%	*****	*****	1,595	4.6%	*****	*****
25-40 years	112,568	103,901	25.7%	*****	*****	7,506	21.6%	*****	*****
41-64 years	250,442	228,289	56.4%	2,856	57.7%	19,246	55.4%	51	50.0%
≥ 65 years	56,956	50,016	12.4%	694	14.0%	6,233	17.9%	13	12.7%
duvelisib	**3,006**	**2,989**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	435	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	2,539	2,525	84.5%	*****	*****	*****	*****	0	NaN
galcanezumab-gnlm	**1,201,355**	**1,145,569**	**100.0%**	**10,361**	**100.0%**	**45,259**	**100.0%**	**166**	**100.0%**
0-17 years	5,068	4,848	0.4%	*****	*****	152	0.3%	*****	*****
18-24 years	61,892	60,128	5.2%	*****	*****	1,304	2.9%	*****	*****

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Total Number of Dispensings | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	316,369	305,547	26.7%	2,545	24.6%	8,244	18.2%	33	19.9%
41-64 years	667,679	636,408	55.6%	5,637	54.4%	25,548	56.4%	86	51.8%
≥ 65 years	150,347	138,638	12.1%	1,663	16.1%	10,011	22.1%	35	21.1%
dacomitinib	**429**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	115	115	26.9%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	314	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**61,923**	**61,923**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	5,134	5,134	8.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	56,563	56,563	91.3%	0	NaN	0	NaN	0	NaN
sarecycline	**44,895**	*****	*****	*****	**100.0%**	**256**	**100.0%**	*****	**100.0%**
0-17 years	21,025	20,902	46.9%	*****	*****	77	30.1%	*****	*****
18-24 years	11,878	11,758	26.4%	*****	*****	89	34.8%	*****	*****
25-40 years	7,440	7,397	16.6%	11	11.6%	32	12.5%	0	0.0%
41-64 years	4,203	4,143	9.3%	11	11.6%	49	19.1%	0	0.0%
≥ 65 years	349	*****	*****	*****	*****	*****	*****	0	0.0%
omadacycline	**21,814**	**21,663**	**100.0%**	**62**	**100.0%**	**89**	**100.0%**	**0**	**NaN**
0-17 years	201	*****	*****	0	0.0%	*****	*****	0	NaN
18-24 years	681	681	3.1%	0	0.0%	0	0.0%	0	NaN
25-40 years	1,172	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	7,774	7,723	35.7%	*****	*****	*****	*****	0	NaN

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	11,986	11,898	54.9%	34	54.8%	54	60.7%	0	NaN
elapegademase-lvlr	**596**	**585**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	231	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	165	165	28.2%	0	0.0%	0	NaN	0	NaN
25-40 years	184	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	16	16	2.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
inotersen	**1,584**	**1,584**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	30	30	1.9%	0	NaN	0	NaN	0	NaN
41-64 years	274	274	17.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,280	1,280	80.8%	0	NaN	0	NaN	0	NaN
talazoparib	**2,447**	**2,431**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	283	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	1,299	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	833	833	34.3%	0	0.0%	0	0.0%	0	NaN
baloxavir marboxil	**116,976**	**116,902**	**100.0%**	**49**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	20,314	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	12,080	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	27,588	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	36,902	36,886	31.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	20,092	20,040	17.1%	38	77.6%	*****	*****	*****	*****
lorlatinib	**9,251**	**9,165**	**100.0%**	**58**	**100.0%**	*****	*****	*****	*****
0-17 years	245	225	2.5%	20	34.5%	0	0.0%	0	0.0%
18-24 years	90	*****	*****	*****	*****	*****	*****	0	0.0%

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	661	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	4,407	4,379	47.8%	14	24.1%	14	51.9%	0	0.0%
≥ 65 years	3,848	3,823	41.7%	*****	*****	*****	*****	0	0.0%
revefenacin	**37,270**	**36,367**	**100.0%**	*****	**100.0%**	**768**	**100.0%**	*****	*****
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	466	432	1.2%	*****	*****	*****	*****	0	0.0%
41-64 years	9,807	9,411	25.9%	*****	*****	333	43.4%	*****	*****
≥ 65 years	26,910	26,441	72.7%	*****	*****	401	52.2%	*****	*****
rifamycin	**111**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	62	62	56.9%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
emapalumab-lzsg	**517**	**517**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	385	385	74.5%	0	NaN	0	NaN	0	NaN
18-24 years	14	14	2.7%	0	NaN	0	NaN	0	NaN
25-40 years	55	55	10.6%	0	NaN	0	NaN	0	NaN
41-64 years	47	47	9.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	16	16	3.1%	0	NaN	0	NaN	0	NaN
glasdegib	**760**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	11	1.4%	0	0.0%	0	NaN	0	NaN
41-64 years	74	74	9.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	672	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	**2,000**	**1,949**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Total Number of Dispensings | Number of Dispensings by Days Supplied | | | | | | | |
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	442	405	20.8%	37	78.7%	0	0.0%	0	NaN
18-24 years	43	43	2.2%	0	0.0%	0	0.0%	0	NaN
25-40 years	128	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	631	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	756	*****	*****	*****	*****	*****	*****	0	NaN
amifampridine	**7,716**	**7,478**	**100.0%**	**36**	**100.0%**	**202**	**100.0%**	**0**	**NaN**
0-17 years	85	85	1.1%	0	0.0%	0	0.0%	0	NaN
18-24 years	146	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	466	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	2,178	2,113	28.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	4,841	4,686	62.7%	*****	*****	*****	*****	0	NaN
gilteritinib	**9,808**	**9,691**	**100.0%**	**96**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	136	136	1.4%	0	0.0%	0	0.0%	0	0.0%
18-24 years	212	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	628	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,694	2,669	27.5%	*****	*****	*****	*****	0	0.0%
≥ 65 years	6,138	6,050	62.4%	74	77.1%	*****	*****	0	0.0%
prucalopride	**184,840**	**157,658**	**100.0%**	**3,532**	**100.0%**	**23,600**	**100.0%**	**50**	**100.0%**
0-17 years	2,565	2,420	1.5%	*****	*****	103	0.4%	*****	*****
18-24 years	9,856	8,737	5.5%	*****	*****	947	4.0%	*****	*****
25-40 years	30,072	26,429	16.8%	*****	*****	3,047	12.9%	*****	*****
41-64 years	80,304	68,170	43.2%	1,525	43.2%	10,595	44.9%	14	28.0%
≥ 65 years	62,043	51,902	32.9%	1,213	34.3%	8,908	37.7%	20	40.0%
calaspargase pegol-mknl	**51**	**51**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**1,132**	**1,132**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	35	35	3.1%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	45	45	4.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,036	1,036	91.5%	0	NaN	0	NaN	0	NaN
ravulizumab	**13,413**	**12,917**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	855	840	6.5%	15	3.1%	0	0.0%	0	0.0%
18-24 years	618	596	4.6%	22	4.5%	0	0.0%	0	0.0%
25-40 years	2,730	2,601	20.1%	*****	*****	*****	*****	0	0.0%
41-64 years	3,977	3,830	29.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	5,233	5,050	39.1%	*****	*****	*****	*****	*****	*****

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**12,446**	**1**	**1**	**1**	**1**	**30**	**1.3**	**2.6**
0-17 years	19	1	1	1	1	1	1.0	0.0
18-24 years	18	1	1	1	1	1	1.0	0.0
25-40 years	291	1	1	1	1	28	1.5	3.5
41-64 years	2,119	1	1	1	1	30	1.6	3.8
≥ 65 years	9,999	1	1	1	1	30	1.2	2.2
patisiran	**12,700**	**1**	**1**	**1**	**1**	**42**	**2.1**	**4.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	119	1	1	1	21	21	8.9	9.7
41-64 years	2,109	1	1	1	1	28	2.9	5.8
≥ 65 years	10,472	1	1	1	1	42	1.8	3.9
ethinyl estradiol and segesterone acetate	**15,936**	**1**	**28**	**50**	**127**	**615**	**108.3**	**116.5**
0-17 years	*****	1	30	49	110	615	107.0	116.8
18-24 years	5,043	1	30	74	161	365	117.5	122.3
25-40 years	8,791	1	28	40	111	394	103.5	113.1
41-64 years	1,507	1	28	34	126	365	106.0	114.3
≥ 65 years	*****	27	27	27	27	27	27.0	NaN
migalastat	**3,089**	**1**	**28**	**28**	**28**	**168**	**28.0**	**7.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	181	4	28	28	28	28	27.4	3.1
25-40 years	643	2	28	28	28	84	27.9	5.7
41-64 years	1,417	1	28	28	28	168	28.0	7.8
≥ 65 years	848	2	28	28	28	84	28.3	7.1
stiripentol	**4,710**	**1**	**24**	**30**	**30**	**180**	**29.5**	**12.6**
0-17 years	3,466	1	24	30	30	144	29.3	11.2
18-24 years	965	1	24	30	30	136	29.4	12.4
25-40 years	279	4	20	30	30	180	32.6	24.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

cder_mpl1r_wp251

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
cenegermin-bkbj	**27,321**	**1**	**14**	**14**	**14**	**34**	**12.6**	**3.3**
0-17 years	228	2	7	14	14	21	11.6	3.5
18-24 years	126	1	7	14	14	28	11.2	4.7
25-40 years	1,123	1	7	14	14	30	11.4	3.5
41-64 years	5,505	1	7	14	14	34	12.2	3.5
≥ 65 years	20,339	1	14	14	14	30	12.7	3.2
lanadelumab	**17,975**	**1**	**28**	**28**	**28**	**84**	**27.0**	**5.6**
0-17 years	1,322	1	28	28	28	56	26.2	5.5
18-24 years	1,228	1	28	28	28	56	26.5	5.3
25-40 years	3,770	1	28	28	28	84	26.6	6.1
41-64 years	7,167	1	28	28	28	84	26.9	5.2
≥ 65 years	4,488	1	28	28	28	84	28.0	5.6
eravacycline	**7,109**	**1**	**1**	**1**	**1**	**41**	**1.7**	**1.9**
0-17 years	22	1	1	1	1	1	1.0	0.0
18-24 years	81	1	1	1	1	8	1.9	1.9
25-40 years	383	1	1	1	1	8	1.6	1.6
41-64 years	2,641	1	1	1	1	26	1.7	1.9
≥ 65 years	3,982	1	1	1	1	41	1.7	2.0
doravirine	**65,449**	**1**	**30**	**30**	**30**	**210**	**30.4**	**10.5**
0-17 years	40	9	30	30	30	30	28.8	4.5
18-24 years	239	4	30	30	30	30	28.9	4.4
25-40 years	5,364	1	30	30	30	180	30.7	11.3
41-64 years	42,935	1	30	30	30	210	30.4	9.8
≥ 65 years	16,871	1	30	30	30	120	30.5	11.8
fumarate	**9,742**	**1**	**30**	**30**	**30**	**180**	**30.6**	**10.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	205	1	30	30	30	60	28.8	5.6
25-40 years	1,703	1	30	30	30	180	31.3	12.5
41-64 years	6,434	1	30	30	30	180	30.4	9.5
≥ 65 years	1,400	1	30	30	30	90	30.4	9.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
moxetumomab pasudotox-tdfk	**421**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.2	2.6
≥ 65 years	306	1	1	1	1	28	1.1	1.5
fremanezumab-vfrm	**444,324**	**1**	**30**	**30**	**30**	**360**	**33.6**	**16.8**
0-17 years	2,016	1	28	30	30	117	33.0	16.7
18-24 years	22,342	1	30	30	30	360	33.1	16.5
25-40 years	112,568	1	30	30	30	360	32.8	15.7
41-64 years	250,442	1	30	30	30	210	33.6	16.6
≥ 65 years	56,956	1	30	30	30	270	35.6	19.3
duvelisib	**3,006**	**1**	**28**	**28**	**28**	**84**	**27.5**	**3.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	28	28	28	26.7	4.9
41-64 years	435	2	28	28	28	60	27.4	4.2
≥ 65 years	2,539	1	28	28	28	84	27.5	3.9
galcanezumab-gnlm	**1,201,355**	**1**	**28**	**30**	**30**	**651**	**31.0**	**12.4**
0-17 years	5,068	1	28	30	30	180	30.4	12.0
18-24 years	61,892	1	28	30	30	180	29.8	10.1
25-40 years	316,369	1	28	30	30	365	30.2	10.8
41-64 years	667,679	1	28	30	30	651	31.1	12.4
≥ 65 years	150,347	1	28	30	30	254	33.0	15.6
dacomitinib	**429**	**1**	**30**	**30**	**30**	**90**	**29.1**	**5.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	115	1	30	30	30	30	28.2	5.3
≥ 65 years	314	2	30	30	30	90	29.4	5.5

cder_mpl1r_wp251

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
cemiplimab-rwlc	**61,923**	**1**	**1**	**1**	**1**	**21**	**1.2**	**1.8**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	21	1.2	1.9
41-64 years	5,134	1	1	1	1	21	1.2	2.0
≥ 65 years	56,563	1	1	1	1	21	1.2	1.8
sarecycline	**44,895**	**1**	**30**	**30**	**30**	**180**	**29.9**	**5.8**
0-17 years	21,025	1	30	30	30	92	29.8	4.9
18-24 years	11,878	1	30	30	30	180	30.0	6.6
25-40 years	7,440	1	30	30	30	90	29.6	5.4
41-64 years	4,203	1	30	30	30	90	30.3	7.3
≥ 65 years	349	3	30	30	30	90	30.4	10.5
omadacycline	**21,814**	**1**	**1**	**1**	**14**	**90**	**7.9**	**11.4**
0-17 years	201	1	10	30	30	83	22.4	13.1
18-24 years	681	1	1	1	10	30	6.7	10.0
25-40 years	1,172	1	1	13	30	90	13.5	12.2
41-64 years	7,774	1	1	1	14	90	8.5	11.2
≥ 65 years	11,986	1	1	1	9	90	6.7	11.2
elapegademase-lvlr	**596**	**2**	**28**	**28**	**28**	**56**	**27.1**	**5.8**
0-17 years	231	3	28	28	28	56	28.4	5.2
18-24 years	165	2	28	28	28	28	25.1	6.2
25-40 years	184	4	28	28	28	56	27.4	5.8
41-64 years	16	3	28	28	30	30	27.1	6.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**1,584**	**2**	**28**	**28**	**28**	**30**	**27.8**	**2.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	30	2	28	28	28	28	26.9	4.8
41-64 years	274	2	28	28	28	30	27.6	3.1
≥ 65 years	1,280	4	28	28	28	30	27.8	1.8

cder_mpl1r_wp251

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
talazoparib	**2,447**	**1**	**30**	**30**	**30**	**90**	**28.2**	**5.7**
0-17 years	*****	11	30	30	42	42	30.9	9.5
18-24 years	*****	15	15	15	15	15	15.0	0.0
25-40 years	283	1	30	30	30	90	27.3	7.6
41-64 years	1,299	2	30	30	30	90	27.7	6.0
≥ 65 years	833	2	30	30	30	30	29.2	3.6
baloxavir marboxil	**116,976**	**1**	**1**	**1**	**1**	**180**	**2.1**	**5.6**
0-17 years	20,314	1	1	1	1	90	1.1	1.9
18-24 years	12,080	1	1	1	1	60	1.2	2.4
25-40 years	27,588	1	1	1	1	90	1.2	2.5
41-64 years	36,902	1	1	1	1	100	1.5	3.7
≥ 65 years	20,092	1	1	1	1	180	6.2	11.0
lorlatinib	**9,251**	**1**	**30**	**30**	**30**	**213**	**28.4**	**7.0**
0-17 years	245	1	30	30	30	60	30.2	10.2
18-24 years	90	2	30	30	30	90	29.8	9.0
25-40 years	661	1	30	30	30	213	28.1	10.7
41-64 years	4,407	1	30	30	30	90	27.6	7.3
≥ 65 years	3,848	1	30	30	30	90	29.2	5.4
revefenacin	**37,270**	**1**	**1**	**30**	**30**	**120**	**19.2**	**17.3**
0-17 years	*****	1	1	25	30	30	18.7	15.5
18-24 years	*****	1	30	30	30	90	29.8	15.7
25-40 years	466	1	30	30	30	90	29.5	18.6
41-64 years	9,807	1	14	30	30	120	24.8	17.3
≥ 65 years	26,910	1	1	23	30	120	16.9	16.7
rifamycin	**111**	**2**	**3**	**3**	**7**	**36**	**7.1**	**7.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	3	3	7	7	4.2	2.2
25-40 years	25	2	3	3	14	36	9.3	8.9
41-64 years	62	3	3	3	6	30	6.3	6.8
≥ 65 years	*****	3	3	3	6	30	8.1	10.0

cder_mpl1r_wp251

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	**517**	**1**	**1**	**1**	**1**	**7**	**1.3**	**1.1**
0-17 years	385	1	1	1	1	7	1.3	1.1
18-24 years	14	1	1	3	3	7	2.9	2.0
25-40 years	55	1	1	1	1	1	1.0	0.0
41-64 years	47	1	1	1	1	1	1.0	0.0
≥ 65 years	16	1	1	1	1	1	1.0	0.0
glasdegib	**760**	**1**	**28**	**30**	**30**	**32**	**27.2**	**6.1**
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	28	28	28	28	26.8	2.9
41-64 years	74	9	15	30	30	30	24.8	7.1
≥ 65 years	672	1	28	30	30	32	27.5	5.9
larotrectinib	**2,000**	**1**	**30**	**30**	**30**	**90**	**28.0**	**6.4**
0-17 years	442	1	20	28	30	60	25.6	7.0
18-24 years	43	5	30	30	30	30	29.1	4.1
25-40 years	128	5	30	30	30	60	28.8	6.1
41-64 years	631	1	30	30	30	60	28.2	5.7
≥ 65 years	756	1	30	30	30	90	29.1	6.4
amifampridine	**7,716**	**1**	**30**	**30**	**30**	**90**	**31.1**	**10.2**
0-17 years	85	2	30	30	30	30	28.9	4.4
18-24 years	146	4	30	30	30	90	30.4	7.9
25-40 years	466	2	30	30	30	90	30.9	10.8
41-64 years	2,178	1	30	30	30	90	31.0	10.3
≥ 65 years	4,841	1	30	30	30	90	31.2	10.3
gilteritinib	**9,808**	**1**	**30**	**30**	**30**	**149**	**27.6**	**8.4**
0-17 years	136	1	30	30	30	30	26.3	8.9
18-24 years	212	1	30	30	30	45	28.8	5.1
25-40 years	628	1	30	30	30	149	27.9	8.9
41-64 years	2,694	1	30	30	30	90	28.2	7.4
≥ 65 years	6,138	1	30	30	30	90	27.2	8.8

cder_mpl1r_wp251

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
prucalopride	**184,840**	**1**	**30**	**30**	**30**	**180**	**36.8**	**20.9**
0-17 years	2,565	1	30	30	30	120	31.2	13.4
18-24 years	9,856	1	30	30	30	180	34.8	18.6
25-40 years	30,072	1	30	30	30	180	35.2	19.0
41-64 years	80,304	1	30	30	30	180	37.1	21.0
≥ 65 years	62,043	1	30	30	30	180	37.8	22.0
calaspargase pegol-mknl	**51**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	**1,132**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	35	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	45	1	1	1	1	1	1.0	0.0
≥ 65 years	1,036	1	1	1	1	1	1.0	0.0
ravulizumab	**13,413**	**1**	**1**	**1**	**1**	**112**	**3.5**	**10.7**
0-17 years	855	1	1	1	1	56	3.4	9.0
18-24 years	618	1	1	1	1	56	3.4	10.4
25-40 years	2,730	1	1	1	1	90	3.9	11.7
41-64 years	3,977	1	1	1	1	102	3.4	10.8
≥ 65 years	5,233	1	1	1	1	112	3.3	10.4

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	816	708	86.8%	97	11.9%	*****	*****	*****	*****	*****	*****
patisiran	570	373	65.4%	160	28.1%	23	4.0%	*****	*****	*****	*****
ethinyl estradiol and segesterone acetate	12,072	4,158	34.4%	2,947	24.4%	4,208	34.9%	649	5.4%	110	0.9%
migalastat	170	*****	*****	21	12.4%	59	34.7%	*****	*****	49	28.8%
stiripentol	402	40	10.0%	49	12.2%	157	39.1%	119	29.6%	37	9.2%
cenegermin-bkbj	5,521	*****	*****	4,301	77.9%	700	12.7%	*****	*****	*****	*****
lanadelumab	1,109	99	8.9%	138	12.4%	385	34.7%	242	21.8%	245	22.1%
eravacycline	723	614	84.9%	98	13.6%	11	1.5%	0	0.0%	0	0.0%
doravirine	4,812	484	10.1%	647	13.4%	1,590	33.0%	1,140	23.7%	951	19.8%
doravirine/lamivudine/tenofovir disoproxil fumarate	995	138	13.9%	160	16.1%	414	41.6%	195	19.6%	88	8.8%
moxetumomab pasudotox-tdfk	49	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	59,590	9,410	15.8%	13,219	22.2%	23,745	39.8%	9,135	15.3%	4,081	6.8%
duvelisib	483	94	19.5%	144	29.8%	191	39.5%	40	8.3%	14	2.9%
galcanezumab-gnlm	145,444	22,901	15.7%	30,579	21.0%	58,025	39.9%	22,668	15.6%	11,271	7.7%
dacomitinib	70	*****	*****	21	30.0%	25	35.7%	*****	*****	*****	*****
cemiplimab-rwlc	6,645	6,262	94.2%	343	5.2%	*****	*****	*****	*****	*****	*****
sarecycline	14,322	4,685	32.7%	5,639	39.4%	3,716	25.9%	245	1.7%	37	0.3%
omadacycline	3,970	3,030	76.3%	524	13.2%	346	8.7%	*****	*****	*****	*****
elapegademase-lvlr	32	*****	*****	0	0.0%	*****	*****	15	46.9%	*****	*****
inotersen	115	*****	*****	*****	*****	42	36.5%	23	20.0%	21	18.3%
talazoparib	372	60	16.1%	102	27.4%	167	44.9%	31	8.3%	12	3.2%
baloxavir marboxil	110,106	109,769	99.7%	304	0.3%	*****	*****	*****	*****	0	0.0%
lorlatinib	1,055	195	18.5%	242	22.9%	388	36.8%	148	14.0%	82	7.8%
revefenacin	8,196	4,886	59.6%	1,392	17.0%	1,457	17.8%	345	4.2%	116	1.4%
rifamycin	68	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
emapalumab-lzsg	37	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
glasdegib	325	148	45.5%	120	36.9%	*****	*****	*****	*****	0	0.0%
larotrectinib	340	73	21.5%	108	31.8%	118	34.7%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
amifampridine	402	30	7.5%	46	11.4%	113	28.1%	63	15.7%	150	37.3%
gilteritinib	1,788	454	25.4%	513	28.7%	647	36.2%	137	7.7%	37	2.1%
prucalopride	33,124	9,318	28.1%	7,562	22.8%	10,429	31.5%	3,893	11.8%	1,922	5.8%
calaspargase pegol-mknl	32	32	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
tagraxofusp-erzs	88	76	86.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
ravulizumab	1,859	1,721	92.6%	36	1.9%	75	4.0%	15	0.8%	12	0.6%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	816	1	5	10	21	1,161	19.3	53.9
patisiran	570	1	8	19	42	1,056	45.6	108.8
ethinyl estradiol and segesterone acetate	12,072	1	30	86	200	1,125	143.0	160.5
migalastat	170	16	148	345	810	1,690	508.7	434.8
stiripentol	402	1	100	240	522	1,360	345.9	319.3
cenegermin-bkbj	5,521	1	56	56	56	991	62.1	38.4
lanadelumab	1,109	1	112	300	674	1,559	438.2	403.2
eravacycline	723	1	5	10	21	337	17.0	24.5
doravirine	4,812	1	105	299	621	1,702	413.9	376.9
doravirine/lamivudine/tenofovir disoproxil fumarate	995	2	79	210	408	1,488	299.2	297.2
moxetumomab pasudotox-tdfk	49	1	3	7	17	43	9.7	8.6
fremanezumab-vfrm	59,590	1	60	150	339	1,695	250.9	270.7
duvelisib	483	3	56	98	209	1,260	171.1	207.2
galcanezumab-gnlm	145,444	1	60	150	352	1,618	256.1	272.7
dacomitinib	70	1	44	90	240	1,196	178.2	215.4
cemiplimab-rwlc	6,645	1	3	6	13	756	10.8	24.2
sarecycline	14,322	1	30	60	120	1,260	93.6	94.1
omadacycline	3,970	1	10	14	30	1,323	43.2	89.9
elapegademase-lvlr	32	28	326	462	694	1,271	505.5	293.1
inotersen	115	28	88	224	588	1,372	382.4	357.7
talazoparib	372	6	60	120	240	1,297	185.3	189.4
baloxavir marboxil	110,106	1	1	1	1	400	2.3	6.5
lorlatinib	1,055	1	60	125	330	1,582	248.8	285.9
revefenacin	8,196	1	4	30	90	1,302	87.2	157.4
rifamycin	68	2	3	3	12	86	11.6	17.9

cder_mpl1r_wp251

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	37	1	2	8	28	91	17.6	22.1
glasdegib	325	1	28	47	84	420	63.6	61.7
larotrectinib	340	1	47	90	200	1,251	164.9	197.4
amifampridine	402	6	120	404	1,133	1,516	593.4	501.1
gilteritinib	1,788	1	30	90	195	1,486	151.1	182.8
prucalopride	33,124	1	30	90	270	1,501	205.4	248.8
calaspargase pegol-mknl	32	1	1	1	2	3	1.6	0.7
tagraxofusp-erzs	88	1	1	5	16	106	12.9	18.7
ravulizumab	1,859	1	3	5	13	1,155	25.1	94.0

![Sentinel logo]

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	**816**	**708**	**100.0%**	**97**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	348	300	42.4%	*****	*****	*****	*****	*****	*****	*****	*****
Male	468	408	57.6%	*****	*****	*****	*****	*****	*****	0	0.0%
patisiran	**570**	**373**	**100.0%**	**160**	**100.0%**	**23**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	209	138	37.0%	54	33.8%	*****	*****	*****	*****	*****	*****
Male	361	235	63.0%	106	66.3%	*****	*****	*****	*****	*****	*****
ethinyl estradiol and segesterone acetate	**12,072**	**4,158**	**100.0%**	**2,947**	**100.0%**	**4,208**	**100.0%**	**649**	**100.0%**	**110**	**100.0%**
Female	12,043	*****	*****	*****	*****	4,193	99.6%	649	100.0%	110	100.0%
Male	29	*****	*****	*****	*****	15	0.4%	0	0.0%	0	0.0%
migalastat	**170**	*****	**100.0%**	*****	**100.0%**	**59**	**100.0%**	**34**	**100.0%**	**49**	**100.0%**
Female	86	*****	*****	*****	*****	26	44.1%	20	58.8%	25	51.0%
Male	84	*****	*****	*****	*****	33	55.9%	14	41.2%	24	49.0%
stiripentol	**402**	**40**	**100.0%**	**49**	**100.0%**	**157**	**100.0%**	**119**	**100.0%**	**37**	**100.0%**
Female	211	20	50.0%	24	49.0%	74	47.1%	70	58.8%	23	62.2%
Male	191	20	50.0%	25	51.0%	83	52.9%	49	41.2%	14	37.8%
cenegermin-bkbj	**5,521**	*****	**100.0%**	**4,301**	**100.0%**	**700**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	3,544	*****	*****	2,727	63.4%	466	66.6%	*****	*****	*****	*****
Male	1,977	*****	*****	1,574	36.6%	234	33.4%	*****	*****	0	0.0%
lanadelumab	**1,109**	**99**	**100.0%**	**138**	**100.0%**	**385**	**100.0%**	**242**	**100.0%**	**245**	**100.0%**
Female	754	70	70.7%	93	67.4%	248	64.4%	174	71.9%	169	69.0%
Male	355	29	29.3%	45	32.6%	137	35.6%	68	28.1%	76	31.0%
eravacycline	**723**	**614**	**100.0%**	**98**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**

cder_mpl1r_wp251

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	378	337	54.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	345	277	45.1%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**4,812**	**484**	**100.0%**	**647**	**100.0%**	**1,590**	**100.0%**	**1,140**	**100.0%**	**951**	**100.0%**
Female	1,176	145	30.0%	194	30.0%	397	25.0%	278	24.4%	162	17.0%
Male	3,636	339	70.0%	453	70.0%	1,193	75.0%	862	75.6%	789	83.0%
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**138**	**100.0%**	**160**	**100.0%**	**414**	**100.0%**	**195**	**100.0%**	**88**	**100.0%**
Female	311	59	42.8%	47	29.4%	131	31.6%	56	28.7%	18	20.5%
Male	684	79	57.2%	113	70.6%	283	68.4%	139	71.3%	70	79.5%
moxetumomab pasudotox-tdfk	**49**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**59,590**	**9,410**	**100.0%**	**13,219**	**100.0%**	**23,745**	**100.0%**	**9,135**	**100.0%**	**4,081**	**100.0%**
Female	51,464	8,044	85.5%	11,522	87.2%	20,497	86.3%	7,899	86.5%	3,502	85.8%
Male	8,126	1,366	14.5%	1,697	12.8%	3,248	13.7%	1,236	13.5%	579	14.2%
duvelisib	**483**	**94**	**100.0%**	**144**	**100.0%**	**191**	**100.0%**	**40**	**100.0%**	**14**	**100.0%**
Female	212	41	43.6%	62	43.1%	89	46.6%	*****	*****	*****	*****
Male	271	53	56.4%	82	56.9%	102	53.4%	*****	*****	*****	*****
galcanezumab-gnlm	**145,444**	**22,901**	**100.0%**	**30,579**	**100.0%**	**58,025**	**100.0%**	**22,668**	**100.0%**	**11,271**	**100.0%**
Female	123,311	19,097	83.4%	25,824	84.5%	49,513	85.3%	19,307	85.2%	9,570	84.9%
Male	22,133	3,804	16.6%	4,755	15.5%	8,512	14.7%	3,361	14.8%	1,701	15.1%
dacomitinib	**70**	**16**	**100.0%**	**21**	**100.0%**	**25**	**100.0%**	*****	**100.0%**	*****	**100.0%**

cder_mpl1r_wp251

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	44	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	26	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	**6,645**	**6,262**	**100.0%**	**343**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	1,786	1,700	27.1%	73	21.3%	*****	*****	*****	*****	*****	*****
Male	4,859	4,562	72.9%	270	78.7%	*****	*****	*****	*****	0	0.0%
sarecycline	**14,322**	**4,685**	**100.0%**	**5,639**	**100.0%**	**3,716**	**100.0%**	**245**	**100.0%**	**37**	**100.0%**
Female	8,946	3,046	65.0%	3,537	62.7%	2,190	58.9%	152	62.0%	21	56.8%
Male	5,376	1,639	35.0%	2,102	37.3%	1,526	41.1%	93	38.0%	16	43.2%
omadacycline	**3,970**	**3,030**	**100.0%**	**524**	**100.0%**	**346**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	2,059	1,539	50.8%	286	54.6%	191	55.2%	*****	*****	*****	*****
Male	1,911	1,491	49.2%	238	45.4%	155	44.8%	*****	*****	*****	*****
elapegademase-lvlr	**32**	*****	**100.0%**	**0**	**NaN**	*****	**100.0%**	**15**	**100.0%**	*****	**100.0%**
Female	14	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
Male	18	0	0.0%	0	NaN	*****	*****	*****	*****	*****	*****
inotersen	**115**	*****	**100.0%**	*****	**100.0%**	**42**	**100.0%**	**23**	**100.0%**	**21**	**100.0%**
Female	54	*****	*****	*****	*****	18	42.9%	*****	*****	*****	*****
Male	61	*****	*****	*****	*****	24	57.1%	*****	*****	*****	*****
talazoparib	**372**	**60**	**100.0%**	**102**	**100.0%**	**167**	**100.0%**	**31**	**100.0%**	**12**	**100.0%**
Female	344	*****	*****	*****	*****	156	93.4%	31	100.0%	12	100.0%
Male	28	*****	*****	*****	*****	11	6.6%	0	0.0%	0	0.0%
baloxavir marboxil	**110,106**	**109,769**	**100.0%**	**304**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	60,027	59,854	54.5%	157	51.6%	16	50.0%	0	0.0%	0	NaN

cder_mpl1r_wp251

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	50,079	49,915	45.5%	147	48.4%	*****	*****	*****	*****	0	NaN
lorlatinib	**1,055**	**195**	**100.0%**	**242**	**100.0%**	**388**	**100.0%**	**148**	**100.0%**	**82**	**100.0%**
Female	587	107	54.9%	143	59.1%	219	56.4%	75	50.7%	43	52.4%
Male	468	88	45.1%	99	40.9%	169	43.6%	73	49.3%	39	47.6%
revefenacin	**8,196**	**4,886**	**100.0%**	**1,392**	**100.0%**	**1,457**	**100.0%**	**345**	**100.0%**	**116**	**100.0%**
Female	4,743	2,786	57.0%	802	57.6%	875	60.1%	209	60.6%	71	61.2%
Male	3,453	2,100	43.0%	590	42.4%	582	39.9%	136	39.4%	45	38.8%
rifamycin	**68**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	39	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	29	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**37**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	17	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
glasdegib	**325**	**148**	**100.0%**	**120**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	139	63	42.6%	53	44.2%	*****	*****	*****	*****	0	NaN
Male	186	85	57.4%	67	55.8%	*****	*****	*****	*****	0	NaN
larotrectinib	**340**	**73**	**100.0%**	**108**	**100.0%**	**118**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	200	44	60.3%	69	63.9%	73	61.9%	*****	*****	*****	*****
Male	140	29	39.7%	39	36.1%	45	38.1%	*****	*****	*****	*****
amifampridine	**402**	**30**	**100.0%**	**46**	**100.0%**	**113**	**100.0%**	**63**	**100.0%**	**150**	**100.0%**
Female	226	15	50.0%	27	58.7%	52	46.0%	39	61.9%	93	62.0%
Male	176	15	50.0%	19	41.3%	61	54.0%	24	38.1%	57	38.0%

cder_mpl1r_wp251

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
gilteritinib	**1,788**	**454**	**100.0%**	**513**	**100.0%**	**647**	**100.0%**	**137**	**100.0%**	**37**	**100.0%**
Female	860	209	46.0%	257	50.1%	302	46.7%	73	53.3%	19	51.4%
Male	928	245	54.0%	256	49.9%	345	53.3%	64	46.7%	18	48.6%
prucalopride	**33,124**	**9,318**	**100.0%**	**7,562**	**100.0%**	**10,429**	**100.0%**	**3,893**	**100.0%**	**1,922**	**100.0%**
Female	26,134	7,312	78.5%	5,975	79.0%	8,250	79.1%	3,099	79.6%	1,498	77.9%
Male	6,990	2,006	21.5%	1,587	21.0%	2,179	20.9%	794	20.4%	424	22.1%
calaspargase pegol-mknl	**32**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	11	11	34.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	21	21	65.6%	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**88**	**76**	**100.0%**	*********	**100.0%**	*********	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	13	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	75	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
ravulizumab	**1,859**	**1,721**	**100.0%**	**36**	**100.0%**	**75**	**100.0%**	**15**	**100.0%**	**12**	**100.0%**
Female	1,002	926	53.8%	19	52.8%	41	54.7%	*****	*****	*****	*****
Male	857	795	46.2%	17	47.2%	34	45.3%	*****	*****	*****	*****

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**816**	**1**	**5**	**10**	**21**	**1,161**	**19.3**	**53.9**
Female	348	1	5	11	22	1,161	22.0	72.6
Male	468	1	5	9	19	608	17.2	33.9
patisiran	**570**	**1**	**8**	**19**	**42**	**1,056**	**45.6**	**108.8**
Female	209	1	8	19	42	1,056	53.7	132.9
Male	361	1	8	19	41	976	40.9	91.8
ethinyl estradiol and segesterone acetate	**12,072**	**1**	**30**	**86**	**200**	**1,125**	**143.0**	**160.5**
Female	12,043	1	30	86	200	1,125	143.0	160.5
Male	29	1	32	93	170	365	136.1	122.9
migalastat	**170**	**16**	**148**	**345**	**810**	**1,690**	**508.7**	**434.8**
Female	86	20	148	389	824	1,528	504.2	406.2
Male	84	16	146	301	794	1,690	513.3	464.7
stiripentol	**402**	**1**	**100**	**240**	**522**	**1,360**	**345.9**	**319.3**
Female	211	1	110	285	539	1,352	370.1	330.3
Male	191	3	93	220	510	1,360	319.1	305.3
cenegermin-bkbj	**5,521**	**1**	**56**	**56**	**56**	**991**	**62.1**	**38.4**
Female	3,544	1	56	56	56	991	62.4	40.2
Male	1,977	2	56	56	56	658	61.7	34.8
lanadelumab	**1,109**	**1**	**112**	**300**	**674**	**1,559**	**438.2**	**403.2**
Female	754	1	112	308	678	1,559	444.5	405.1
Male	355	1	113	280	632	1,535	424.8	399.5
eravacycline	**723**	**1**	**5**	**10**	**21**	**337**	**17.0**	**24.5**
Female	378	1	4	9	19	337	15.6	26.5
Male	345	1	5	11	24	183	18.4	22.1
doravirine	**4,812**	**1**	**105**	**299**	**621**	**1,702**	**413.9**	**376.9**

cder_mpl1r_wp251

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	1,176	1	82	240	518	1,533	347.5	332.0
Male	3,636	1	120	315	660	1,702	435.4	388.0
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**2**	**79**	**210**	**408**	**1,488**	**299.2**	**297.2**
Female	311	6	60	180	360	1,408	254.2	260.2
Male	684	2	90	240	420	1,488	319.6	310.6
moxetumomab pasudotox-tdfk	**49**	**1**	**3**	**7**	**17**	**43**	**9.7**	**8.6**
Female	*****	1	9	12	15	18	11.0	6.0
Male	*****	1	3	6	17	43	9.5	9.0
fremanezumab-vfrm	**59,590**	**1**	**60**	**150**	**339**	**1,695**	**250.9**	**270.7**
Female	51,464	1	60	150	339	1,695	250.6	270.2
Male	8,126	1	60	150	336	1,574	252.3	274.0
duvelisib	**483**	**3**	**56**	**98**	**209**	**1,260**	**171.1**	**207.2**
Female	212	3	56	102	196	1,260	174.5	228.7
Male	271	5	56	97	224	1,152	168.4	189.1
galcanezumab-gnlm	**145,444**	**1**	**60**	**150**	**352**	**1,618**	**256.1**	**272.7**
Female	123,311	1	60	150	353	1,618	257.0	272.7
Male	22,133	1	60	148	344	1,604	250.9	272.6
dacomitinib	**70**	**1**	**44**	**90**	**240**	**1,196**	**178.2**	**215.4**
Female	44	1	49	90	240	796	168.6	178.3
Male	26	2	34	86	270	1,196	194.6	270.1
cemiplimab-rwlc	**6,645**	**1**	**3**	**6**	**13**	**756**	**10.8**	**24.2**
Female	1,786	1	2	6	11	756	10.5	31.0
Male	4,859	1	3	6	13	575	11.0	21.2
sarecycline	**14,322**	**1**	**30**	**60**	**120**	**1,260**	**93.6**	**94.1**

cder_mpl1r_wp251

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	8,946	1	30	60	120	1,170	91.1	92.6
Male	5,376	1	30	60	120	1,260	97.7	96.5
omadacycline	**3,970**	**1**	**10**	**14**	**30**	**1,323**	**43.2**	**89.9**
Female	2,059	1	10	14	32	1,323	46.4	94.3
Male	1,911	1	9	14	29	1,096	39.7	84.7
elapegademase-lvlr	**32**	**28**	**326**	**462**	**694**	**1,271**	**505.5**	**293.1**
Female	14	28	343	482	666	1,141	515.4	305.0
Male	18	106	308	430	722	1,271	497.8	292.3
inotersen	**115**	**28**	**88**	**224**	**588**	**1,372**	**382.4**	**357.7**
Female	54	28	112	337	700	1,372	437.7	385.0
Male	61	28	84	196	482	1,308	333.5	327.1
talazoparib	**372**	**6**	**60**	**120**	**240**	**1,297**	**185.3**	**189.4**
Female	344	6	60	120	244	1,297	191.0	194.0
Male	28	10	43	68	180	330	115.7	95.6
baloxavir marboxil	**110,106**	**1**	**1**	**1**	**1**	**400**	**2.3**	**6.5**
Female	60,027	1	1	1	1	270	2.3	6.4
Male	50,079	1	1	1	1	400	2.2	6.7
lorlatinib	**1,055**	**1**	**60**	**125**	**330**	**1,582**	**248.8**	**285.9**
Female	587	1	60	120	330	1,582	241.3	278.3
Male	468	1	60	137	359	1,461	258.2	295.2
revefenacin	**8,196**	**1**	**4**	**30**	**90**	**1,302**	**87.2**	**157.4**
Female	4,743	1	4	30	90	1,301	90.1	159.5
Male	3,453	1	3	30	90	1,302	83.1	154.5
rifamycin	**68**	**2**	**3**	**3**	**12**	**86**	**11.6**	**17.9**
Female	39	2	3	4	12	86	11.3	17.7

cder_mpl1r_wp251

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	29	2	3	3	12	81	12.1	18.5
emapalumab-lzsg	**37**	**1**	**2**	**8**	**28**	**91**	**17.6**	**22.1**
Female	20	1	2	13	35	91	21.6	24.5
Male	17	1	2	6	13	72	12.9	18.5
glasdegib	**325**	**1**	**28**	**47**	**84**	**420**	**63.6**	**61.7**
Female	139	4	30	45	90	420	62.9	57.9
Male	186	1	28	48	82	390	64.2	64.5
larotrectinib	**340**	**1**	**47**	**90**	**200**	**1,251**	**164.9**	**197.4**
Female	200	1	43	90	157	1,046	143.0	169.9
Male	140	5	55	104	240	1,251	196.2	228.0
amifampridine	**402**	**6**	**120**	**404**	**1,133**	**1,516**	**593.4**	**501.1**
Female	226	6	139	508	1,146	1,516	631.5	499.9
Male	176	8	119	299	1,018	1,446	544.6	499.8
gilteritinib	**1,788**	**1**	**30**	**90**	**195**	**1,486**	**151.1**	**182.8**
Female	860	1	31	90	202	1,455	156.9	190.1
Male	928	1	30	90	186	1,486	145.6	175.8
prucalopride	**33,124**	**1**	**30**	**90**	**270**	**1,501**	**205.4**	**248.8**
Female	26,134	1	30	90	270	1,501	205.3	248.1
Male	6,990	1	30	90	270	1,389	205.9	251.6
calaspargase pegol-mknl	**32**	**1**	**1**	**1**	**2**	**3**	**1.6**	**0.7**
Female	11	1	1	1	1	2	1.1	0.3
Male	21	1	1	2	2	3	1.9	0.7
tagraxofusp-erzs	**88**	**1**	**1**	**5**	**16**	**106**	**12.9**	**18.7**
Female	13	1	1	5	6	65	14.2	23.3
Male	75	1	1	5	16	106	12.6	18.0

cder_mpl1r_wp251

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	**1,859**	**1**	**3**	**5**	**13**	**1,155**	**25.1**	**94.0**
Female	1,002	1	3	6	14	1,155	26.9	99.4
Male	857	1	3	5	12	971	23.0	87.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	816	708	100.0%	97	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
41-64 years	171	151	21.3%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	616	529	74.7%	*****	*****	*****	*****	*****	*****	*****	*****
patisiran	570	373	100.0%	160	100.0%	23	100.0%	*****	100.0%	*****	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	12	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
41-64 years	122	*****	*****	21	13.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	436	273	73.2%	139	86.9%	*****	*****	*****	*****	*****	*****
ethinyl estradiol and segesterone acetate	12,072	4,158	100.0%	2,947	100.0%	4,208	100.0%	649	100.0%	110	100.0%
0-17 years	*****	*****	*****	107	3.6%	154	3.7%	25	3.9%	*****	*****
18-24 years	3,833	1,233	29.7%	906	30.7%	1,423	33.8%	239	36.8%	32	29.1%
25-40 years	6,682	2,370	57.0%	1,665	56.5%	2,265	53.8%	325	50.1%	57	51.8%
41-64 years	1,107	395	9.5%	269	9.1%	366	8.7%	60	9.2%	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
migalastat	170	*****	100.0%	*****	100.0%	59	100.0%	34	100.0%	49	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	44	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	74	*****	*****	*****	*****	26	44.1%	15	44.1%	24	49.0%
≥ 65 years	40	*****	*****	*****	*****	13	22.0%	*****	*****	14	28.6%
stiripentol	**402**	**40**	**100.0%**	**49**	**100.0%**	**157**	**100.0%**	**119**	**100.0%**	**37**	**100.0%**
0-17 years	303	*****	*****	*****	*****	123	78.3%	84	70.6%	*****	*****
18-24 years	79	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	20	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	**5,521**	*****	**100.0%**	**4,301**	**100.0%**	**700**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	43	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	27	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	199	23	4.5%	140	3.3%	36	5.1%	0	0.0%	0	0.0%
41-64 years	1,025	*****	*****	733	17.0%	178	25.4%	*****	*****	0	0.0%
≥ 65 years	4,227	*****	*****	3,382	78.6%	474	67.7%	*****	*****	*****	*****
lanadelumab	**1,109**	**99**	**100.0%**	**138**	**100.0%**	**385**	**100.0%**	**242**	**100.0%**	**245**	**100.0%**
0-17 years	102	*****	*****	15	10.9%	41	10.6%	31	12.8%	*****	*****
18-24 years	103	*****	*****	16	11.6%	47	12.2%	16	6.6%	*****	*****
25-40 years	303	29	29.3%	48	34.8%	130	33.8%	56	23.1%	40	16.3%
41-64 years	404	36	36.4%	47	34.1%	124	32.2%	93	38.4%	104	42.4%
≥ 65 years	197	15	15.2%	12	8.7%	43	11.2%	46	19.0%	81	33.1%
eravacycline	**723**	**614**	**100.0%**	**98**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	60	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	274	236	38.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	377	311	50.7%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**4,812**	**484**	**100.0%**	**647**	**100.0%**	**1,590**	**100.0%**	**1,140**	**100.0%**	**951**	**100.0%**
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	601	*****	*****	*****	*****	233	14.7%	*****	*****	*****	*****
41-64 years	3,111	296	61.2%	405	62.6%	1,035	65.1%	748	65.6%	627	65.9%
≥ 65 years	1,061	98	20.2%	119	18.4%	304	19.1%	254	22.3%	286	30.1%
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**138**	**100.0%**	**160**	**100.0%**	**414**	**100.0%**	**195**	**100.0%**	**88**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	27	*****	*****	*****	*****	14	3.4%	*****	*****	0	0.0%
25-40 years	241	*****	*****	*****	*****	112	27.1%	*****	*****	*****	*****
41-64 years	616	80	58.0%	91	56.9%	254	61.4%	129	66.2%	62	70.5%
≥ 65 years	111	*****	7.2%	20	12.5%	34	8.2%	29	14.9%	*****	*****
moxetumomab pasudotox-tdfk	**49**	*********	**100.0%**	*********	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**59,590**	**9,410**	**100.0%**	**13,219**	**100.0%**	**23,745**	**100.0%**	**9,135**	**100.0%**	**4,081**	**100.0%**
0-17 years	338	56	0.6%	91	0.7%	137	0.6%	43	0.5%	11	0.3%
18-24 years	3,605	616	6.5%	919	7.0%	1,466	6.2%	472	5.2%	132	3.2%
25-40 years	16,253	2,698	28.7%	3,852	29.1%	6,564	27.6%	2,320	25.4%	819	20.1%
41-64 years	31,745	4,677	49.7%	6,760	51.1%	12,689	53.4%	5,149	56.4%	2,470	60.5%
≥ 65 years	7,649	1,363	14.5%	1,597	12.1%	2,889	12.2%	1,151	12.6%	649	15.9%
duvelisib	**483**	**94**	**100.0%**	**144**	**100.0%**	**191**	**100.0%**	**40**	**100.0%**	**14**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	90	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	381	76	80.9%	104	72.2%	152	79.6%	*****	*****	*****	*****
galcanezumab-gnlm	**145,444**	**22,901**	**100.0%**	**30,579**	**100.0%**	**58,025**	**100.0%**	**22,668**	**100.0%**	**11,271**	**100.0%**
0-17 years	720	103	0.4%	189	0.6%	318	0.5%	77	0.3%	33	0.3%
18-24 years	8,573	1,496	6.5%	1,993	6.5%	3,550	6.1%	1,128	5.0%	406	3.6%
25-40 years	41,582	6,726	29.4%	9,425	30.8%	17,252	29.7%	5,857	25.8%	2,322	20.6%
41-64 years	75,850	11,309	49.4%	15,074	49.3%	29,964	51.6%	12,736	56.2%	6,767	60.0%
≥ 65 years	18,719	3,267	14.3%	3,898	12.7%	6,941	12.0%	2,870	12.7%	1,743	15.5%
dacomitinib	**70**	**16**	**100.0%**	**21**	**100.0%**	**25**	**100.0%**	**6**	**100.0%**	**2**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	20	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	50	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	**6,645**	**6,262**	**100.0%**	**343**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	556	523	8.4%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	6,060	5,712	91.2%	312	91.0%	*****	*****	*****	*****	*****	*****
sarecycline	**14,322**	**4,685**	**100.0%**	**5,639**	**100.0%**	**3,716**	**100.0%**	**245**	**100.0%**	**37**	**100.0%**
0-17 years	6,312	1,738	37.1%	2,609	46.3%	1,839	49.5%	*****	*****	*****	*****
18-24 years	3,945	1,361	29.1%	1,525	27.0%	991	26.7%	55	22.4%	13	35.1%
25-40 years	2,704	1,060	22.6%	1,027	18.2%	582	15.7%	*****	*****	*****	*****
41-64 years	1,258	480	10.2%	442	7.8%	287	7.7%	*****	*****	*****	*****
≥ 65 years	103	46	1.0%	36	0.6%	*****	*****	*****	*****	*****	*****
omadacycline	**3,970**	**3,030**	**100.0%**	**524**	**100.0%**	**346**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	31	13	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	75	51	1.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	319	237	7.8%	42	8.0%	*****	*****	*****	*****	0	0.0%
41-64 years	1,610	1,247	41.2%	212	40.5%	124	35.8%	*****	*****	*****	*****
≥ 65 years	1,935	1,482	48.9%	254	48.5%	168	48.6%	31	49.2%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
elapegademase-lvlr	**32**	*****	**100.0%**	**0**	**NaN**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	13	0	0.0%	0	NaN	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	0	NaN	*****	*****	*****	*****	*****	*****
25-40 years	*****	0	0.0%	0	NaN	*****	*****	*****	*****	*****	*****
41-64 years	*****	0	0.0%	0	NaN	0	0.0%	*****	*****	0	0.0%
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	0.0%	0	0.0%
inotersen	**115**	*****	**100.0%**	*****	**100.0%**	**42**	**100.0%**	**23**	**100.0%**	**21**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	88	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
talazoparib	**372**	**60**	**100.0%**	**102**	**100.0%**	**167**	**100.0%**	**31**	**100.0%**	**12**	**100.0%**
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	24	14.4%	*****	*****	*****	*****
41-64 years	190	31	51.7%	43	42.2%	93	55.7%	*****	*****	*****	*****
≥ 65 years	133	22	36.7%	45	44.1%	50	29.9%	*****	*****	*****	*****
baloxavir marboxil	**110,106**	**109,769**	**100.0%**	**304**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	19,064	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	11,454	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	26,040	26,024	23.7%	16	5.3%	0	0.0%	0	0.0%	0	NaN

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	34,588	34,532	31.5%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	18,960	18,713	17.0%	223	73.4%	*****	*****	*****	*****	0	NaN
lorlatinib	**1,055**	**195**	**100.0%**	**242**	**100.0%**	**388**	**100.0%**	**148**	**100.0%**	**82**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	80	*****	*****	20	8.3%	30	7.7%	*****	*****	*****	*****
41-64 years	448	59	30.3%	104	43.0%	172	44.3%	73	49.3%	*****	*****
≥ 65 years	475	116	59.5%	102	42.1%	165	42.5%	55	37.2%	37	45.1%
revefenacin	**8,196**	**4,886**	**100.0%**	**1,392**	**100.0%**	**1,457**	**100.0%**	**345**	**100.0%**	**116**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	111	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,438	1,255	25.7%	476	34.2%	562	38.6%	*****	*****	*****	*****
≥ 65 years	5,627	3,571	73.1%	892	64.1%	860	59.0%	223	64.6%	81	69.8%
rifamycin	**68**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	33	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	15	15	23.8%	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**37**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
glasdegib	**325**	**148**	**100.0%**	**120**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	286	128	86.5%	108	90.0%	*****	*****	*****	*****	0	NaN
larotrectinib	**340**	**73**	**100.0%**	**108**	**100.0%**	**118**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	48	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	101	23	31.5%	28	25.9%	38	32.2%	*****	*****	*****	*****
≥ 65 years	163	35	47.9%	64	59.3%	51	43.2%	*****	*****	*****	*****
amifampridine	**402**	**30**	**100.0%**	**46**	**100.0%**	**113**	**100.0%**	**63**	**100.0%**	**150**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	31	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	128	*****	*****	*****	*****	46	40.7%	17	27.0%	40	26.7%
≥ 65 years	223	13	43.3%	21	45.7%	55	48.7%	35	55.6%	99	66.0%

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Number of Patients (1-30 Days)	Percent of Total Patients (1-30 Days)	Number of Patients (31-90 Days)	Percent of Total Patients (31-90 Days)	Number of Patients (91-365 Days)	Percent of Total Patients (91-365 Days)	Number of Patients (366-730 Days)	Percent of Total Patients (366-730 Days)	Number of Patients (731+ Days)	Percent of Total Patients (731+ Days)
gilteritinib	**1,788**	**454**	**100.0%**	**513**	**100.0%**	**647**	**100.0%**	**137**	**100.0%**	**37**	**100.0%**
0-17 years	24	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	30	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	117	16	3.5%	41	8.0%	*****	*****	*****	*****	*****	*****
41-64 years	453	116	25.6%	129	25.1%	152	23.5%	43	31.4%	13	35.1%
≥ 65 years	1,164	304	67.0%	331	64.5%	428	66.2%	81	59.1%	20	54.1%
prucalopride	**33,124**	**9,318**	**100.0%**	**7,562**	**100.0%**	**10,429**	**100.0%**	**3,893**	**100.0%**	**1,922**	**100.0%**
0-17 years	440	118	1.3%	114	1.5%	139	1.3%	49	1.3%	20	1.0%
18-24 years	1,763	505	5.4%	402	5.3%	571	5.5%	209	5.4%	76	4.0%
25-40 years	5,304	1,440	15.5%	1,227	16.2%	1,765	16.9%	596	15.3%	276	14.4%
41-64 years	13,804	3,490	37.5%	3,156	41.7%	4,570	43.8%	1,733	44.5%	855	44.5%
≥ 65 years	11,813	3,765	40.4%	2,663	35.2%	3,384	32.4%	1,306	33.5%	695	36.2%
calaspargase pegol-mknl	**32**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**88**	**76**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Number of Patients (1-30 Days)	Percent of Total Patients (1-30 Days)	Number of Patients (31-90 Days)	Percent of Total Patients (31-90 Days)	Number of Patients (91-365 Days)	Percent of Total Patients (91-365 Days)	Number of Patients (366-730 Days)	Percent of Total Patients (366-730 Days)	Number of Patients (731+ Days)	Percent of Total Patients (731+ Days)
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	71	60	78.9%	*****	*****	*****	*****	0	NaN	0	NaN
ravulizumab	**1,859**	**1,721**	**100.0%**	**36**	**100.0%**	**75**	**100.0%**	**15**	**100.0%**	**12**	**100.0%**
0-17 years	119	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	94	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
25-40 years	361	337	19.6%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	508	475	27.6%	*****	*****	18	24.0%	*****	*****	*****	*****
≥ 65 years	777	711	41.3%	22	61.1%	*****	*****	*****	*****	*****	*****

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**816**	**1**	**5**	**10**	**21**	**1,161**	**19.3**	**53.9**
0-17 years	*****	5	5	10	14	14	9.5	6.4
18-24 years	*****	8	8	9	10	10	9.0	1.4
25-40 years	*****	1	4	9	12	199	17.0	38.5
41-64 years	171	1	4	9	16	628	19.2	53.6
≥ 65 years	616	1	6	10	22	1,161	19.4	54.8
patisiran	**570**	**1**	**8**	**19**	**42**	**1,056**	**45.6**	**108.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	1	3	7	19	723	88.3	213.3
41-64 years	122	1	5	13	31	985	49.5	128.5
≥ 65 years	436	1	10	21	42	1,056	43.4	98.4
ethinyl estradiol and segesterone acetate	**12,072**	**1**	**30**	**86**	**200**	**1,125**	**143.0**	**160.5**
0-17 years	*****	1	30	84	210	994	141.5	160.7
18-24 years	3,833	1	30	90	240	1,034	154.6	165.1
25-40 years	6,682	1	30	82	182	1,125	136.2	155.6
41-64 years	1,107	1	30	84	192	1,112	144.3	170.5
≥ 65 years	*****	27	27	27	27	27	27.0	NaN
migalastat	**170**	**16**	**148**	**345**	**810**	**1,690**	**508.7**	**434.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	67	167	382	655	1,008	413.3	288.8
25-40 years	44	16	84	243	603	1,515	407.8	423.0
41-64 years	74	20	151	389	862	1,548	535.4	453.7
≥ 65 years	40	28	274	480	914	1,690	599.1	435.0
stiripentol	**402**	**1**	**100**	**240**	**522**	**1,360**	**345.9**	**319.3**

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	303	1	100	240	516	1,360	335.2	315.1
18-24 years	79	3	131	270	535	1,330	358.9	312.1
25-40 years	20	15	85	403	649	1,306	455.4	397.9
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**5,521**	**1**	**56**	**56**	**56**	**991**	**62.1**	**38.4**
0-17 years	43	2	44	56	70	140	61.8	32.7
18-24 years	27	10	37	56	56	133	52.2	27.0
25-40 years	199	1	56	56	56	212	64.6	36.9
41-64 years	1,025	1	56	56	56	658	65.3	41.0
≥ 65 years	4,227	2	56	56	56	991	61.3	37.8
lanadelumab	**1,109**	**1**	**112**	**300**	**674**	**1,559**	**438.2**	**403.2**
0-17 years	102	2	112	271	504	1,441	339.9	288.9
18-24 years	103	1	84	223	423	1,456	316.1	326.1
25-40 years	303	1	85	210	448	1,559	330.6	333.1
41-64 years	404	1	127	351	760	1,552	477.6	423.0
≥ 65 years	197	5	224	602	1,002	1,535	637.6	455.9
eravacycline	**723**	**1**	**5**	**10**	**21**	**337**	**17.0**	**24.5**
0-17 years	*****	1	1	2	19	19	7.3	10.1
18-24 years	*****	1	2	8	27	59	17.0	19.3
25-40 years	60	1	3	7	14	39	10.5	9.8
41-64 years	274	1	4	10	21	152	16.6	21.9
≥ 65 years	377	1	5	10	23	337	18.3	27.8
doravirine	**4,812**	**1**	**105**	**299**	**621**	**1,702**	**413.9**	**376.9**
0-17 years	*****	279	279	282	590	590	383.7	178.7

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	10	48	162	240	720	191.7	183.1
25-40 years	601	4	63	183	412	1,462	273.6	263.2
41-64 years	3,111	1	112	300	626	1,702	419.5	377.8
≥ 65 years	1,061	1	125	383	759	1,541	484.7	409.4
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**2**	**79**	**210**	**408**	**1,488**	**299.2**	**297.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	27	10	31	209	337	689	218.6	178.2
25-40 years	241	2	60	162	330	1,301	221.2	217.4
41-64 years	616	5	90	223	424	1,488	317.9	312.2
≥ 65 years	111	20	90	247	560	1,474	384.0	344.1
moxetumomab pasudotox-tdfk	**49**	**1**	**3**	**7**	**17**	**43**	**9.7**	**8.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	2	3	3	2.0	1.4
41-64 years	*****	9	11	18	21	30	17.3	7.3
≥ 65 years	*****	1	3	6	14	43	8.5	8.2
fremanezumab-vfrm	**59,590**	**1**	**60**	**150**	**339**	**1,695**	**250.9**	**270.7**
0-17 years	338	1	60	118	244	1,217	196.7	213.1
18-24 years	3,605	1	60	120	276	1,518	205.2	214.6
25-40 years	16,253	1	60	140	302	1,633	227.5	246.3
41-64 years	31,745	1	61	168	360	1,695	265.1	281.5
≥ 65 years	7,649	1	60	151	360	1,569	265.3	293.8
duvelisib	**483**	**3**	**56**	**98**	**209**	**1,260**	**171.1**	**207.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	56	84	224	75.4	61.6
41-64 years	90	5	56	84	196	563	132.3	110.8
≥ 65 years	381	3	56	112	224	1,260	183.4	225.1
galcanezumab-gnlm	**145,444**	**1**	**60**	**150**	**352**	**1,618**	**256.1**	**272.7**
0-17 years	720	1	60	134	284	1,506	213.8	233.4
18-24 years	8,573	1	60	126	290	1,556	215.3	230.1
25-40 years	41,582	1	60	142	307	1,604	229.5	246.3
41-64 years	75,850	1	60	168	379	1,618	273.4	285.4
≥ 65 years	18,719	1	60	150	360	1,549	265.4	288.2
dacomitinib	**70**	**1**	**44**	**90**	**240**	**1,196**	**178.2**	**215.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	1	30	60	150	1,196	162.0	270.5
≥ 65 years	50	2	60	105	270	796	184.8	191.9
cemiplimab-rwlc	**6,645**	**1**	**3**	**6**	**13**	**756**	**10.8**	**24.2**
0-17 years	*****	3	3	3	3	3	3.0	NaN
18-24 years	*****	1	1	2	3	3	2.0	1.4
25-40 years	*****	1	3	6	14	42	10.0	10.8
41-64 years	556	1	3	6	12	529	11.0	26.2
≥ 65 years	6,060	1	3	6	13	756	10.8	24.1
sarecycline	**14,322**	**1**	**30**	**60**	**120**	**1,260**	**93.6**	**94.1**
0-17 years	6,312	1	30	71	120	943	99.3	90.1
18-24 years	3,945	1	30	60	120	1,260	90.3	93.5

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	2,704	1	30	60	90	885	81.5	81.8
41-64 years	1,258	5	30	60	120	1,002	101.1	122.8
≥ 65 years	103	3	30	60	90	1,130	103.0	183.0
omadacycline	**3,970**	**1**	**10**	**14**	**30**	**1,323**	**43.2**	**89.9**
0-17 years	31	1	10	60	270	653	145.1	165.9
18-24 years	75	1	9	14	56	372	61.0	95.4
25-40 years	319	1	10	14	36	714	49.4	98.7
41-64 years	1,610	1	10	14	30	1,323	41.0	93.7
≥ 65 years	1,935	1	8	14	30	714	41.7	81.9
elapegademase-lvlr	**32**	**28**	**326**	**462**	**694**	**1,271**	**505.5**	**293.1**
0-17 years	13	106	392	448	722	925	504.7	245.2
18-24 years	*****	28	173	420	627	752	413.8	256.6
25-40 years	*****	168	296	605	903	1,271	630.6	402.6
41-64 years	*****	433	433	433	433	433	433.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**115**	**28**	**88**	**224**	**588**	**1,372**	**382.4**	**357.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	338	338	404	470	470	404.0	93.3
41-64 years	*****	28	56	168	364	1,314	302.7	347.3
≥ 65 years	88	28	112	266	626	1,372	404.6	363.3
talazoparib	**372**	**6**	**60**	**120**	**240**	**1,297**	**185.3**	**189.4**
0-17 years	*****	60	60	432	804	804	432.0	526.1
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	15	60	120	182	930	167.9	183.1

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	190	6	60	147	240	921	189.4	178.8
≥ 65 years	133	9	60	90	270	1,297	182.7	200.7
baloxavir marboxil	**110,106**	**1**	**1**	**1**	**1**	**400**	**2.3**	**6.5**
0-17 years	19,064	1	1	1	1	90	1.2	2.1
18-24 years	11,454	1	1	1	1	91	1.3	2.6
25-40 years	26,040	1	1	1	1	90	1.3	2.7
41-64 years	34,588	1	1	1	1	270	1.6	4.4
≥ 65 years	18,960	1	1	1	1	400	6.5	13.1
lorlatinib	**1,055**	**1**	**60**	**125**	**330**	**1,582**	**248.8**	**285.9**
0-17 years	*****	2	60	112	150	1,011	164.3	185.4
18-24 years	*****	2	46	261	885	908	383.3	380.6
25-40 years	80	1	60	138	352	1,230	232.1	238.6
41-64 years	448	1	63	157	373	1,582	271.4	298.0
≥ 65 years	475	3	40	120	305	1,487	236.3	286.2
revefenacin	**8,196**	**1**	**4**	**30**	**90**	**1,302**	**87.2**	**157.4**
0-17 years	*****	1	1	28	55	55	28.0	38.2
18-24 years	*****	1	1	40	263	600	139.1	188.9
25-40 years	111	1	13	60	150	1,125	124.0	190.8
41-64 years	2,438	1	7	30	120	1,302	99.8	157.6
≥ 65 years	5,627	1	3	30	81	1,301	80.8	156.1
rifamycin	**68**	**2**	**3**	**3**	**12**	**86**	**11.6**	**17.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	3	3	3	14	5.0	5.0
25-40 years	*****	2	3	3	6	86	15.5	26.9
41-64 years	33	3	3	6	12	81	11.8	16.8

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	15	3	3	3	14	30	9.7	10.9
emapalumab-lzsg	**37**	**1**	**2**	**8**	**28**	**91**	**17.6**	**22.1**
0-17 years	20	1	7	14	35	91	24.6	25.6
18-24 years	*****	1	1	4	36	36	13.7	19.4
25-40 years	*****	3	4	12	24	28	13.8	11.9
41-64 years	*****	1	1	2	23	43	11.8	20.8
≥ 65 years	*****	1	1	2	4	7	2.7	2.4
glasdegib	**325**	**1**	**28**	**47**	**84**	**420**	**63.6**	**61.7**
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	24	28	28	196	59.0	76.7
41-64 years	*****	14	29	39	87	210	57.3	44.4
≥ 65 years	286	1	29	49	84	420	64.6	63.4
larotrectinib	**340**	**1**	**47**	**90**	**200**	**1,251**	**164.9**	**197.4**
0-17 years	48	3	85	188	336	1,046	235.9	198.9
18-24 years	*****	5	30	120	409	420	178.9	174.4
25-40 years	*****	19	30	78	142	1,251	175.2	290.8
41-64 years	101	1	47	90	202	1,105	176.4	231.3
≥ 65 years	163	3	45	90	150	864	135.0	151.4
amifampridine	**402**	**6**	**120**	**404**	**1,133**	**1,516**	**593.4**	**501.1**
0-17 years	*****	30	30	66	332	1,275	243.2	390.9
18-24 years	*****	53	184	353	619	1,102	444.0	358.3
25-40 years	31	15	74	298	750	1,386	463.9	455.7
41-64 years	128	6	120	300	897	1,516	522.7	483.8
≥ 65 years	223	12	184	610	1,252	1,424	674.5	511.7

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	**1,788**	**1**	**30**	**90**	**195**	**1,486**	**151.1**	**182.8**
0-17 years	24	1	29	44	219	899	148.8	209.0
18-24 years	30	12	30	91	308	852	203.3	244.2
25-40 years	117	1	60	112	180	990	149.8	148.5
41-64 years	453	1	30	90	212	1,486	167.4	205.6
≥ 65 years	1,164	1	30	90	180	1,456	143.5	173.6
prucalopride	**33,124**	**1**	**30**	**90**	**270**	**1,501**	**205.4**	**248.8**
0-17 years	440	1	30	90	230	1,193	181.6	220.2
18-24 years	1,763	1	30	90	270	1,414	194.5	231.3
25-40 years	5,304	1	30	90	265	1,371	199.4	241.6
41-64 years	13,804	1	30	112	295	1,475	216.0	254.0
≥ 65 years	11,813	1	30	90	270	1,501	198.3	248.9
calaspargase pegol-mknl	**32**	**1**	**1**	**1**	**2**	**3**	**1.6**	**0.7**
0-17 years	*****	1	1	1	2	3	1.5	0.7
18-24 years	*****	2	2	2	2	2	2.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	2	2	2	2	2	2.0	NaN
tagraxofusp-erzs	**88**	**1**	**1**	**5**	**16**	**106**	**12.9**	**18.7**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	3	31	31	11.7	16.8
25-40 years	*****	1	1	2	5	5	2.8	2.0
41-64 years	*****	1	1	5	6	24	6.4	8.0
≥ 65 years	71	1	1	6	17	106	14.6	20.1
ravulizumab	**1,859**	**1**	**3**	**5**	**13**	**1,155**	**25.1**	**94.0**

cder_mpl1r_wp251

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	**Minimum**	**Q1**	**Median**	**Q3**	**Maximum**	**Mean**	**Standard Deviation**
0-17 years	119	1	3	6	11	727	24.2	81.0
18-24 years	94	1	3	5	10	520	22.5	70.5
25-40 years	361	1	3	6	13	1,035	29.6	112.4
41-64 years	508	1	3	6	13	1,058	27.0	105.6
≥ 65 years	777	1	3	4	13	1,155	22.3	79.9

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*NaN: Not a Number

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	12,281	12,257	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
patisiran	12,106	12,013	99.2%	*****	*****	53	0.4%	*****	*****	0	0.0%
ethinyl estradiol and segesterone acetate	13,768	5,707	41.5%	3,201	23.2%	4,336	31.5%	452	3.3%	72	0.5%
migalastat	705	302	42.8%	196	27.8%	156	22.1%	32	4.5%	19	2.7%
stiripentol	1,120	472	42.1%	317	28.3%	231	20.6%	79	7.1%	21	1.9%
cenegermin-bkbj	8,299	3,207	38.6%	4,899	59.0%	*****	*****	*****	*****	0	0.0%
lanadelumab	5,982	3,498	58.5%	1,324	22.1%	958	16.0%	131	2.2%	71	1.2%
eravacycline	1,517	1,440	94.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
doravirine	16,829	8,213	48.8%	4,201	25.0%	3,154	18.7%	843	5.0%	418	2.5%
doravirine/lamivudine/tenofovir disoproxil fumarate	3,004	1,572	52.3%	745	24.8%	538	17.9%	108	3.6%	41	1.4%
moxetumomab pasudotox-tdfk	418	418	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	192,410	102,169	53.1%	55,358	28.8%	30,471	15.8%	3,628	1.9%	784	0.4%
duvelisib	1,216	658	54.1%	335	27.5%	206	16.9%	*****	*****	*****	*****
galcanezumab-gnlm	496,084	280,314	56.5%	129,895	26.2%	73,418	14.8%	9,694	2.0%	2,763	0.6%
dacomitinib	156	91	58.3%	34	21.8%	*****	*****	*****	*****	0	0.0%
cemiplimab-rwlc	61,461	61,364	99.8%	70	0.1%	27	0.0%	0	0.0%	0	0.0%
sarecycline	31,451	24,330	77.4%	5,737	18.2%	1,334	4.2%	*****	*****	*****	*****
omadacycline	6,973	6,060	86.9%	633	9.1%	253	3.6%	*****	*****	*****	*****
elapegademase-lvlr	262	171	65.3%	63	24.0%	*****	*****	*****	*****	*****	*****
inotersen	483	250	51.8%	116	24.0%	99	20.5%	*****	*****	*****	*****
talazoparib	954	520	54.5%	257	26.9%	161	16.9%	*****	*****	*****	*****
baloxavir marboxil	114,747	114,614	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%

cder_mpl1r_wp251

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
lorlatinib	2,622	1,290	49.2%	693	26.4%	506	19.3%	97	3.7%	36	1.4%
revefenacin	25,449	21,547	84.7%	2,604	10.2%	1,135	4.5%	129	0.5%	34	0.1%
rifamycin	87	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
emapalumab-lzsg	506	506	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
glasdegib	470	312	66.4%	126	26.8%	32	6.8%	0	0.0%	0	0.0%
larotrectinib	712	379	53.2%	201	28.2%	112	15.7%	*****	*****	*****	*****
amifampridine	1,528	656	42.9%	396	25.9%	299	19.6%	105	6.9%	72	4.7%
gilteritinib	4,113	2,346	57.0%	1,093	26.6%	619	15.0%	44	1.1%	11	0.3%
prucalopride	86,613	48,896	56.5%	23,060	26.6%	12,267	14.2%	1,875	2.2%	515	0.6%
calaspargase pegol-mknl	50	50	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
tagraxofusp-erzs	395	395	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
ravulizumab	12,906	12,680	98.2%	104	0.8%	109	0.8%	13	0.1%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	12,281	1	1	1	1	323	1.3	6.0
patisiran	12,106	1	1	1	1	651	2.1	15.1
ethinyl estradiol and segesterone acetate	13,768	1	30	63	179	1,125	125.4	145.8
migalastat	705	2	28	56	112	1,372	122.7	193.4
stiripentol	1,120	1	30	50	120	1,306	124.1	187.3
cenegermin-bkbj	8,299	1	21	42	56	413	41.3	24.0
lanadelumab	5,982	1	28	28	84	1,559	81.2	140.8
eravacycline	1,517	1	1	3	10	337	8.1	14.7
doravirine	16,829	1	30	44	116	1,702	118.4	192.5
doravirine/lamivudine/tenofovir disoproxil fumarate	3,004	1	30	30	90	1,488	99.1	153.0
moxetumomab pasudotox-tdfk	418	1	1	1	1	28	1.1	1.9
fremanezumab-vfrm	192,410	1	30	30	90	1,626	77.7	104.3
duvelisib	1,216	1	28	28	84	1,098	67.9	82.3
galcanezumab-gnlm	496,084	1	30	30	84	1,610	75.1	108.9
dacomitinib	156	1	30	30	89	614	80.0	107.0
cemiplimab-rwlc	61,461	1	1	1	1	357	1.2	4.4
sarecycline	31,451	1	30	30	30	1,230	42.6	37.0
omadacycline	6,973	1	7	14	28	1,145	24.6	49.0
elapegademase-lvlr	262	2	28	28	56	1,243	61.7	116.1
inotersen	483	2	28	28	84	1,314	91.1	140.0
talazoparib	954	1	30	30	90	930	72.3	90.6
baloxavir marboxil	114,747	1	1	1	1	270	2.2	5.8
lorlatinib	2,622	1	30	40	90	1,582	100.1	157.6
revefenacin	25,449	1	1	1	30	1,301	28.1	63.8
rifamycin	87	2	3	3	9	72	9.1	11.7

cder_mpl1r_wp251

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	**Minimum**	**Q1**	**Median**	**Q3**	**Maximum**	**Mean**	**Standard Deviation**
emapalumab-lzsg	506	1	1	1	1	28	1.3	1.7
glasdegib	470	1	28	30	60	240	44.0	34.3
larotrectinib	712	1	30	30	89	1,251	78.7	117.5
amifampridine	1,528	2	30	60	150	1,423	156.1	251.6
gilteritinib	4,113	1	30	30	60	1,486	65.7	89.9
prucalopride	86,613	1	30	30	90	1,501	78.6	112.2
calaspargase pegol-mknl	50	1	1	1	1	2	1.0	0.1
tagraxofusp-erzs	395	1	1	2	5	5	2.9	1.8
ravulizumab	12,906	1	1	1	1	721	3.6	23.4

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	**12,281**	**12,257**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	5,403	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	6,878	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	**12,106**	**12,013**	**100.0%**	*****	**100.0%**	**53**	**100.0%**	*****	*****	**0**	**NaN**
Female	4,086	4,040	33.6%	*****	*****	27	50.9%	*****	*****	0	NaN
Male	8,020	7,973	66.4%	*****	*****	26	49.1%	*****	*****	0	NaN
ethinyl estradiol and segesterone acetate	**13,768**	**5,707**	**100.0%**	**3,201**	**100.0%**	**4,336**	**100.0%**	**452**	**100.0%**	**72**	**100.0%**
Female	13,738	*****	*****	*****	*****	*****	*****	452	100.0%	72	100.0%
Male	30	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
migalastat	**705**	**302**	**100.0%**	**196**	**100.0%**	**156**	**100.0%**	**32**	**100.0%**	**19**	**100.0%**
Female	348	146	48.3%	99	50.5%	80	51.3%	*****	*****	*****	*****
Male	357	156	51.7%	97	49.5%	76	48.7%	*****	*****	*****	*****
stiripentol	**1,120**	**472**	**100.0%**	**317**	**100.0%**	**231**	**100.0%**	**79**	**100.0%**	**21**	**100.0%**
Female	653	291	61.7%	172	54.3%	134	58.0%	*****	*****	*****	*****
Male	467	181	38.3%	145	45.7%	97	42.0%	*****	*****	*****	*****
cenegermin-bkbj	**8,299**	**3,207**	**100.0%**	**4,899**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	5,407	2,158	67.3%	3,121	63.7%	128	66.7%	0	0.0%	0	NaN
Male	2,892	1,049	32.7%	1,778	36.3%	*****	*****	*****	*****	0	NaN
lanadelumab	**5,982**	**3,498**	**100.0%**	**1,324**	**100.0%**	**958**	**100.0%**	**131**	**100.0%**	**71**	**100.0%**
Female	3,971	2,275	65.0%	890	67.2%	663	69.2%	91	69.5%	52	73.2%
Male	2,011	1,223	35.0%	434	32.8%	295	30.8%	*****	30.5%	19	26.8%
eravacycline	**1,517**	**1,440**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**

cder_mpl1r_wp251

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	879	851	59.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	638	589	40.9%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**16,829**	**8,213**	**100.0%**	**4,201**	**100.0%**	**3,154**	**100.0%**	**843**	**100.0%**	**418**	**100.0%**
Female	3,949	2,046	24.9%	969	23.1%	687	21.8%	180	21.4%	67	16.0%
Male	12,880	6,167	75.1%	3,232	76.9%	2,467	78.2%	663	78.6%	351	84.0%
doravirine/lamivudine/tenofovir disoproxil fumarate	**3,004**	**1,572**	**100.0%**	**745**	**100.0%**	**538**	**100.0%**	**108**	**100.0%**	**41**	**100.0%**
Female	932	530	33.7%	218	29.3%	153	28.4%	*****	*****	*****	*****
Male	2,072	1,042	66.3%	527	70.7%	385	71.6%	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	**418**	**418**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	66	66	15.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	352	352	84.2%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**192,410**	**102,169**	**100.0%**	**55,358**	**100.0%**	**30,471**	**100.0%**	**3,628**	**100.0%**	**784**	**100.0%**
Female	166,563	88,596	86.7%	47,909	86.5%	26,291	86.3%	3,102	85.5%	665	84.8%
Male	25,847	13,573	13.3%	7,449	13.5%	4,180	13.7%	526	14.5%	119	15.2%
duvelisib	**1,216**	**658**	**100.0%**	**335**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	532	288	43.8%	148	44.2%	*****	*****	*****	*****	*****	*****
Male	684	370	56.2%	187	55.8%	114	55.3%	13	86.7%	0	0.0%
galcanezumab-gnlm	**496,084**	**280,314**	**100.0%**	**129,895**	**100.0%**	**73,418**	**100.0%**	**9,694**	**100.0%**	**2,763**	**100.0%**
Female	422,589	238,613	85.1%	110,784	85.3%	62,686	85.4%	8,157	84.1%	2,349	85.0%
Male	73,495	41,701	14.9%	19,111	14.7%	10,732	14.6%	1,537	15.9%	414	15.0%
dacomitinib	**156**	**91**	**100.0%**	**34**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**

cder_mpl1r_wp251

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	92	53	58.2%	21	61.8%	*****	*****	*****	*****	0	NaN
Male	64	38	41.8%	13	38.2%	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**61,461**	**61,364**	**100.0%**	**70**	**100.0%**	**27**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	14,956	14,920	24.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	46,505	46,444	75.7%	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**31,451**	**24,330**	**100.0%**	**5,737**	**100.0%**	**1,334**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	19,186	14,843	61.0%	3,534	61.6%	780	58.5%	*****	*****	*****	*****
Male	12,265	9,487	39.0%	2,203	38.4%	554	41.5%	*****	*****	*****	*****
omadacycline	**6,973**	**6,060**	**100.0%**	**633**	**100.0%**	**253**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	3,632	3,118	51.5%	354	55.9%	147	58.1%	*****	*****	*****	*****
Male	3,341	2,942	48.5%	279	44.1%	106	41.9%	*****	*****	*****	*****
elapegademase-lvlr	**262**	**171**	**100.0%**	**63**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	143	99	57.9%	*****	*****	*****	*****	*****	*****	*****	*****
Male	119	72	42.1%	*****	*****	*****	*****	*****	*****	*****	*****
inotersen	**483**	**250**	**100.0%**	**116**	**100.0%**	**99**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	268	139	55.6%	67	57.8%	*****	*****	*****	*****	*****	*****
Male	215	111	44.4%	49	42.2%	*****	*****	*****	*****	*****	*****
talazoparib	**954**	**520**	**100.0%**	**257**	**100.0%**	**161**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	896	484	93.1%	*****	*****	*****	*****	*****	*****	*****	*****
Male	58	36	6.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
baloxavir marboxil	**114,747**	**114,614**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	62,568	62,502	54.5%	*****	*****	*****	*****	0	NaN	0	NaN

cder_mpl1r_wp251

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	52,179	52,112	45.5%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	**2,622**	**1,290**	**100.0%**	**693**	**100.0%**	**506**	**100.0%**	**97**	**100.0%**	**36**	**100.0%**
Female	1,412	709	55.0%	368	53.1%	259	51.2%	57	58.8%	19	52.8%
Male	1,210	581	45.0%	325	46.9%	247	48.8%	40	41.2%	17	47.2%
revefenacin	**25,449**	**21,547**	**100.0%**	**2,604**	**100.0%**	**1,135**	**100.0%**	**129**	**100.0%**	**34**	**100.0%**
Female	14,642	12,287	57.0%	1,568	60.2%	691	60.9%	77	59.7%	19	55.9%
Male	10,807	9,260	43.0%	1,036	39.8%	444	39.1%	52	40.3%	15	44.1%
rifamycin	**87**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	47	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	40	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**506**	**506**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	391	391	77.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	115	115	22.7%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**470**	**312**	**100.0%**	**126**	**100.0%**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	207	145	46.5%	50	39.7%	12	37.5%	0	NaN	0	NaN
Male	263	167	53.5%	76	60.3%	20	62.5%	0	NaN	0	NaN
larotrectinib	**712**	**379**	**100.0%**	**201**	**100.0%**	**112**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	406	220	58.0%	118	58.7%	*****	*****	*****	*****	*****	*****
Male	306	159	42.0%	83	41.3%	*****	*****	*****	*****	*****	*****
amifampridine	**1,528**	**656**	**100.0%**	**396**	**100.0%**	**299**	**100.0%**	**105**	**100.0%**	**72**	**100.0%**
Female	919	413	63.0%	228	57.6%	170	56.9%	65	61.9%	43	59.7%
Male	609	243	37.0%	168	42.4%	129	43.1%	40	38.1%	29	40.3%

cder_mpl1r_wp251

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
gilteritinib	**4,113**	**2,346**	**100.0%**	**1,093**	**100.0%**	**619**	**100.0%**	**44**	**100.0%**	**11**	**100.0%**
Female	2,050	1,171	49.9%	546	50.0%	310	50.1%	*****	*****	*****	*****
Male	2,063	1,175	50.1%	547	50.0%	309	49.9%	*****	*****	*****	*****
prucalopride	**86,613**	**48,896**	**100.0%**	**23,060**	**100.0%**	**12,267**	**100.0%**	**1,875**	**100.0%**	**515**	**100.0%**
Female	68,971	39,093	80.0%	18,406	79.8%	9,623	78.4%	1,456	77.7%	393	76.3%
Male	17,642	9,803	20.0%	4,654	20.2%	2,644	21.6%	419	22.3%	122	23.7%
calaspargase pegol-mknl	**50**	**50**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	12	12	24.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	38	38	76.0%	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**395**	**395**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	68	68	17.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	327	327	82.8%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**12,906**	**12,680**	**100.0%**	**104**	**100.0%**	**109**	**100.0%**	**13**	**100.0%**	**0**	**NaN**
Female	7,353	7,222	57.0%	56	53.8%	*****	*****	*****	*****	0	NaN
Male	5,553	5,458	43.0%	48	46.2%	*****	*****	*****	*****	0	NaN

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

				Distribution of Treatment Episode Durations, days				
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**12,281**	**1**	**1**	**1**	**1**	**323**	**1.3**	**6.0**
Female	5,403	1	1	1	1	308	1.4	7.2
Male	6,878	1	1	1	1	323	1.2	4.9
patisiran	**12,106**	**1**	**1**	**1**	**1**	**651**	**2.1**	**15.1**
Female	4,086	1	1	1	1	651	2.7	19.7
Male	8,020	1	1	1	1	462	1.8	12.1
ethinyl estradiol and segesterone acetate	**13,768**	**1**	**30**	**63**	**179**	**1,125**	**125.4**	**145.8**
Female	13,738	1	30	63	179	1,125	125.3	145.9
Male	30	1	30	90	170	365	131.6	122.6
migalastat	**705**	**2**	**28**	**56**	**112**	**1,372**	**122.7**	**193.4**
Female	348	3	28	56	112	1,232	124.6	193.7
Male	357	2	28	56	112	1,372	120.8	193.4
stiripentol	**1,120**	**1**	**30**	**50**	**120**	**1,306**	**124.1**	**187.3**
Female	653	1	30	46	120	1,265	119.6	178.6
Male	467	1	30	60	136	1,306	130.5	198.7
cenegermin-bkbj	**8,299**	**1**	**21**	**42**	**56**	**413**	**41.3**	**24.0**
Female	5,407	1	16	42	56	364	40.9	23.9
Male	2,892	1	27	48	56	413	42.2	24.3
lanadelumab	**5,982**	**1**	**28**	**28**	**84**	**1,559**	**81.2**	**140.8**
Female	3,971	1	28	28	84	1,559	84.4	145.9
Male	2,011	1	28	28	56	1,489	75.0	129.9
eravacycline	**1,517**	**1**	**1**	**3**	**10**	**337**	**8.1**	**14.7**
Female	879	1	1	2	7	337	6.7	14.8
Male	638	1	1	5	12	141	10.0	14.5
doravirine	**16,829**	**1**	**30**	**44**	**116**	**1,702**	**118.4**	**192.5**

cder_mpl1r_wp251

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
				Distribution of Treatment Episode Durations, days				
Female	3,949	1	30	30	90	1,458	103.5	163.3
Male	12,880	1	30	55	120	1,702	122.9	200.4
doravirine/lamivudine/tenofovir disoproxil fumarate	**3,004**	**1**	**30**	**30**	**90**	**1,488**	**99.1**	**153.0**
Female	932	2	30	30	90	1,378	84.8	132.0
Male	2,072	1	30	30	90	1,488	105.5	161.2
moxetumomab pasudotox-tdfk	**418**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.9**
Female	66	1	1	1	1	1	1.0	0.0
Male	352	1	1	1	1	28	1.2	2.0
fremanezumab-vfrm	**192,410**	**1**	**30**	**30**	**90**	**1,626**	**77.7**	**104.3**
Female	166,563	1	30	30	90	1,626	77.4	103.8
Male	25,847	1	30	30	90	1,485	79.3	107.5
duvelisib	**1,216**	**1**	**28**	**28**	**84**	**1,098**	**67.9**	**82.3**
Female	532	3	28	28	84	1,098	69.5	89.1
Male	684	1	28	28	84	644	66.7	76.7
galcanezumab-gnlm	**496,084**	**1**	**30**	**30**	**84**	**1,610**	**75.1**	**108.9**
Female	422,589	1	30	30	84	1,610	75.0	108.6
Male	73,495	1	30	30	84	1,525	75.6	110.4
dacomitinib	**156**	**1**	**30**	**30**	**89**	**614**	**80.0**	**107.0**
Female	92	1	30	30	90	614	80.6	104.3
Male	64	2	30	30	60	596	79.1	111.7
cemiplimab-rwlc	**61,461**	**1**	**1**	**1**	**1**	**357**	**1.2**	**4.4**
Female	14,956	1	1	1	1	315	1.3	5.6
Male	46,505	1	1	1	1	357	1.1	3.9
sarecycline	**31,451**	**1**	**30**	**30**	**30**	**1,230**	**42.6**	**37.0**

cder_mpl1r_wp251

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
				Distribution of Treatment Episode Durations, days				
Female	19,186	1	30	30	30	844	42.5	36.0
Male	12,265	1	30	30	30	1,230	42.8	38.3
omadacycline	**6,973**	**1**	**7**	**14**	**28**	**1,145**	**24.6**	**49.0**
Female	3,632	1	7	14	30	1,145	26.3	50.7
Male	3,341	1	6	13	21	1,096	22.7	47.0
elapegademase-lvlr	**262**	**2**	**28**	**28**	**56**	**1,243**	**61.7**	**116.1**
Female	143	5	28	28	56	746	50.5	81.0
Male	119	2	28	28	56	1,243	75.3	146.8
inotersen	**483**	**2**	**28**	**28**	**84**	**1,314**	**91.1**	**140.0**
Female	268	2	28	28	84	1,314	88.2	145.9
Male	215	28	28	28	112	819	94.6	132.4
talazoparib	**954**	**1**	**30**	**30**	**90**	**930**	**72.3**	**90.6**
Female	896	1	30	30	90	930	73.3	92.3
Male	58	10	30	30	60	330	55.8	56.4
baloxavir marboxil	**114,747**	**1**	**1**	**1**	**1**	**270**	**2.2**	**5.8**
Female	62,568	1	1	1	1	270	2.2	5.8
Male	52,179	1	1	1	1	180	2.1	5.7
lorlatinib	**2,622**	**1**	**30**	**40**	**90**	**1,582**	**100.1**	**157.6**
Female	1,412	1	30	30	90	1,582	100.3	158.8
Male	1,210	1	30	45	97	1,424	99.9	156.2
revefenacin	**25,449**	**1**	**1**	**1**	**30**	**1,301**	**28.1**	**63.8**
Female	14,642	1	1	2	30	1,301	29.2	64.5
Male	10,807	1	1	1	30	1,248	26.5	62.8
rifamycin	**87**	**2**	**3**	**3**	**9**	**72**	**9.1**	**11.7**
Female	47	2	3	3	12	72	9.4	12.7

cder_mpl1r_wp251

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
				Distribution of Treatment Episode Durations, days				
Male	40	2	3	3	9	42	8.8	10.5
emapalumab-lzsg	**506**	**1**	**1**	**1**	**1**	**28**	**1.3**	**1.7**
Female	391	1	1	1	1	13	1.1	0.8
Male	115	1	1	1	1	28	1.9	3.3
glasdegib	**470**	**1**	**28**	**30**	**60**	**240**	**44.0**	**34.3**
Female	207	4	28	30	57	210	42.2	31.3
Male	263	1	28	30	60	240	45.4	36.6
larotrectinib	**712**	**1**	**30**	**30**	**89**	**1,251**	**78.7**	**117.5**
Female	406	1	30	30	86	864	70.4	91.7
Male	306	4	30	30	90	1,251	89.8	144.3
amifampridine	**1,528**	**2**	**30**	**60**	**150**	**1,423**	**156.1**	**251.6**
Female	919	2	30	60	150	1,423	155.3	251.3
Male	609	4	30	60	150	1,420	157.4	252.3
gilteritinib	**4,113**	**1**	**30**	**30**	**60**	**1,486**	**65.7**	**89.9**
Female	2,050	1	30	30	61	1,335	65.8	90.4
Male	2,063	1	30	30	60	1,486	65.5	89.3
prucalopride	**86,613**	**1**	**30**	**30**	**90**	**1,501**	**78.6**	**112.2**
Female	68,971	1	30	30	90	1,501	77.8	110.9
Male	17,642	1	30	30	90	1,371	81.6	117.2
calaspargase pegol-mknl	**50**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.1**
Female	12	1	1	1	1	1	1.0	0.0
Male	38	1	1	1	1	2	1.0	0.2
tagraxofusp-erzs	**395**	**1**	**1**	**2**	**5**	**5**	**2.9**	**1.8**
Female	68	1	1	2	5	5	2.7	1.8
Male	327	1	1	2	5	5	2.9	1.8

cder_mpl1r_wp251

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

				Distribution of Treatment Episode Durations, days				
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	**12,906**	**1**	**1**	**1**	**1**	**721**	**3.6**	**23.4**
Female	7,353	1	1	1	1	686	3.7	24.6
Male	5,553	1	1	1	1	721	3.5	21.7

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	**12,281**	**12,257**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	19	19	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	18	18	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	287	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	2,085	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	9,872	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	**12,106**	**12,013**	**100.0%**	*****	**100.0%**	**53**	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	82	*****	*****	*****	*****	*****	*****	*****	0.0%	0	NaN
41-64 years	1,912	*****	*****	*****	*****	*****	*****	*****	0.0%	0	NaN
≥ 65 years	10,112	10,054	83.7%	24	64.9%	*****	*****	*****	*****	0	NaN
ethinyl estradiol and segesterone acetate	**13,768**	**5,707**	**100.0%**	**3,201**	**100.0%**	**4,336**	**100.0%**	**452**	**100.0%**	**72**	**100.0%**
0-17 years	*****	*****	*****	151	4.7%	144	3.3%	*****	*****	*****	*****
18-24 years	4,349	1,688	29.6%	990	30.9%	1,478	34.1%	176	38.9%	17	23.6%
25-40 years	7,597	3,230	56.6%	1,784	55.7%	2,327	53.7%	212	46.9%	44	61.1%
41-64 years	1,304	586	10.3%	276	8.6%	387	8.9%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
migalastat	**705**	**302**	**100.0%**	**196**	**100.0%**	**156**	**100.0%**	**32**	**100.0%**	**19**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	68	36	11.9%	18	9.2%	14	9.0%	0	0.0%	0	0.0%
25-40 years	176	82	27.2%	53	27.0%	33	21.2%	*****	*****	*****	*****
41-64 years	322	135	44.7%	91	46.4%	67	42.9%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	139	49	16.2%	34	17.3%	42	26.9%	*****	*****	*****	*****
stiripentol	**1,120**	**472**	**100.0%**	**317**	**100.0%**	**231**	**100.0%**	**79**	**100.0%**	**21**	**100.0%**
0-17 years	838	349	73.9%	244	77.0%	178	77.1%	*****	*****	*****	*****
18-24 years	230	101	21.4%	62	19.6%	*****	*****	*****	*****	*****	*****
25-40 years	52	22	4.7%	11	3.5%	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	**8,299**	**3,207**	**100.0%**	**4,899**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	68	32	1.0%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	40	19	0.6%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	332	163	5.1%	152	3.1%	17	8.9%	0	0.0%	0	NaN
41-64 years	1,588	653	20.4%	857	17.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	6,271	2,340	73.0%	3,839	78.4%	92	47.9%	0	0.0%	0	NaN
lanadelumab	**5,982**	**3,498**	**100.0%**	**1,324**	**100.0%**	**958**	**100.0%**	**131**	**100.0%**	**71**	**100.0%**
0-17 years	454	259	7.4%	110	8.3%	*****	*****	*****	*****	*****	*****
18-24 years	572	377	10.8%	113	8.5%	*****	*****	*****	*****	0	0.0%
25-40 years	1,434	917	26.2%	289	21.8%	193	20.1%	*****	*****	*****	*****
41-64 years	2,263	1,295	37.0%	514	38.8%	366	38.2%	58	44.3%	30	42.3%
≥ 65 years	1,259	650	18.6%	298	22.5%	251	26.2%	37	28.2%	23	32.4%
eravacycline	**1,517**	**1,440**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	20	20	1.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	53	53	3.7%	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	131	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	572	542	37.6%	30	41.1%	0	0.0%	0	NaN	0	NaN
≥ 65 years	741	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**16,829**	**8,213**	**100.0%**	**4,201**	**100.0%**	**3,154**	**100.0%**	**843**	**100.0%**	**418**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	24	0.6%	*****	*****	*****	*****	0	0.0%
25-40 years	1,959	1,117	13.6%	448	10.7%	319	10.1%	*****	*****	*****	*****
41-64 years	11,223	5,522	67.2%	2,815	67.0%	2,076	65.8%	*****	*****	*****	*****
≥ 65 years	3,522	1,492	18.2%	914	21.8%	743	23.6%	239	28.4%	134	32.1%
doravirine/lamivudine/tenofovir disoproxil fumarate	**3,004**	**1,572**	**100.0%**	**745**	**100.0%**	**538**	**100.0%**	**108**	**100.0%**	**41**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	77	38	2.4%	26	3.5%	*****	*****	*****	*****	0	0.0%
25-40 years	643	356	22.6%	163	21.9%	108	20.1%	*****	*****	*****	*****
41-64 years	1,892	984	62.6%	456	61.2%	*****	*****	82	75.9%	*****	*****
≥ 65 years	392	194	12.3%	100	13.4%	74	13.8%	13	12.0%	11	26.8%
moxetumomab pasudotox-tdfk	**418**	**418**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	303	303	72.5%	0	NaN	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
fremanezumab-vfrm	**192,410**	**102,169**	**100.0%**	**55,358**	**100.0%**	**30,471**	**100.0%**	**3,628**	**100.0%**	**784**	**100.0%**
0-17 years	1,000	581	0.6%	283	0.5%	117	0.4%	*****	*****	*****	*****
18-24 years	10,831	5,958	5.8%	3,237	5.8%	1,494	4.9%	*****	*****	*****	*****
25-40 years	50,782	27,979	27.4%	14,290	25.8%	7,530	24.7%	836	23.0%	147	18.8%
41-64 years	105,996	55,646	54.5%	30,581	55.2%	17,200	56.4%	2,093	57.7%	476	60.7%
≥ 65 years	23,801	12,005	11.8%	6,967	12.6%	4,130	13.6%	558	15.4%	141	18.0%
duvelisib	**1,216**	**658**	**100.0%**	**335**	**100.0%**	**206**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	197	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,004	542	82.4%	273	81.5%	173	84.0%	*****	*****	*****	*****
galcanezumab-gnlm	**496,084**	**280,314**	**100.0%**	**129,895**	**100.0%**	**73,418**	**100.0%**	**9,694**	**100.0%**	**2,763**	**100.0%**
0-17 years	2,019	1,147	0.4%	515	0.4%	302	0.4%	41	0.4%	14	0.5%
18-24 years	27,907	16,576	5.9%	7,197	5.5%	3,674	5.0%	370	3.8%	90	3.3%
25-40 years	136,332	79,109	28.2%	35,497	27.3%	18,969	25.8%	2,185	22.5%	572	20.7%
41-64 years	268,534	150,775	53.8%	69,809	53.7%	40,555	55.2%	5,700	58.8%	1,695	61.3%
≥ 65 years	61,292	32,707	11.7%	16,877	13.0%	9,918	13.5%	1,398	14.4%	392	14.2%
dacomitinib	**156**	**91**	**100.0%**	**34**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	37	21	23.1%	*****	*****	*****	*****	*****	*****	0	NaN

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	119	70	76.9%	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**61,461**	**61,364**	**100.0%**	**70**	**100.0%**	**27**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	5,070	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	56,166	56,079	91.4%	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**31,451**	**24,330**	**100.0%**	**5,737**	**100.0%**	**1,334**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	14,828	11,497	47.3%	2,722	47.4%	590	44.2%	*****	*****	*****	*****
18-24 years	8,244	6,374	26.2%	1,473	25.7%	380	28.5%	*****	*****	*****	*****
25-40 years	5,325	4,150	17.1%	955	16.6%	*****	*****	*****	*****	0	0.0%
41-64 years	2,816	2,128	8.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	238	181	0.7%	*****	*****	*****	*****	*****	*****	0	0.0%
omadacycline	**6,973**	**6,060**	**100.0%**	**633**	**100.0%**	**253**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	111	83	1.4%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	156	135	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	600	526	8.7%	46	7.3%	*****	*****	*****	*****	0	0.0%
41-64 years	2,803	2,459	40.6%	252	39.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	3,303	2,857	47.1%	304	48.0%	131	51.8%	11	45.8%	0	0.0%
elapegademase-lvlr	**262**	**171**	**100.0%**	**63**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	112	78	45.6%	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	80	54	31.6%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
inotersen	**483**	**250**	**100.0%**	**116**	**100.0%**	**99**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	78	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	390	193	77.2%	99	85.3%	84	84.8%	*****	*****	*****	*****
talazoparib	**954**	**520**	**100.0%**	**257**	**100.0%**	**161**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	510	279	53.7%	134	52.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	320	169	32.5%	89	34.6%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	**114,747**	**114,614**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	19,932	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	11,809	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	26,985	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	36,073	36,041	31.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	19,948	19,864	17.3%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	**2,622**	**1,290**	**100.0%**	**693**	**100.0%**	**506**	**100.0%**	**97**	**100.0%**	**36**	**100.0%**
0-17 years	98	62	4.8%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	28	15	1.2%	*****	*****	*****	*****	*****	*****	0	0.0%

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	200	93	7.2%	62	8.9%	*****	*****	*****	*****	0	0.0%
41-64 years	1,149	523	40.5%	311	44.9%	251	49.6%	45	46.4%	19	52.8%
≥ 65 years	1,147	597	46.3%	291	42.0%	207	40.9%	36	37.1%	*****	*****
revefenacin	**25,449**	**21,547**	**100.0%**	**2,604**	**100.0%**	**1,135**	**100.0%**	**129**	**100.0%**	**34**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	237	166	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	5,877	4,502	20.9%	914	35.1%	403	35.5%	*****	*****	*****	*****
≥ 65 years	19,302	16,856	78.2%	1,637	62.9%	714	62.9%	75	58.1%	20	58.8%
rifamycin	**87**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	47	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	18	18	21.4%	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**506**	**506**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	377	377	74.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	11	11	2.2%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	55	55	10.9%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	47	47	9.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	16	16	3.2%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**470**	**312**	**100.0%**	**126**	**100.0%**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	413	273	87.5%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	**712**	**379**	**100.0%**	**201**	**100.0%**	**112**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	170	86	22.7%	56	27.9%	*****	*****	*****	*****	0	0.0%
18-24 years	11	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	31	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	193	103	27.2%	45	22.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	307	169	44.6%	86	42.8%	*****	*****	*****	*****	*****	*****
amifampridine	**1,528**	**656**	**100.0%**	**396**	**100.0%**	**299**	**100.0%**	**105**	**100.0%**	**72**	**100.0%**
0-17 years	22	11	1.7%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	47	21	3.2%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	103	46	7.0%	29	7.3%	16	5.4%	*****	*****	*****	*****
41-64 years	500	256	39.0%	117	29.5%	78	26.1%	*****	*****	*****	*****
≥ 65 years	856	322	49.1%	229	57.8%	193	64.5%	62	59.0%	50	69.4%
gilteritinib	**4,113**	**2,346**	**100.0%**	**1,093**	**100.0%**	**619**	**100.0%**	**44**	**100.0%**	**11**	**100.0%**
0-17 years	52	26	1.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	72	46	2.0%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	268	151	6.4%	71	6.5%	*****	*****	*****	*****	0	0.0%
41-64 years	1,101	619	26.4%	302	27.6%	167	27.0%	*****	*****	*****	*****
≥ 65 years	2,620	1,504	64.1%	697	63.8%	383	61.9%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
prucalopride	**86,613**	**48,896**	**100.0%**	**23,060**	**100.0%**	**12,267**	**100.0%**	**1,875**	**100.0%**	**515**	**100.0%**
0-17 years	1,110	656	1.3%	266	1.2%	161	1.3%	*****	*****	*****	*****
18-24 years	4,601	2,691	5.5%	1,196	5.2%	597	4.9%	*****	*****	*****	*****
25-40 years	14,025	8,069	16.5%	3,676	15.9%	1,907	15.5%	294	15.7%	79	15.3%
41-64 years	37,082	20,458	41.8%	10,179	44.1%	5,367	43.8%	854	45.5%	224	43.5%
≥ 65 years	29,795	17,022	34.8%	7,743	33.6%	4,235	34.5%	613	32.7%	182	35.3%
calaspargase pegol-mknl	**50**	**50**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**395**	**395**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	23	23	5.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	351	351	88.9%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**12,906**	**12,680**	**100.0%**	**104**	**100.0%**	**109**	**100.0%**	**13**	**100.0%**	**0**	**NaN**
0-17 years	817	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	592	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	2,613	2,562	20.2%	29	27.9%	*****	*****	*****	*****	0	NaN

cder_mpl1r_wp251

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Treatment Episodes by Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	3,855	3,792	29.9%	*****	*****	39	35.8%	*****	*****	0	NaN
≥ 65 years	5,029	4,942	39.0%	*****	*****	42	38.5%	*****	*****	0	NaN

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**12,281**	**1**	**1**	**1**	**1**	**323**	**1.3**	**6.0**
0-17 years	19	1	1	1	1	1	1.0	0.0
18-24 years	18	1	1	1	1	1	1.0	0.0
25-40 years	287	1	1	1	1	140	1.5	8.2
41-64 years	2,085	1	1	1	1	252	1.6	7.0
≥ 65 years	9,872	1	1	1	1	323	1.2	5.8
patisiran	**12,106**	**1**	**1**	**1**	**1**	**651**	**2.1**	**15.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	82	1	1	1	1	273	12.9	45.0
41-64 years	1,912	1	1	1	1	336	3.2	18.2
≥ 65 years	10,112	1	1	1	1	651	1.9	13.8
ethinyl estradiol and segesterone acetate	**13,768**	**1**	**30**	**63**	**179**	**1,125**	**125.4**	**145.8**
0-17 years	*****	1	30	60	144	994	122.9	146.4
18-24 years	4,349	1	30	84	196	1,022	136.2	149.7
25-40 years	7,597	1	28	60	160	1,125	119.8	142.5
41-64 years	1,304	1	28	59	165	1,112	122.5	149.6
≥ 65 years	*****	27	27	27	27	27	27.0	NaN
migalastat	**705**	**2**	**28**	**56**	**112**	**1,372**	**122.7**	**193.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	68	11	28	28	84	364	72.9	77.3
25-40 years	176	8	28	56	84	1,320	101.9	169.9
41-64 years	322	2	28	56	112	1,335	123.0	191.6
≥ 65 years	139	12	28	56	196	1,372	172.4	248.3
stiripentol	**1,120**	**1**	**30**	**50**	**120**	**1,306**	**124.1**	**187.3**

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	838	1	30	51	120	1,280	121.2	182.9
18-24 years	230	3	30	40	133	1,265	123.3	179.3
25-40 years	52	9	30	60	200	1,306	175.2	271.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**8,299**	**1**	**21**	**42**	**56**	**413**	**41.3**	**24.0**
0-17 years	68	2	14	39	56	140	39.1	28.9
18-24 years	40	1	14	37	56	112	35.3	25.7
25-40 years	332	1	14	35	56	184	38.7	27.4
41-64 years	1,588	1	14	42	56	413	42.2	29.2
≥ 65 years	6,271	1	25	48	56	364	41.3	22.2
lanadelumab	**5,982**	**1**	**28**	**28**	**84**	**1,559**	**81.2**	**140.8**
0-17 years	454	1	28	28	84	1,441	76.4	129.6
18-24 years	572	1	28	28	56	672	56.9	71.6
25-40 years	1,434	1	28	28	56	1,559	69.8	131.8
41-64 years	2,263	1	28	28	84	1,524	85.3	146.0
≥ 65 years	1,259	1	28	28	88	1,489	99.8	164.0
eravacycline	**1,517**	**1**	**1**	**3**	**10**	**337**	**8.1**	**14.7**
0-17 years	20	1	1	1	1	2	1.1	0.3
18-24 years	53	1	1	1	1	30	2.9	5.0
25-40 years	131	1	1	1	6	39	4.8	7.3
41-64 years	572	1	1	3	9	85	8.0	12.1
≥ 65 years	741	1	1	5	11	337	9.3	17.7
doravirine	**16,829**	**1**	**30**	**44**	**116**	**1,702**	**118.4**	**192.5**
0-17 years	*****	30	30	30	221	560	143.9	189.6

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	5	30	30	60	394	59.0	64.3
25-40 years	1,959	1	30	30	90	1,411	83.9	120.5
41-64 years	11,223	1	30	40	107	1,702	116.3	190.8
≥ 65 years	3,522	1	30	60	150	1,524	146.0	226.5
doravirine/lamivudine/tenofovir disoproxil fumarate	**3,004**	**1**	**30**	**30**	**90**	**1,488**	**99.1**	**153.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	77	1	30	38	90	444	76.7	82.7
25-40 years	643	2	30	30	90	1,301	82.9	118.8
41-64 years	1,892	1	30	30	90	1,488	103.5	158.5
≥ 65 years	392	3	30	37	96	1,474	108.7	182.2
moxetumomab pasudotox-tdfk	**418**	**1**	**1**	**1**	**1**	**28**	**1.1**	**1.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	1.2	2.6
≥ 65 years	303	1	1	1	1	28	1.1	1.6
fremanezumab-vfrm	**192,410**	**1**	**30**	**30**	**90**	**1,626**	**77.7**	**104.3**
0-17 years	1,000	1	30	30	77	1,140	66.5	91.2
18-24 years	10,831	1	30	30	90	1,368	68.3	82.0
25-40 years	50,782	1	30	30	90	1,626	72.8	95.7
41-64 years	105,996	1	30	30	90	1,580	79.4	107.4
≥ 65 years	23,801	1	30	30	90	1,464	85.2	115.8
duvelisib	**1,216**	**1**	**28**	**28**	**84**	**1,098**	**67.9**	**82.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	25	25	25	25	25.0	NaN

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	4	28	35	56	224	59.2	57.9
41-64 years	197	2	28	28	56	380	60.5	58.4
≥ 65 years	1,004	1	28	28	84	1,098	69.6	86.5
galcanezumab-gnlm	**496,084**	**1**	**30**	**30**	**84**	**1,610**	**75.1**	**108.9**
0-17 years	2,019	1	28	30	76	1,248	76.2	114.1
18-24 years	27,907	1	30	30	60	1,556	66.1	90.4
25-40 years	136,332	1	30	30	60	1,576	70.0	98.9
41-64 years	268,534	1	30	30	84	1,610	77.2	113.7
≥ 65 years	61,292	1	30	30	90	1,476	81.0	115.3
dacomitinib	**156**	**1**	**30**	**30**	**89**	**614**	**80.0**	**107.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	37	1	30	30	90	596	87.5	125.4
≥ 65 years	119	2	30	30	88	614	77.6	101.1
cemiplimab-rwlc	**61,461**	**1**	**1**	**1**	**1**	**357**	**1.2**	**4.4**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	42	1.2	2.8
41-64 years	5,070	1	1	1	1	213	1.2	5.0
≥ 65 years	56,166	1	1	1	1	357	1.2	4.4
sarecycline	**31,451**	**1**	**30**	**30**	**30**	**1,230**	**42.6**	**37.0**
0-17 years	14,828	1	30	30	30	750	42.3	35.3
18-24 years	8,244	1	30	30	30	1,230	43.2	39.8

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	5,325	1	30	30	30	480	41.4	32.3
41-64 years	2,816	1	30	30	30	844	45.2	43.2
≥ 65 years	238	3	30	30	30	611	44.6	50.0
omadacycline	**6,973**	**1**	**7**	**14**	**28**	**1,145**	**24.6**	**49.0**
0-17 years	111	1	1	30	35	414	40.5	65.5
18-24 years	156	1	7	14	30	372	29.3	54.9
25-40 years	600	1	8	14	30	619	26.3	50.9
41-64 years	2,803	1	7	14	24	1,145	23.5	51.4
≥ 65 years	3,303	1	7	13	27	640	24.4	45.4
elapegademase-lvlr	**262**	**2**	**28**	**28**	**56**	**1,243**	**61.7**	**116.1**
0-17 years	112	17	28	28	56	746	58.6	104.4
18-24 years	80	2	14	28	56	500	51.7	76.6
25-40 years	*****	4	28	28	56	1,243	80.1	170.6
41-64 years	*****	3	28	56	88	118	61.9	38.7
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**483**	**2**	**28**	**28**	**84**	**1,314**	**91.1**	**140.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	15	2	28	28	56	252	53.9	59.2
41-64 years	78	21	28	28	84	1,314	97.0	189.5
≥ 65 years	390	5	28	42	112	1,260	91.3	130.3
talazoparib	**954**	**1**	**30**	**30**	**90**	**930**	**72.3**	**90.6**
0-17 years	*****	15	15	15	15	804	172.8	352.9
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	1	30	30	60	930	65.4	100.4

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	510	4	30	30	90	921	70.6	83.9
≥ 65 years	320	8	30	30	90	660	75.9	88.7
baloxavir marboxil	**114,747**	**1**	**1**	**1**	**1**	**270**	**2.2**	**5.8**
0-17 years	19,932	1	1	1	1	90	1.2	2.0
18-24 years	11,809	1	1	1	1	90	1.3	2.5
25-40 years	26,985	1	1	1	1	90	1.3	2.6
41-64 years	36,073	1	1	1	1	270	1.5	4.0
≥ 65 years	19,948	1	1	1	1	180	6.2	11.2
lorlatinib	**2,622**	**1**	**30**	**40**	**90**	**1,582**	**100.1**	**157.6**
0-17 years	98	2	30	30	65	1,011	75.4	131.2
18-24 years	28	2	30	30	90	622	95.8	147.3
25-40 years	200	1	30	60	90	674	92.8	118.6
41-64 years	1,149	1	30	57	120	1,582	105.8	165.6
≥ 65 years	1,147	1	30	30	90	1,424	97.9	157.5
revefenacin	**25,449**	**1**	**1**	**1**	**30**	**1,301**	**28.1**	**63.8**
0-17 years	*****	1	1	25	30	30	18.7	15.5
18-24 years	*****	1	22	30	60	600	83.4	142.9
25-40 years	237	1	22	30	60	935	58.1	109.1
41-64 years	5,877	1	1	30	30	1,144	41.4	74.9
≥ 65 years	19,302	1	1	1	30	1,301	23.6	58.3
rifamycin	**87**	**2**	**3**	**3**	**9**	**72**	**9.1**	**11.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	3	3	3	14	5.0	5.0
25-40 years	*****	2	3	3	28	72	13.7	18.7
41-64 years	47	3	3	3	9	42	8.3	9.2

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	18	3	3	3	6	30	8.1	10.0
emapalumab-lzsg	**506**	**1**	**1**	**1**	**1**	**28**	**1.3**	**1.7**
0-17 years	377	1	1	1	1	28	1.3	1.8
18-24 years	11	1	1	3	6	13	3.7	3.7
25-40 years	55	1	1	1	1	1	1.0	0.0
41-64 years	47	1	1	1	1	1	1.0	0.0
≥ 65 years	16	1	1	1	1	1	1.0	0.0
glasdegib	**470**	**1**	**28**	**30**	**60**	**240**	**44.0**	**34.3**
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	24	28	56	112	42.1	33.0
41-64 years	*****	10	24	30	60	120	38.2	24.7
≥ 65 years	413	1	28	30	60	240	44.7	35.4
larotrectinib	**712**	**1**	**30**	**30**	**89**	**1,251**	**78.7**	**117.5**
0-17 years	170	3	25	30	60	480	66.6	82.8
18-24 years	11	5	30	60	210	409	113.8	132.6
25-40 years	31	15	30	30	84	1,251	118.7	248.7
41-64 years	193	1	30	30	90	944	92.3	144.5
≥ 65 years	307	3	30	30	90	864	71.7	90.1
amifampridine	**1,528**	**2**	**30**	**60**	**150**	**1,423**	**156.1**	**251.6**
0-17 years	22	2	30	35	112	480	110.5	140.7
18-24 years	47	4	30	60	90	529	94.5	109.4
25-40 years	103	2	30	60	120	1,252	139.6	227.7
41-64 years	500	4	30	30	102	1,423	133.8	237.1
≥ 65 years	856	2	30	60	180	1,420	175.7	268.2

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
gilteritinib	**4,113**	**1**	**30**	**30**	**60**	**1,486**	**65.7**	**89.9**
0-17 years	52	1	30	31	101	300	68.7	63.3
18-24 years	72	1	30	30	81	690	84.7	129.2
25-40 years	268	1	30	30	84	488	65.4	70.5
41-64 years	1,101	1	30	30	60	1,486	68.9	102.1
≥ 65 years	2,620	1	30	30	60	1,216	63.8	85.2
prucalopride	**86,613**	**1**	**30**	**30**	**90**	**1,501**	**78.6**	**112.2**
0-17 years	1,110	1	30	30	81	977	72.0	101.6
18-24 years	4,601	1	30	30	90	1,305	74.5	105.3
25-40 years	14,025	1	30	30	90	1,371	75.4	107.4
41-64 years	37,082	1	30	30	90	1,372	80.4	114.2
≥ 65 years	29,795	1	30	30	90	1,501	78.6	113.2
calaspargase pegol-mknl	**50**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.1**
0-17 years	*****	1	1	1	1	2	1.0	0.2
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	**395**	**1**	**1**	**2**	**5**	**5**	**2.9**	**1.8**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	3	5	5	2.9	1.9
25-40 years	*****	1	1	1	4	5	2.0	1.7
41-64 years	23	1	1	1	4	4	2.0	1.3
≥ 65 years	351	1	1	3	5	5	3.0	1.9
ravulizumab	**12,906**	**1**	**1**	**1**	**1**	**721**	**3.6**	**23.4**

cder_mpl1r_wp251

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	817	1	1	1	1	280	3.5	16.9
18-24 years	592	1	1	1	1	448	3.6	25.9
25-40 years	2,613	1	1	1	1	649	4.1	29.0
41-64 years	3,855	1	1	1	1	686	3.6	22.1
≥ 65 years	5,029	1	1	1	1	721	3.4	21.7

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	816	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
patisiran	570	550	96.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
ethinyl estradiol and segesterone acetate	12,072	4,886	40.5%	2,774	23.0%	3,916	32.4%	424	3.5%	72	0.6%
migalastat	170	49	28.8%	36	21.2%	56	32.9%	14	8.2%	15	8.8%
stiripentol	402	147	36.6%	98	24.4%	90	22.4%	55	13.7%	12	3.0%
cenegermin-bkbj	5,521	1,542	27.9%	3,823	69.2%	156	2.8%	0	0.0%	0	0.0%
lanadelumab	1,109	580	52.3%	210	18.9%	237	21.4%	44	4.0%	38	3.4%
eravacycline	723	666	92.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
doravirine	4,812	1,942	40.4%	1,045	21.7%	1,141	23.7%	410	8.5%	274	5.7%
doravirine/lamivudine/tenofovir disoproxil fumarate	995	429	43.1%	217	21.8%	266	26.7%	60	6.0%	23	2.3%
moxetumomab pasudotox-tdfk	49	49	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	59,590	30,293	50.8%	16,858	28.3%	10,462	17.6%	1,586	2.7%	391	0.7%
duvelisib	483	240	49.7%	145	30.0%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	145,444	80,621	55.4%	35,332	24.3%	23,985	16.5%	4,039	2.8%	1,467	1.0%
dacomitinib	70	43	61.4%	13	18.6%	*****	*****	*****	*****	0	0.0%
cemiplimab-rwlc	6,645	6,617	99.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
sarecycline	14,322	10,655	74.4%	2,893	20.2%	740	5.2%	*****	*****	*****	*****
omadacycline	3,970	3,548	89.4%	277	7.0%	126	3.2%	*****	*****	*****	*****
elapegademase-lvlr	32	16	50.0%	*****	*****	*****	*****	0	0.0%	*****	*****
inotersen	115	53	46.1%	*****	*****	29	25.2%	*****	*****	*****	*****
talazoparib	372	179	48.1%	110	29.6%	72	19.4%	*****	*****	*****	*****
baloxavir marboxil	110,106	109,990	99.9%	*****	*****	*****	0.0%	0	0.0%	0	0.0%

cder_mpl1r_wp251

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
lorlatinib	1,055	450	42.7%	270	25.6%	255	24.2%	56	5.3%	24	2.3%
revefenacin	8,196	6,599	80.5%	1,019	12.4%	495	6.0%	65	0.8%	18	0.2%
rifamycin	68	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
emapalumab-lzsg	37	37	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
glasdegib	325	214	65.8%	90	27.7%	21	6.5%	0	0.0%	0	0.0%
larotrectinib	340	163	47.9%	98	28.8%	66	19.4%	*****	*****	*****	*****
amifampridine	402	123	30.6%	83	20.6%	112	27.9%	42	10.4%	42	10.4%
gilteritinib	1,788	999	55.9%	472	26.4%	288	16.1%	*****	*****	*****	*****
prucalopride	33,124	19,024	57.4%	8,083	24.4%	4,709	14.2%	993	3.0%	315	1.0%
calaspargase pegol-mknl	32	32	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
tagraxofusp-erzs	88	88	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
ravulizumab	1,859	1,788	96.2%	*****	*****	36	1.9%	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	816	1	1	1	1	252	2.0	11.1
patisiran	570	1	1	1	1	231	5.2	21.6
ethinyl estradiol and segesterone acetate	12,072	1	30	71	182	1,125	130.1	150.1
migalastat	170	16	28	97	285	1,372	233.2	310.6
stiripentol	402	1	30	60	210	1,306	175.4	243.6
cenegermin-bkbj	5,521	1	28	56	56	266	46.1	22.4
lanadelumab	1,109	1	28	28	112	1,559	122.9	216.7
eravacycline	723	1	2	6	14	337	11.0	17.6
doravirine	4,812	1	30	60	184	1,702	178.2	266.1
doravirine/lamivudine/tenofovir disoproxil fumarate	995	2	30	60	164	1,488	137.0	194.9
moxetumomab pasudotox-tdfk	49	1	1	1	1	28	2.1	5.4
fremanezumab-vfrm	59,590	1	30	30	90	1,626	87.5	122.4
duvelisib	483	3	28	33	84	477	72.0	75.7
galcanezumab-gnlm	145,444	1	30	30	90	1,610	85.8	133.8
dacomitinib	70	1	30	30	88	614	72.9	102.1
cemiplimab-rwlc	6,645	1	1	1	1	357	1.5	7.4
sarecycline	14,322	1	30	30	52	1,230	45.3	41.9
omadacycline	3,970	1	7	14	16	1,096	23.1	49.1
elapegademase-lvlr	32	14	28	43	84	746	111.5	182.2
inotersen	115	28	28	56	112	1,314	110.9	174.7
talazoparib	372	6	30	49	90	930	87.2	115.0
baloxavir marboxil	110,106	1	1	1	1	270	2.1	5.7
lorlatinib	1,055	1	30	60	122	1,582	126.1	190.0
revefenacin	8,196	1	1	30	30	1,301	37.6	74.9
rifamycin	68	2	3	3	8	72	8.3	11.4

cder_mpl1r_wp251

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	37	1	1	1	1	28	2.0	4.5
glasdegib	325	1	28	30	60	240	43.4	34.2
larotrectinib	340	1	30	37	90	1,251	89.5	128.5
amifampridine	402	6	30	90	270	1,423	248.7	347.9
gilteritinib	1,788	1	30	30	79	1,486	67.0	95.2
prucalopride	33,124	1	30	30	90	1,501	85.7	132.4
calaspargase pegol-mknl	32	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	88	1	1	1	1	5	1.6	1.4
ravulizumab	1,859	1	1	1	1	686	6.4	32.6

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	**816**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	348	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	468	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	**570**	**550**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	209	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	361	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
ethinyl estradiol and segesterone acetate	**12,072**	**4,886**	**100.0%**	**2,774**	**100.0%**	**3,916**	**100.0%**	**424**	**100.0%**	**72**	**100.0%**
Female	12,043	*****	*****	*****	*****	3,902	99.6%	424	100.0%	72	100.0%
Male	29	*****	*****	*****	*****	14	0.4%	0	0.0%	0	0.0%
migalastat	**170**	**49**	**100.0%**	**36**	**100.0%**	**56**	**100.0%**	**14**	**100.0%**	**15**	**100.0%**
Female	86	25	51.0%	22	61.1%	24	42.9%	*****	*****	*****	*****
Male	84	24	49.0%	14	38.9%	32	57.1%	*****	*****	*****	*****
stiripentol	**402**	**147**	**100.0%**	**98**	**100.0%**	**90**	**100.0%**	**55**	**100.0%**	**12**	**100.0%**
Female	211	76	51.7%	56	57.1%	45	50.0%	*****	*****	*****	*****
Male	191	71	48.3%	42	42.9%	45	50.0%	*****	*****	*****	*****
cenegermin-bkbj	**5,521**	**1,542**	**100.0%**	**3,823**	**100.0%**	**156**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	3,544	1,028	66.7%	2,413	63.1%	103	66.0%	0	NaN	0	NaN
Male	1,977	514	33.3%	1,410	36.9%	53	34.0%	0	NaN	0	NaN
lanadelumab	**1,109**	**580**	**100.0%**	**210**	**100.0%**	**237**	**100.0%**	**44**	**100.0%**	**38**	**100.0%**
Female	754	385	66.4%	142	67.6%	164	69.2%	*****	*****	*****	*****
Male	355	195	33.6%	68	32.4%	73	30.8%	*****	*****	*****	*****
eravacycline	**723**	**666**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	378	358	53.8%	*****	*****	*****	*****	0	NaN	0	NaN

cder_mpl1r_wp251

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	345	308	46.2%	37	67.3%	0	0.0%	0	NaN	0	NaN
doravirine	**4,812**	**1,942**	**100.0%**	**1,045**	**100.0%**	**1,141**	**100.0%**	**410**	**100.0%**	**274**	**100.0%**
Female	1,176	516	26.6%	276	26.4%	249	21.8%	90	22.0%	45	16.4%
Male	3,636	1,426	73.4%	769	73.6%	892	78.2%	320	78.0%	229	83.6%
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**429**	**100.0%**	**217**	**100.0%**	**266**	**100.0%**	**60**	**100.0%**	**23**	**100.0%**
Female	311	154	35.9%	64	29.5%	72	27.1%	*****	*****	*****	*****
Male	684	275	64.1%	153	70.5%	194	72.9%	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	**49**	**49**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**59,590**	**30,293**	**100.0%**	**16,858**	**100.0%**	**10,462**	**100.0%**	**1,586**	**100.0%**	**391**	**100.0%**
Female	51,464	26,115	86.2%	14,616	86.7%	9,057	86.6%	1,354	85.4%	322	82.4%
Male	8,126	4,178	13.8%	2,242	13.3%	1,405	13.4%	232	14.6%	69	17.6%
duvelisib	**483**	**240**	**100.0%**	**145**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	212	100	41.7%	70	48.3%	42	45.7%	0	0.0%	0	NaN
Male	271	140	58.3%	75	51.7%	*****	*****	*****	*****	0	NaN
galcanezumab-gnlm	**145,444**	**80,621**	**100.0%**	**35,332**	**100.0%**	**23,985**	**100.0%**	**4,039**	**100.0%**	**1,467**	**100.0%**
Female	123,311	68,199	84.6%	30,058	85.1%	20,431	85.2%	3,380	83.7%	1,243	84.7%
Male	22,133	12,422	15.4%	5,274	14.9%	3,554	14.8%	659	16.3%	224	15.3%
dacomitinib	**70**	**43**	**100.0%**	**13**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	44	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN

cder_mpl1r_wp251

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	26	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
cemiplimab-rwlc	**6,645**	**6,617**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	1,786	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	4,859	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**14,322**	**10,655**	**100.0%**	**2,893**	**100.0%**	**740**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	8,946	6,657	62.5%	1,843	63.7%	426	57.6%	*****	*****	*****	*****
Male	5,376	3,998	37.5%	1,050	36.3%	314	42.4%	*****	*****	*****	*****
omadacycline	**3,970**	**3,548**	**100.0%**	**277**	**100.0%**	**126**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	2,059	1,833	51.7%	152	54.9%	*****	*****	*****	*****	*****	*****
Male	1,911	1,715	48.3%	125	45.1%	*****	*****	*****	*****	*****	*****
elapegademase-lvlr	**32**	**16**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**NaN**	*****	**100.0%**
Female	14	*****	*****	*****	*****	0	*****	0	NaN	*****	*****
Male	18	*****	*****	*****	*****	*****	*****	0	NaN	*****	*****
inotersen	**115**	**53**	**100.0%**	**27**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	54	25	47.2%	13	48.1%	*****	*****	*****	*****	*****	*****
Male	61	28	52.8%	14	51.9%	*****	*****	*****	*****	0	0.0%
talazoparib	**372**	**179**	**100.0%**	**110**	**100.0%**	**72**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	344	165	92.2%	*****	*****	*****	*****	*****	*****	*****	*****
Male	28	14	7.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
baloxavir marboxil	**110,106**	**109,990**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	60,027	59,969	54.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	50,079	50,021	45.5%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	**1,055**	**450**	**100.0%**	**270**	**100.0%**	**255**	**100.0%**	**56**	**100.0%**	**24**	**100.0%**

cder_mpl1r_wp251

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	587	246	54.7%	157	58.1%	142	55.7%	30	53.6%	12	50.0%
Male	468	204	45.3%	113	41.9%	113	44.3%	26	46.4%	12	50.0%
revefenacin	**8,196**	**6,599**	**100.0%**	**1,019**	**100.0%**	**495**	**100.0%**	**65**	**100.0%**	**18**	**100.0%**
Female	4,743	3,788	57.4%	607	59.6%	297	60.0%	*****	*****	*****	*****
Male	3,453	2,811	42.6%	412	40.4%	198	40.0%	*****	*****	*****	*****
rifamycin	**68**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	39	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	29	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**37**	**37**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	20	20	54.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	17	17	45.9%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**325**	**214**	**100.0%**	**90**	**100.0%**	**21**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	139	95	44.4%	*****	*****	*****	*****	0	NaN	0	NaN
Male	186	119	55.6%	*****	*****	*****	*****	0	NaN	0	NaN
larotrectinib	**340**	**163**	**100.0%**	**98**	**100.0%**	**66**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	200	92	56.4%	61	62.2%	*****	*****	*****	*****	*****	*****
Male	140	71	43.6%	37	37.8%	*****	*****	*****	*****	*****	*****
amifampridine	**402**	**123**	**100.0%**	**83**	**100.0%**	**112**	**100.0%**	**42**	**100.0%**	**42**	**100.0%**
Female	226	70	56.9%	47	56.6%	60	53.6%	26	61.9%	23	54.8%
Male	176	53	43.1%	36	43.4%	52	46.4%	16	38.1%	19	45.2%
gilteritinib	**1,788**	**999**	**100.0%**	**472**	**100.0%**	**288**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	860	496	49.6%	220	46.6%	132	45.8%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	928	503	50.4%	252	53.4%	156	54.2%	*****	*****	*****	*****
prucalopride	**33,124**	**19,024**	**100.0%**	**8,083**	**100.0%**	**4,709**	**100.0%**	**993**	**100.0%**	**315**	**100.0%**
Female	26,134	15,054	79.1%	6,387	79.0%	3,694	78.4%	763	76.8%	236	74.9%
Male	6,990	3,970	20.9%	1,696	21.0%	1,015	21.6%	230	23.2%	79	25.1%
calaspargase pegol-mknl	**32**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	11	11	34.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	21	21	65.6%	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**88**	**88**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	13	13	14.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	75	75	85.2%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**1,859**	**1,788**	**100.0%**	**32**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	1,002	960	53.7%	*****	*****	*****	*****	*****	100.0%	0	NaN
Male	857	828	46.3%	*****	*****	*****	*****	0	0.0%	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**816**	**1**	**1**	**1**	**1**	**252**	**2.0**	**11.1**
Female	348	1	1	1	1	252	2.4	14.2
Male	468	1	1	1	1	140	1.8	8.1
patisiran	**570**	**1**	**1**	**1**	**1**	**231**	**5.2**	**21.6**
Female	209	1	1	1	1	231	5.8	22.5
Male	361	1	1	1	1	210	4.9	21.0
ethinyl estradiol and segesterone acetate	**12,072**	**1**	**30**	**71**	**182**	**1,125**	**130.1**	**150.1**
Female	12,043	1	30	71	182	1,125	130.1	150.1
Male	29	1	30	90	170	365	133.0	124.5
migalastat	**170**	**16**	**28**	**97**	**285**	**1,372**	**233.2**	**310.6**
Female	86	20	28	84	308	1,232	234.4	308.3
Male	84	16	28	112	273	1,372	232.0	314.8
stiripentol	**402**	**1**	**30**	**60**	**210**	**1,306**	**175.4**	**243.6**
Female	211	1	30	60	201	1,265	170.4	235.4
Male	191	3	30	60	210	1,306	180.9	252.8
cenegermin-bkbj	**5,521**	**1**	**28**	**56**	**56**	**266**	**46.1**	**22.4**
Female	3,544	1	28	56	56	252	45.7	22.3
Male	1,977	2	28	56	56	266	46.8	22.5
lanadelumab	**1,109**	**1**	**28**	**28**	**112**	**1,559**	**122.9**	**216.7**
Female	754	1	28	28	140	1,559	131.4	227.9
Male	355	1	28	28	108	1,489	104.9	189.8
eravacycline	**723**	**1**	**2**	**6**	**14**	**337**	**11.0**	**17.6**
Female	378	1	1	6	13	337	10.3	20.3
Male	345	1	2	7	15	89	11.8	14.0
doravirine	**4,812**	**1**	**30**	**60**	**184**	**1,702**	**178.2**	**266.1**

cder_mpl1r_wp251

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	1,176	1	30	60	150	1,458	147.1	219.3
Male	3,636	1	30	60	210	1,702	188.2	278.9
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**2**	**30**	**60**	**164**	**1,488**	**137.0**	**194.9**
Female	311	6	30	42	132	1,305	117.4	172.0
Male	684	2	30	60	180	1,488	145.9	204.0
moxetumomab pasudotox-tdfk	**49**	**1**	**1**	**1**	**1**	**28**	**2.1**	**5.4**
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	28	2.3	5.8
fremanezumab-vfrm	**59,590**	**1**	**30**	**30**	**90**	**1,626**	**87.5**	**122.4**
Female	51,464	1	30	30	90	1,626	87.3	121.3
Male	8,126	1	30	30	90	1,485	89.1	128.9
duvelisib	**483**	**3**	**28**	**33**	**84**	**477**	**72.0**	**75.7**
Female	212	3	28	54	84	364	72.4	69.6
Male	271	5	28	28	84	477	71.7	80.3
galcanezumab-gnlm	**145,444**	**1**	**30**	**30**	**90**	**1,610**	**85.8**	**133.8**
Female	123,311	1	30	30	90	1,610	85.7	133.5
Male	22,133	1	30	30	90	1,525	86.4	135.7
dacomitinib	**70**	**1**	**30**	**30**	**88**	**614**	**72.9**	**102.1**
Female	44	1	30	30	89	614	78.9	118.9
Male	26	2	30	30	60	330	62.8	65.4
cemiplimab-rwlc	**6,645**	**1**	**1**	**1**	**1**	**357**	**1.5**	**7.4**
Female	1,786	1	1	1	1	294	1.5	8.3
Male	4,859	1	1	1	1	357	1.4	7.0
sarecycline	**14,322**	**1**	**30**	**30**	**52**	**1,230**	**45.3**	**41.9**

cder_mpl1r_wp251

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	8,946	1	30	30	50	844	44.9	40.2
Male	5,376	1	30	30	58	1,230	46.0	44.6
omadacycline	**3,970**	**1**	**7**	**14**	**16**	**1,096**	**23.1**	**49.1**
Female	2,059	1	7	14	17	734	23.2	46.6
Male	1,911	1	7	13	16	1,096	23.0	51.6
elapegademase-lvlr	**32**	**14**	**28**	**43**	**84**	**746**	**111.5**	**182.2**
Female	14	28	28	28	56	746	91.3	189.6
Male	18	14	28	56	127	746	127.2	180.1
inotersen	**115**	**28**	**28**	**56**	**112**	**1,314**	**110.9**	**174.7**
Female	54	28	28	56	116	1,314	118.8	215.8
Male	61	28	28	56	112	700	103.9	129.4
talazoparib	**372**	**6**	**30**	**49**	**90**	**930**	**87.2**	**115.0**
Female	344	6	30	49	90	930	88.5	117.8
Male	28	10	30	43	83	330	71.0	71.2
baloxavir marboxil	**110,106**	**1**	**1**	**1**	**1**	**270**	**2.1**	**5.7**
Female	60,027	1	1	1	1	270	2.2	5.8
Male	50,079	1	1	1	1	180	2.1	5.5
lorlatinib	**1,055**	**1**	**30**	**60**	**122**	**1,582**	**126.1**	**190.0**
Female	587	1	30	60	129	1,582	124.1	185.9
Male	468	1	30	60	120	1,424	128.7	195.1
revefenacin	**8,196**	**1**	**1**	**30**	**30**	**1,301**	**37.6**	**74.9**
Female	4,743	1	1	30	30	1,301	38.9	76.6
Male	3,453	1	1	30	30	1,244	35.9	72.5
rifamycin	**68**	**2**	**3**	**3**	**8**	**72**	**8.3**	**11.4**
Female	39	2	3	3	9	72	8.6	12.8

cder_mpl1r_wp251

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	29	2	3	3	6	31	7.9	9.6
emapalumab-lzsg	**37**	**1**	**1**	**1**	**1**	**28**	**2.0**	**4.5**
Female	20	1	1	1	1	4	1.2	0.7
Male	17	1	1	1	1	28	2.9	6.6
glasdegib	**325**	**1**	**28**	**30**	**60**	**240**	**43.4**	**34.2**
Female	139	4	28	30	60	150	42.1	29.1
Male	186	1	28	30	60	240	44.4	37.7
larotrectinib	**340**	**1**	**30**	**37**	**90**	**1,251**	**89.5**	**128.5**
Female	200	1	30	50	90	864	85.6	109.9
Male	140	5	30	30	90	1,251	95.1	151.5
amifampridine	**402**	**6**	**30**	**90**	**270**	**1,423**	**248.7**	**347.9**
Female	226	6	30	90	300	1,423	250.4	342.1
Male	176	8	30	90	240	1,420	246.4	356.1
gilteritinib	**1,788**	**1**	**30**	**30**	**79**	**1,486**	**67.0**	**95.2**
Female	860	1	30	30	60	1,118	65.9	96.1
Male	928	1	30	30	90	1,486	68.0	94.5
prucalopride	**33,124**	**1**	**30**	**30**	**90**	**1,501**	**85.7**	**132.4**
Female	26,134	1	30	30	90	1,501	84.8	130.5
Male	6,990	1	30	30	90	1,371	89.2	139.1
calaspargase pegol-mknl	**32**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
Female	11	1	1	1	1	1	1.0	0.0
Male	21	1	1	1	1	1	1.0	0.0
tagraxofusp-erzs	**88**	**1**	**1**	**1**	**1**	**5**	**1.6**	**1.4**
Female	13	1	1	1	1	4	1.2	0.8
Male	75	1	1	1	1	5	1.6	1.4

cder_mpl1r_wp251

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	**1,859**	**1**	**1**	**1**	**1**	**686**	**6.4**	**32.6**
Female	1,002	1	1	1	1	686	8.0	40.7
Male	857	1	1	1	1	233	4.6	19.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**816**	**1**	**1**	**1**	**1**	**252**	**2.0**	**11.1**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	140	6.6	27.8
41-64 years	171	1	1	1	1	252	3.4	19.8
≥ 65 years	616	1	1	1	1	84	1.5	4.8
patisiran	**570**	**1**	**1**	**1**	**1**	**231**	**5.2**	**21.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	1	1	1	1	42	6.1	12.7
41-64 years	122	1	1	1	1	168	8.1	29.0
≥ 65 years	436	1	1	1	1	231	4.4	19.2
ethinyl estradiol and segesterone acetate	**12,072**	**1**	**30**	**71**	**182**	**1,125**	**130.1**	**150.1**
0-17 years	*****	1	30	60	167	994	126.5	151.5
18-24 years	3,833	1	30	90	215	1,022	141.2	153.8
25-40 years	6,682	1	30	62	174	1,125	124.3	146.6
41-64 years	1,107	1	30	62	178	1,112	127.9	154.7
≥ 65 years	*****	27	27	27	27	27	27.0	NaN
migalastat	**170**	**16**	**28**	**97**	**285**	**1,372**	**233.2**	**310.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	28	28	70	140	364	112.3	108.8
25-40 years	44	16	28	83	210	1,320	182.6	283.8
41-64 years	74	20	56	112	336	1,335	242.9	305.4
≥ 65 years	40	28	28	177	335	1,372	307.2	371.5
stiripentol	**402**	**1**	**30**	**60**	**210**	**1,306**	**175.4**	**243.6**

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	303	1	30	60	192	1,280	169.0	238.4
18-24 years	79	3	30	60	216	1,265	175.8	233.0
25-40 years	20	15	30	150	431	1,306	270.6	339.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**5,521**	**1**	**28**	**56**	**56**	**266**	**46.1**	**22.4**
0-17 years	43	2	14	42	56	140	44.1	32.6
18-24 years	27	7	28	49	56	112	45.1	24.1
25-40 years	199	1	14	49	56	184	43.7	29.7
41-64 years	1,025	1	28	56	56	252	48.5	29.0
≥ 65 years	4,227	2	28	56	56	266	45.6	19.8
lanadelumab	**1,109**	**1**	**28**	**28**	**112**	**1,559**	**122.9**	**216.7**
0-17 years	102	1	28	28	84	1,441	109.2	220.1
18-24 years	103	1	28	28	84	672	66.6	84.8
25-40 years	303	1	28	28	84	1,559	105.6	210.5
41-64 years	404	1	28	48	140	1,524	132.8	217.7
≥ 65 years	197	5	28	56	168	1,489	165.8	258.5
eravacycline	**723**	**1**	**2**	**6**	**14**	**337**	**11.0**	**17.6**
0-17 years	*****	1	1	1	2	2	1.3	0.6
18-24 years	*****	1	1	6	8	30	7.3	9.4
25-40 years	60	1	1	4	12	39	7.9	9.4
41-64 years	274	1	1	6	13	84	10.1	13.1
≥ 65 years	377	1	3	7	15	337	12.3	21.2
doravirine	**4,812**	**1**	**30**	**60**	**184**	**1,702**	**178.2**	**266.1**
0-17 years	*****	30	30	30	30	30	30.0	0.0

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	10	30	30	60	209	54.2	47.3
25-40 years	601	4	30	56	121	1,411	113.3	155.1
41-64 years	3,111	1	30	60	183	1,702	179.6	269.0
≥ 65 years	1,061	1	30	84	240	1,524	215.4	301.7
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**2**	**30**	**60**	**164**	**1,488**	**137.0**	**194.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	27	10	30	30	150	444	101.7	116.9
25-40 years	241	2	30	59	132	1,301	110.2	149.3
41-64 years	616	5	30	60	180	1,488	146.8	201.6
≥ 65 years	111	20	30	60	150	1,474	149.1	248.5
moxetumomab pasudotox-tdfk	**49**	**1**	**1**	**1**	**1**	**28**	**2.1**	**5.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	28	4.4	9.5
≥ 65 years	*****	1	1	1	1	28	1.7	4.3
fremanezumab-vfrm	**59,590**	**1**	**30**	**30**	**90**	**1,626**	**87.5**	**122.4**
0-17 years	338	1	30	30	90	735	70.5	86.9
18-24 years	3,605	1	30	30	90	1,368	74.9	93.6
25-40 years	16,253	1	30	30	90	1,626	82.2	111.5
41-64 years	31,745	1	30	31	90	1,580	90.7	128.6
≥ 65 years	7,649	1	30	30	90	1,448	92.3	130.3
duvelisib	**483**	**3**	**28**	**33**	**84**	**477**	**72.0**	**75.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	**Minimum**	**Q1**	**Median**	**Q3**	**Maximum**	**Mean**	**Standard Deviation**
18-24 years	*****	25	25	25	25	25	25.0	NaN
25-40 years	*****	4	28	55	84	224	67.7	63.1
41-64 years	90	5	28	29	84	252	62.1	52.1
≥ 65 years	381	3	28	33	84	477	74.7	80.5
galcanezumab-gnlm	**145,444**	**1**	**30**	**30**	**90**	**1,610**	**85.8**	**133.8**
0-17 years	720	1	30	30	90	1,248	92.7	136.6
18-24 years	8,573	1	30	30	84	1,556	74.5	110.9
25-40 years	41,582	1	30	30	86	1,576	80.2	121.5
41-64 years	75,850	1	30	30	90	1,610	89.6	141.6
≥ 65 years	18,719	1	30	30	90	1,454	88.0	136.3
dacomitinib	**70**	**1**	**30**	**30**	**88**	**614**	**72.9**	**102.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	20	1	30	30	101	510	79.2	110.9
≥ 65 years	50	2	30	30	60	614	70.4	99.4
cemiplimab-rwlc	**6,645**	**1**	**1**	**1**	**1**	**357**	**1.5**	**7.4**
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	42	2.6	8.0
41-64 years	556	1	1	1	1	147	1.6	6.9
≥ 65 years	6,060	1	1	1	1	357	1.4	7.4
sarecycline	**14,322**	**1**	**30**	**30**	**52**	**1,230**	**45.3**	**41.9**
0-17 years	6,312	1	30	30	60	630	45.3	39.9

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	3,945	1	30	30	55	1,230	46.0	46.0
25-40 years	2,704	1	30	30	30	480	43.2	35.2
41-64 years	1,258	5	30	30	60	844	47.4	49.0
≥ 65 years	103	3	30	30	30	611	43.0	61.5
omadacycline	**3,970**	**1**	**7**	**14**	**16**	**1,096**	**23.1**	**49.1**
0-17 years	31	1	9	30	75	414	63.7	100.4
18-24 years	75	1	8	14	28	372	31.1	63.7
25-40 years	319	1	10	14	20	619	25.8	54.9
41-64 years	1,610	1	8	14	16	1,096	22.0	51.0
≥ 65 years	1,935	1	7	12	16	510	22.6	44.1
elapegademase-lvlr	**32**	**14**	**28**	**43**	**84**	**746**	**111.5**	**182.2**
0-17 years	13	28	28	56	127	746	178.5	263.5
18-24 years	*****	14	28	28	56	280	60.2	79.8
25-40 years	*****	28	28	56	70	252	73.5	74.7
41-64 years	*****	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**115**	**28**	**28**	**56**	**112**	**1,314**	**110.9**	**174.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	56	84	84	56.0	39.6
41-64 years	*****	28	28	56	116	1,314	171.4	307.9
≥ 65 years	88	28	28	56	112	700	94.9	111.6
talazoparib	**372**	**6**	**30**	**49**	**90**	**930**	**87.2**	**115.0**
0-17 years	*****	15	15	410	804	804	409.5	557.9
18-24 years	*****	60	60	60	60	60	60.0	NaN

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	15	30	30	90	930	82.5	137.6
41-64 years	190	6	30	58	94	921	90.2	111.1
≥ 65 years	133	9	30	42	90	630	79.9	95.0
baloxavir marboxil	**110,106**	**1**	**1**	**1**	**1**	**270**	**2.1**	**5.7**
0-17 years	19,064	1	1	1	1	90	1.2	2.0
18-24 years	11,454	1	1	1	1	60	1.2	2.4
25-40 years	26,040	1	1	1	1	90	1.3	2.6
41-64 years	34,588	1	1	1	1	270	1.5	3.9
≥ 65 years	18,960	1	1	1	1	180	6.1	11.1
lorlatinib	**1,055**	**1**	**30**	**60**	**122**	**1,582**	**126.1**	**190.0**
0-17 years	*****	2	30	30	90	1,011	104.2	175.5
18-24 years	*****	2	14	30	90	261	67.3	89.9
25-40 years	80	1	30	60	166	674	128.4	158.1
41-64 years	448	1	30	60	150	1,582	137.8	209.3
≥ 65 years	475	3	30	51	120	1,424	117.7	177.4
revefenacin	**8,196**	**1**	**1**	**30**	**30**	**1,301**	**37.6**	**74.9**
0-17 years	*****	1	1	16	30	30	15.5	20.5
18-24 years	*****	1	1	30	30	600	76.2	160.4
25-40 years	111	1	7	30	60	935	63.5	117.0
41-64 years	2,438	1	2	30	30	1,080	46.9	84.6
≥ 65 years	5,627	1	1	30	30	1,301	32.9	68.2
rifamycin	**68**	**2**	**3**	**3**	**8**	**72**	**8.3**	**11.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	3	3	3	14	5.0	5.0
25-40 years	*****	2	3	3	6	72	11.7	19.0

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	33	3	3	3	9	30	7.6	8.0
≥ 65 years	15	3	3	3	6	30	7.5	9.6
emapalumab-lzsg	**37**	**1**	**1**	**1**	**1**	**28**	**2.0**	**4.5**
0-17 years	20	1	1	1	1	28	2.7	6.1
18-24 years	*****	1	1	1	4	4	2.0	1.7
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
glasdegib	**325**	**1**	**28**	**30**	**60**	**240**	**43.4**	**34.2**
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	19	24	28	28	112	42.2	39.2
41-64 years	*****	14	26	30	60	120	42.0	27.5
≥ 65 years	286	1	28	30	60	240	43.6	35.0
larotrectinib	**340**	**1**	**30**	**37**	**90**	**1,251**	**89.5**	**128.5**
0-17 years	48	3	30	30	83	396	81.8	98.5
18-24 years	*****	5	30	60	210	409	118.9	143.7
25-40 years	*****	19	30	30	90	1,251	156.1	296.4
41-64 years	101	1	30	60	103	648	90.5	115.1
≥ 65 years	163	3	30	34	90	864	81.3	106.2
amifampridine	**402**	**6**	**30**	**90**	**270**	**1,423**	**248.7**	**347.9**
0-17 years	*****	30	30	35	112	480	108.1	146.6
18-24 years	*****	30	30	90	180	443	127.1	134.0
25-40 years	31	15	30	60	300	1,080	183.2	238.0
41-64 years	128	6	30	60	240	1,423	230.8	347.4

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	223	12	30	120	303	1,420	279.8	370.1
gilteritinib	**1,788**	**1**	**30**	**30**	**79**	**1,486**	**67.0**	**95.2**
0-17 years	24	1	18	30	60	120	43.5	40.0
18-24 years	30	1	30	30	120	360	72.8	76.7
25-40 years	117	1	30	44	90	340	67.1	63.6
41-64 years	453	1	30	30	60	1,486	70.0	115.6
≥ 65 years	1,164	1	30	30	81	969	66.1	90.2
prucalopride	**33,124**	**1**	**30**	**30**	**90**	**1,501**	**85.7**	**132.4**
0-17 years	440	1	30	30	80	977	81.2	126.4
18-24 years	1,763	1	30	30	90	1,305	82.7	123.8
25-40 years	5,304	1	30	30	90	1,371	83.0	125.3
41-64 years	13,804	1	30	30	90	1,372	89.7	137.2
≥ 65 years	11,813	1	30	30	90	1,501	82.9	131.1
calaspargase pegol-mknl	**32**	**1**	**1**	**1**	**1**	**1**	**1.0**	**0.0**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
tagraxofusp-erzs	**88**	**1**	**1**	**1**	**1**	**5**	**1.6**	**1.4**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	5	1.8	1.8
41-64 years	*****	1	1	1	1	4	1.4	1.1
≥ 65 years	71	1	1	1	1	5	1.6	1.4

cder_mpl1r_wp251

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
ravulizumab	**1,859**	**1**	**1**	**1**	**1**	**686**	**6.4**	**32.6**
0-17 years	119	1	1	1	1	280	7.4	32.8
18-24 years	94	1	1	1	1	324	7.8	39.7
25-40 years	361	1	1	1	1	452	5.6	31.2
41-64 years	508	1	1	1	1	686	7.0	40.0
≥ 65 years	777	1	1	1	1	370	6.1	26.4

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mogamulizumab-kpkc	**816**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	171	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	616	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
patisiran	**570**	**550**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	12	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	122	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	436	423	76.9%	*****	*****	*****	*****	0	NaN	0	NaN
ethinyl estradiol and segesterone acetate	**12,072**	**4,886**	**100.0%**	**2,774**	**100.0%**	**3,916**	**100.0%**	**424**	**100.0%**	**72**	**100.0%**
0-17 years	*****	*****	*****	122	4.4%	130	3.3%	*****	*****	*****	*****
18-24 years	3,833	1,459	29.9%	850	30.6%	1,340	34.2%	167	39.4%	17	23.6%
25-40 years	6,682	2,768	56.7%	1,562	56.3%	2,109	53.9%	199	46.9%	44	61.1%
41-64 years	1,107	480	9.8%	240	8.7%	337	8.6%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
migalastat	**170**	**49**	**100.0%**	**36**	**100.0%**	**56**	**100.0%**	**14**	**100.0%**	**15**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	44	16	32.7%	11	30.6%	*****	*****	*****	*****	*****	*****

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	74	18	36.7%	15	41.7%	24	42.9%	*****	*****	*****	*****
≥ 65 years	40	*****	*****	*****	*****	14	25.0%	*****	*****	*****	*****
stiripentol	**402**	**147**	**100.0%**	**98**	**100.0%**	**90**	**100.0%**	**55**	**100.0%**	**12**	**100.0%**
0-17 years	303	107	72.8%	79	80.6%	72	80.0%	*****	*****	*****	*****
18-24 years	79	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	20	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	**5,521**	**1,542**	**100.0%**	**3,823**	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	43	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	199	77	5.0%	109	2.9%	*****	*****	0	NaN	0	NaN
41-64 years	1,025	299	19.4%	658	17.2%	68	43.6%	0	NaN	0	NaN
≥ 65 years	4,227	1,141	74.0%	3,017	78.9%	69	44.2%	0	NaN	0	NaN
lanadelumab	**1,109**	**580**	**100.0%**	**210**	**100.0%**	**237**	**100.0%**	**44**	**100.0%**	**38**	**100.0%**
0-17 years	102	53	9.1%	27	12.9%	*****	*****	*****	*****	*****	*****
18-24 years	103	66	11.4%	13	6.2%	*****	*****	*****	*****	0	0.0%
25-40 years	303	174	30.0%	56	26.7%	*****	*****	*****	*****	*****	*****
41-64 years	404	196	33.8%	82	39.0%	91	38.4%	20	45.5%	15	39.5%
≥ 65 years	197	91	15.7%	32	15.2%	50	21.1%	*****	*****	*****	*****
eravacycline	**723**	**666**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	60	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	274	253	38.0%	21	38.2%	0	0.0%	0	NaN	0	NaN
≥ 65 years	377	344	51.7%	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**4,812**	**1,942**	**100.0%**	**1,045**	**100.0%**	**1,141**	**100.0%**	**410**	**100.0%**	**274**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	601	283	14.6%	*****	*****	*****	*****	36	8.8%	*****	*****
41-64 years	3,111	1,256	64.7%	672	64.3%	738	64.7%	262	63.9%	183	66.8%
≥ 65 years	1,061	*****	*****	223	21.3%	263	23.0%	112	27.3%	*****	*****
doravirine/lamivudine/tenofovir disoproxil fumarate	**995**	**429**	**100.0%**	**217**	**100.0%**	**266**	**100.0%**	**60**	**100.0%**	**23**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	27	14	3.3%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	241	108	25.2%	*****	*****	66	24.8%	*****	*****	*****	*****
41-64 years	616	255	59.4%	131	60.4%	167	62.8%	*****	*****	*****	*****
≥ 65 years	111	52	12.1%	22	10.1%	*****	*****	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	**49**	**49**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**59,590**	**30,293**	**100.0%**	**16,858**	**100.0%**	**10,462**	**100.0%**	**1,586**	**100.0%**	**391**	**100.0%**
0-17 years	338	180	0.6%	111	0.7%	*****	*****	*****	*****	*****	*****
18-24 years	3,605	1,881	6.2%	1,097	6.5%	*****	*****	*****	*****	*****	*****
25-40 years	16,253	8,470	28.0%	4,566	27.1%	2,757	26.4%	392	24.7%	68	17.4%
41-64 years	31,745	15,855	52.3%	8,998	53.4%	5,744	54.9%	900	56.7%	248	63.4%
≥ 65 years	7,649	3,907	12.9%	2,086	12.4%	1,357	13.0%	*****	*****	*****	*****
duvelisib	**483**	**240**	**100.0%**	**145**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	90	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	381	189	78.8%	112	77.2%	*****	*****	*****	*****	0	NaN
galcanezumab-gnlm	**145,444**	**80,621**	**100.0%**	**35,332**	**100.0%**	**23,985**	**100.0%**	**4,039**	**100.0%**	**1,467**	**100.0%**
0-17 years	720	367	0.5%	188	0.5%	134	0.6%	*****	*****	*****	*****
18-24 years	8,573	5,012	6.2%	2,040	5.8%	1,294	5.4%	*****	*****	*****	*****
25-40 years	41,582	23,331	28.9%	10,231	29.0%	6,713	28.0%	992	24.6%	315	21.5%
41-64 years	75,850	41,684	51.7%	18,184	51.5%	12,773	53.3%	2,321	57.5%	888	60.5%
≥ 65 years	18,719	10,227	12.7%	4,689	13.3%	3,071	12.8%	523	12.9%	209	14.2%
dacomitinib	**70**	**43**	**100.0%**	**13**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	20	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	50	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**6,645**	**6,617**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	556	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	6,060	6,037	91.2%	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**14,322**	**10,655**	**100.0%**	**2,893**	**100.0%**	**740**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	6,312	4,651	43.7%	1,334	46.1%	314	42.4%	13	40.6%	0	0.0%
18-24 years	3,945	2,930	27.5%	781	27.0%	222	30.0%	*****	*****	*****	*****
25-40 years	2,704	2,059	19.3%	514	17.8%	*****	*****	*****	*****	0	0.0%
41-64 years	1,258	932	8.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	103	83	0.8%	*****	*****	*****	*****	*****	*****	0	0.0%
omadacycline	**3,970**	**3,548**	**100.0%**	**277**	**100.0%**	**126**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	31	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	75	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	319	284	8.0%	*****	*****	*****	*****	*****	*****	0	0.0%

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	1,610	1,453	41.0%	116	41.9%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,935	1,724	48.6%	131	47.3%	*****	*****	*****	*****	0	0.0%
elapegademase-lvlr	**32**	**16**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	*****	**100.0%**
0-17 years	13	*****	*****	*****	*****	*****	*****	0	NaN	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	0.0%
inotersen	**115**	**53**	**100.0%**	**27**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	88	40	75.5%	*****	*****	*****	*****	*****	*****	*****	0.0%
talazoparib	**372**	**179**	**100.0%**	**110**	**100.0%**	**72**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	190	88	49.2%	54	49.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	133	66	36.9%	43	39.1%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	**110,106**	**109,990**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**

cder_mpl1r_wp251

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	19,064	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	11,454	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	26,040	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	34,588	34,559	31.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	18,960	18,888	17.2%	*****	*****	*****	*****	0	NaN	0	NaN
lorlatinib	**1,055**	**450**	**100.0%**	**270**	**100.0%**	**255**	**100.0%**	**56**	**100.0%**	**24**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	80	36	8.0%	17	6.3%	*****	*****	*****	*****	0	0.0%
41-64 years	448	162	36.0%	130	48.1%	118	46.3%	24	42.9%	*****	*****
≥ 65 years	475	225	50.0%	110	40.7%	110	43.1%	*****	*****	*****	*****
revefenacin	**8,196**	**6,599**	**100.0%**	**1,019**	**100.0%**	**495**	**100.0%**	**65**	**100.0%**	**18**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	111	73	1.1%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,438	1,832	27.8%	369	36.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	5,627	4,677	70.9%	625	61.3%	283	57.2%	*****	*****	*****	*****
rifamycin	**68**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Patients by First Treatment Episode Duration | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	33	33	50.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	15	15	22.7%	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**37**	**37**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	20	20	54.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**325**	**214**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	286	189	88.3%	79	87.8%	18	85.7%	0	NaN	0	NaN
larotrectinib	**340**	**163**	**100.0%**	**98**	**100.0%**	**66**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	48	25	15.3%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	101	45	27.6%	29	29.6%	*****	*****	*****	*****	0	0.0%
≥ 65 years	163	80	49.1%	47	48.0%	*****	*****	*****	*****	*****	*****

| | Total Number of Patients | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
amifampridine	**402**	**123**	**100.0%**	**83**	**100.0%**	**112**	**100.0%**	**42**	**100.0%**	**42**	**100.0%**
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	31	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	128	47	38.2%	26	31.3%	29	25.9%	*****	*****	*****	*****
≥ 65 years	223	57	46.3%	45	54.2%	70	62.5%	23	54.8%	28	66.7%
gilteritinib	**1,788**	**999**	**100.0%**	**472**	**100.0%**	**288**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	24	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	30	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	117	57	5.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	453	259	25.9%	123	26.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,164	652	65.3%	301	63.8%	189	65.6%	*****	*****	*****	*****
prucalopride	**33,124**	**19,024**	**100.0%**	**8,083**	**100.0%**	**4,709**	**100.0%**	**993**	**100.0%**	**315**	**100.0%**
0-17 years	440	262	1.4%	98	1.2%	63	1.3%	*****	*****	*****	*****
18-24 years	1,763	1,044	5.5%	416	5.1%	229	4.9%	*****	*****	*****	*****
25-40 years	5,304	3,064	16.1%	1,266	15.7%	769	16.3%	163	16.4%	42	13.3%
41-64 years	13,804	7,559	39.7%	3,596	44.5%	2,055	43.6%	451	45.4%	143	45.4%
≥ 65 years	11,813	7,095	37.3%	2,707	33.5%	1,593	33.8%	305	30.7%	113	35.9%
calaspargase pegol-mknl	**32**	**32**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp251

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Patients	Number of Patients (1-30 Days)	Percent of Total Patients (1-30 Days)	Number of Patients (31-90 Days)	Percent of Total Patients (31-90 Days)	Number of Patients (91-365 Days)	Percent of Total Patients (91-365 Days)	Number of Patients (366-730 Days)	Percent of Total Patients (366-730 Days)	Number of Patients (731+ Days)	Percent of Total Patients (731+ Days)
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**88**	**88**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	71	71	80.7%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**1,859**	**1,788**	**100.0%**	**32**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	119	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	94	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	361	348	19.5%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	508	490	27.4%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	777	746	41.7%	15	46.9%	*****	*****	*****	*****	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)								
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	of Episodes	Percent of Total Episodes	of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	11,465	11,445	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
patisiran	11,536	11,463	99.4%	*****	*****	44	0.4%	*****	*****	0	0.0%
acetate	1,696	821	48.4%	427	25.2%	420	24.8%	28	1.7%	0	0.0%
migalastat	535	253	47.3%	160	29.9%	100	18.7%	*****	*****	*****	*****
stiripentol	718	325	45.3%	219	30.5%	141	19.6%	*****	*****	*****	*****
cenegermin-bkbj	2,778	1,665	59.9%	1,076	38.7%	*****	*****	*****	*****	0	0.0%
lanadelumab	4,873	2,918	59.9%	1,114	22.9%	721	14.8%	87	1.8%	33	0.7%
eravacycline	794	774	97.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
doravirine	12,017	6,271	52.2%	3,156	26.3%	2,013	16.8%	433	3.6%	144	1.2%
doravirine/lamivudine/tenofovir disoproxil fumarate	2,009	1,143	56.9%	528	26.3%	272	13.5%	48	2.4%	18	0.9%
moxetumomab pasudotox-tdfk	369	369	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	132,820	71,876	54.1%	38,500	29.0%	20,009	15.1%	2,042	1.5%	393	0.3%
duvelisib	733	418	57.0%	190	25.9%	114	15.6%	*****	*****	*****	*****
galcanezumab-gnlm	350,640	199,693	57.0%	94,563	27.0%	49,433	14.1%	5,655	1.6%	1,296	0.4%
dacomitinib	86	48	55.8%	21	24.4%	*****	*****	*****	*****	0	0.0%
cemiplimab-rwlc	54,816	54,747	99.9%	49	0.1%	20	0.0%	0	0.0%	0	0.0%
sarecycline	17,129	13,675	79.8%	2,844	16.6%	594	3.5%	*****	*****	*****	*****
omadacycline	3,003	2,512	83.6%	356	11.9%	*****	*****	*****	*****	*****	*****
elapegademase-lvlr	230	155	67.4%	54	23.5%	*****	*****	*****	*****	*****	*****
inotersen	368	197	53.5%	89	24.2%	70	19.0%	*****	*****	*****	*****
talazoparib	582	341	58.6%	147	25.3%	*****	*****	*****	*****	0	0.0%
baloxavir marboxil	4,641	4,624	99.6%	17	0.4%	0	0.0%	0	0.0%	0	0.0%

cder_mpl1r_wp251

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	of Episodes	Percent of Total Episodes	of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
lorlatinib	1,567	840	53.6%	423	27.0%	251	16.0%	41	2.6%	12	0.8%
revefenacin	17,253	14,948	86.6%	1,585	9.2%	640	3.7%	64	0.4%	16	0.1%
rifamycin	19	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
emapalumab-lzsg	469	469	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
glasdegib	145	98	67.6%	36	24.8%	11	7.6%	0	0.0%	0	0.0%
larotrectinib	372	216	58.1%	103	27.7%	*****	*****	*****	*****	*****	*****
amifampridine	1,126	533	47.3%	313	27.8%	187	16.6%	63	5.6%	30	2.7%
gilteritinib	2,325	1,347	57.9%	621	26.7%	331	14.2%	*****	*****	*****	*****
prucalopride	53,489	29,872	55.8%	14,977	28.0%	7,558	14.1%	882	1.6%	200	0.4%
calaspargase pegol-mknl	18	18	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
tagraxofusp-erzs	307	307	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
ravulizumab	11,047	10,892	98.6%	*****	*****	73	0.7%	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	11,465	1	1	1	1	323	1.2	5.5
patisiran	11,536	1	1	1	1	651	2.0	14.7
ethinyl estradiol and segesterone acetate	1,696	1	28	33	91	681	91.8	105.1
migalastat	535	2	28	56	84	828	87.5	116.9
stiripentol	718	1	30	40	90	1,124	95.5	138.8
cenegermin-bkbj	2,778	1	14	28	42	413	31.9	24.4
lanadelumab	4,873	1	28	28	56	1,497	71.8	114.7
eravacycline	794	1	1	1	6	141	5.4	10.8
doravirine	12,017	1	30	30	90	1,565	94.4	146.8
fumarate	2,009	1	30	30	76	1,378	80.3	123.1
moxetumomab pasudotox-tdfk	369	1	1	1	1	2	1.0	0.1
fremanezumab-vfrm	132,820	1	30	30	90	1,543	73.3	94.7
duvelisib	733	1	28	28	65	1,098	65.2	86.4
galcanezumab-gnlm	350,640	1	30	30	75	1,496	70.6	96.3
dacomitinib	86	4	30	30	90	596	85.7	111.2
cemiplimab-rwlc	54,816	1	1	1	1	315	1.1	3.9
sarecycline	17,129	1	30	30	30	750	40.4	32.0
omadacycline	3,003	1	5	14	30	1,145	26.6	48.8
elapegademase-lvlr	230	2	28	28	56	1,243	54.8	102.3
inotersen	368	2	28	28	84	1,260	84.9	126.8
talazoparib	582	1	30	30	60	660	62.7	69.2
baloxavir marboxil	4,641	1	1	1	1	90	2.9	7.3
lorlatinib	1,567	1	30	30	90	1,397	82.6	128.5
revefenacin	17,253	1	1	1	30	1,248	23.5	57.2

cder_mpl1r_wp251

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
rifamycin	19	3	3	6	27	42	12.1	12.5
emapalumab-lzsg	469	1	1	1	1	15	1.2	1.3
glasdegib	145	10	28	30	56	210	45.3	34.6
larotrectinib	372	4	30	30	60	944	68.9	105.7
amifampridine	1,126	2	30	60	90	1,364	123.1	196.5
gilteritinib	2,325	1	30	30	60	1,335	64.7	85.5
prucalopride	53,489	1	30	30	90	1,273	74.1	97.4
calaspargase pegol-mknl	18	1	1	1	1	2	1.1	0.2
tagraxofusp-erzs	307	1	1	4	5	5	3.2	1.8
ravulizumab	11,047	1	1	1	1	721	3.1	21.4

cder_mpl1r_wp251

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	**11,465**	**11,445**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	5,055	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	6,410	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	**11,536**	**11,463**	**100.0%**	**26**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	3,877	3,840	33.5%	11	42.3%	*****	*****	*****	*****	0	NaN
Male	7,659	7,623	66.5%	15	57.7%	*****	*****	*****	*****	0	NaN
ethinyl estradiol and segesterone acetate	**1,696**	**821**	**100.0%**	**427**	**100.0%**	**420**	**100.0%**	**28**	**100.0%**	**0**	**NaN**
Female	*****	821	100.0%	*****	*****	420	100.0%	28	100.0%	0	NaN
Male	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
migalastat	**535**	**253**	**100.0%**	**160**	**100.0%**	**100**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	262	121	47.8%	77	48.1%	*****	*****	*****	*****	*****	*****
Male	273	132	52.2%	83	51.9%	*****	*****	*****	*****	*****	*****
stiripentol	**718**	**325**	**100.0%**	**219**	**100.0%**	**141**	**100.0%**	*****	*****	*****	*****
Female	442	215	66.2%	116	53.0%	89	63.1%	*****	*****	*****	*****
Male	276	110	33.8%	103	47.0%	52	36.9%	*****	*****	*****	*****
cenegermin-bkbj	**2,778**	**1,665**	**100.0%**	**1,076**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	1,863	1,130	67.9%	708	65.8%	*****	*****	0	0.0%	0	NaN
Male	915	535	32.1%	368	34.2%	*****	*****	*****	*****	0	NaN
lanadelumab	**4,873**	**2,918**	**100.0%**	**1,114**	**100.0%**	**721**	**100.0%**	**87**	**100.0%**	**33**	**100.0%**
Female	3,217	1,890	64.8%	748	67.1%	499	69.2%	*****	*****	*****	*****
Male	1,656	1,028	35.2%	366	32.9%	222	30.8%	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
eravacycline	**794**	**774**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	501	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Male	293	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**12,017**	**6,271**	**100.0%**	**3,156**	**100.0%**	**2,013**	**100.0%**	**433**	**100.0%**	**144**	**100.0%**
Female	2,773	1,530	24.4%	693	22.0%	438	21.8%	90	20.8%	22	15.3%
Male	9,244	4,741	75.6%	2,463	78.0%	1,575	78.2%	343	79.2%	122	84.7%
doravirine/lamivudine/tenofovir disoproxil fumarate	**2,009**	**1,143**	**100.0%**	**528**	**100.0%**	**272**	**100.0%**	**48**	**100.0%**	**18**	**100.0%**
Female	621	376	32.9%	154	29.2%	*****	*****	*****	*****	*****	*****
Male	1,388	767	67.1%	374	70.8%	*****	*****	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	**369**	**369**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	60	60	16.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	309	309	83.7%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**132,820**	**71,876**	**100.0%**	**38,500**	**100.0%**	**20,009**	**100.0%**	**2,042**	**100.0%**	**393**	**100.0%**
Female	115,099	62,481	86.9%	33,293	86.5%	17,234	86.1%	1,748	85.6%	343	87.3%
Male	17,721	9,395	13.1%	5,207	13.5%	2,775	13.9%	294	14.4%	50	12.7%
duvelisib	**733**	**418**	**100.0%**	**190**	**100.0%**	**114**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	320	188	45.0%	78	41.1%	*****	*****	*****	*****	*****	*****
Male	413	230	55.0%	112	58.9%	*****	*****	*****	*****	0	0.0%
galcanezumab-gnlm	**350,640**	**199,693**	**100.0%**	**94,563**	**100.0%**	**49,433**	**100.0%**	**5,655**	**100.0%**	**1,296**	**100.0%**
Female	299,278	170,414	85.3%	80,726	85.4%	42,255	85.5%	4,777	84.5%	1,106	85.3%
Male	51,362	29,279	14.7%	13,837	14.6%	7,178	14.5%	878	15.5%	190	14.7%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
dacomitinib	**86**	**48**	**100.0%**	**21**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	48	25	52.1%	*****	*****	*****	*****	*****	*****	0	NaN
Male	38	23	47.9%	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**54,816**	**54,747**	**100.0%**	**49**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	13,170	13,143	24.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	41,646	41,604	76.0%	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**17,129**	**13,675**	**100.0%**	**2,844**	**100.0%**	**594**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	10,240	8,186	59.9%	1,691	59.5%	*****	*****	*****	*****	0	0.0%
Male	6,889	5,489	40.1%	1,153	40.5%	*****	*****	*****	*****	*****	*****
omadacycline	**3,003**	**2,512**	**100.0%**	**356**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	1,573	1,285	51.2%	202	56.7%	*****	*****	*****	*****	*****	*****
Male	1,430	1,227	48.8%	154	43.3%	*****	*****	*****	*****	0	0.0%
elapegademase-lvlr	**230**	**155**	**100.0%**	**54**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	129	90	58.1%	*****	*****	*****	*****	*****	*****	0	0.0%
Male	101	65	41.9%	*****	*****	*****	*****	*****	*****	*****	*****
inotersen	**368**	**197**	**100.0%**	**89**	**100.0%**	**70**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	214	114	57.9%	54	60.7%	*****	*****	*****	*****	*****	*****
Male	154	83	42.1%	35	39.3%	*****	*****	*****	*****	*****	*****
talazoparib	**582**	**341**	**100.0%**	**147**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	552	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	30	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
baloxavir marboxil	**4,641**	**4,624**	**100.0%**	**17**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**

cder_mpl1r_wp251

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	2,541	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	2,100	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
lorlatinib	**1,567**	**840**	**100.0%**	**423**	**100.0%**	**251**	**100.0%**	**41**	**100.0%**	**12**	**100.0%**
Female	825	463	55.1%	211	49.9%	117	46.6%	*****	*****	*****	*****
Male	742	377	44.9%	212	50.1%	134	53.4%	*****	*****	*****	*****
revefenacin	**17,253**	**14,948**	**100.0%**	**1,585**	**100.0%**	**640**	**100.0%**	**64**	**100.0%**	**16**	**100.0%**
Female	9,899	8,499	56.9%	961	60.6%	394	61.6%	*****	*****	*****	*****
Male	7,354	6,449	43.1%	624	39.4%	246	38.4%	*****	*****	*****	*****
rifamycin	**19**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**469**	**469**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	371	371	79.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	98	98	20.9%	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**145**	**98**	**100.0%**	**36**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
Female	68	50	51.0%	*****	*****	*****	45.5%	0	NaN	0	NaN
Male	77	48	49.0%	*****	*****	*****	54.5%	0	NaN	0	NaN
larotrectinib	**372**	**216**	**100.0%**	**103**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	206	128	59.3%	57	55.3%	*****	*****	*****	*****	0	0.0%
Male	166	88	40.7%	46	44.7%	*****	*****	*****	*****	*****	*****
amifampridine	**1,126**	**533**	**100.0%**	**313**	**100.0%**	**187**	**100.0%**	**63**	**100.0%**	**30**	**100.0%**
Female	693	343	64.4%	181	57.8%	110	58.8%	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	433	190	35.6%	132	42.2%	77	41.2%	*****	*****	*****	*****
gilteritinib	**2,325**	**1,347**	**100.0%**	**621**	**100.0%**	**331**	**100.0%**	*****	**100.0%**	*****	**100.0%**
Female	1,190	675	50.1%	326	52.5%	178	53.8%	*****	*****	*****	*****
Male	1,135	672	49.9%	295	47.5%	153	46.2%	*****	*****	*****	*****
prucalopride	**53,489**	**29,872**	**100.0%**	**14,977**	**100.0%**	**7,558**	**100.0%**	**882**	**100.0%**	**200**	**100.0%**
Female	42,837	24,039	80.5%	12,019	80.2%	5,929	78.4%	693	78.6%	157	78.5%
Male	10,652	5,833	19.5%	2,958	19.8%	1,629	21.6%	189	21.4%	43	21.5%
calaspargase pegol-mknl	**18**	**18**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**307**	**307**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
Female	55	55	17.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	252	252	82.1%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**11,047**	**10,892**	**100.0%**	*****	**100.0%**	**73**	**100.0%**	*****	**100.0%**	**0**	**NaN**
Female	6,351	6,262	57.5%	*****	*****	41	56.2%	*****	*****	0	NaN
Male	4,696	4,630	42.5%	*****	*****	32	43.8%	*****	*****	0	NaN

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**11,465**	**1**	**1**	**1**	**1**	**323**	**1.2**	**5.5**
Female	5,055	1	1	1	1	308	1.4	6.5
Male	6,410	1	1	1	1	323	1.1	4.6
patisiran	**11,536**	**1**	**1**	**1**	**1**	**651**	**2.0**	**14.7**
Female	3,877	1	1	1	1	651	2.6	19.5
Male	7,659	1	1	1	1	462	1.7	11.4
ethinyl estradiol and segesterone acetate	**1,696**	**1**	**28**	**33**	**91**	**681**	**91.8**	**105.1**
Female	*****	1	28	33	91	681	91.8	105.1
Male	*****	90	90	90	90	90	90.0	NaN
migalastat	**535**	**2**	**28**	**56**	**84**	**828**	**87.5**	**116.9**
Female	262	3	28	56	84	828	88.6	116.8
Male	273	2	28	44	84	756	86.6	117.2
stiripentol	**718**	**1**	**30**	**40**	**90**	**1,124**	**95.5**	**138.8**
Female	442	3	30	40	94	1,019	95.3	137.8
Male	276	1	30	43	90	1,124	95.7	140.7
cenegermin-bkbj	**2,778**	**1**	**14**	**28**	**42**	**413**	**31.9**	**24.4**
Female	1,863	1	14	28	42	364	31.8	24.1
Male	915	1	14	28	42	413	32.2	25.0
lanadelumab	**4,873**	**1**	**28**	**28**	**56**	**1,497**	**71.8**	**114.7**
Female	3,217	1	28	28	60	1,497	73.4	116.0
Male	1,656	1	28	28	56	1,413	68.6	112.0
eravacycline	**794**	**1**	**1**	**1**	**6**	**141**	**5.4**	**10.8**
Female	501	1	1	1	5	78	4.0	7.3
Male	293	1	1	3	9	141	7.8	14.7
doravirine	**12,017**	**1**	**30**	**30**	**90**	**1,565**	**94.4**	**146.8**

cder_mpl1r_wp251

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	2,773	1	30	30	90	1,402	85.0	128.2
Male	9,244	1	30	30	90	1,565	97.2	151.8
~~dolutivine, lamivudine, tenofovir disoproxil~~ fumarate	2,009	1	30	30	76	1,378	80.3	123.1
Female	621	2	30	30	60	1,378	68.5	102.9
Male	1,388	1	30	30	90	1,252	85.6	130.8
moxetumomab pasudotox-tdfk	**369**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.1**
Female	60	1	1	1	1	1	1.0	0.0
Male	309	1	1	1	1	2	1.0	0.1
fremanezumab-vfrm	**132,820**	**1**	**30**	**30**	**90**	**1,543**	**73.3**	**94.7**
Female	115,099	1	30	30	90	1,543	73.1	94.6
Male	17,721	1	30	30	90	1,254	74.9	95.8
duvelisib	**733**	**1**	**28**	**28**	**65**	**1,098**	**65.2**	**86.4**
Female	320	4	28	28	84	1,098	67.6	100.0
Male	413	1	28	28	56	644	63.4	74.2
galcanezumab-gnlm	**350,640**	**1**	**30**	**30**	**75**	**1,496**	**70.6**	**96.3**
Female	299,278	1	30	30	75	1,483	70.6	96.2
Male	51,362	1	30	30	79	1,496	70.9	97.1
dacomitinib	**86**	**4**	**30**	**30**	**90**	**596**	**85.7**	**111.2**
Female	48	30	30	30	90	390	82.2	90.1
Male	38	4	30	30	60	596	90.2	134.3
cemiplimab-rwlc	**54,816**	**1**	**1**	**1**	**1**	**315**	**1.1**	**3.9**
Female	13,170	1	1	1	1	315	1.2	5.2
Male	41,646	1	1	1	1	273	1.1	3.4
sarecycline	**17,129**	**1**	**30**	**30**	**30**	**750**	**40.4**	**32.0**
Female	10,240	1	30	30	30	660	40.4	31.8

cder_mpl1r_wp251

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	6,889	1	30	30	30	750	40.4	32.4
omadacycline	**3,003**	**1**	**5**	**14**	**30**	**1,145**	**26.6**	**48.8**
Female	1,573	1	7	14	30	1,145	30.4	55.3
Male	1,430	1	2	12	30	640	22.4	40.1
elapegademase-lvlr	**230**	**2**	**28**	**28**	**56**	**1,243**	**54.8**	**102.3**
Female	129	5	28	28	56	581	46.0	58.6
Male	101	2	28	28	56	1,243	66.1	139.1
inotersen	**368**	**2**	**28**	**28**	**84**	**1,260**	**84.9**	**126.8**
Female	214	2	28	28	84	1,260	80.5	121.6
Male	154	28	28	28	84	819	90.9	133.9
talazoparib	**582**	**1**	**30**	**30**	**60**	**660**	**62.7**	**69.2**
Female	552	1	30	30	60	660	63.9	70.5
Male	30	15	28	30	56	180	41.7	33.3
baloxavir marboxil	**4,641**	**1**	**1**	**1**	**1**	**90**	**2.9**	**7.3**
Female	2,541	1	1	1	1	60	2.6	6.6
Male	2,100	1	1	1	1	90	3.2	8.0
lorlatinib	**1,567**	**1**	**30**	**30**	**90**	**1,397**	**82.6**	**128.5**
Female	825	1	30	30	90	1,397	83.4	133.9
Male	742	1	30	30	90	1,389	81.6	122.3
revefenacin	**17,253**	**1**	**1**	**1**	**30**	**1,248**	**23.5**	**57.2**
Female	9,899	1	1	1	30	1,144	24.6	57.3
Male	7,354	1	1	1	30	1,248	22.2	57.1
rifamycin	**19**	**3**	**3**	**6**	**27**	**42**	**12.1**	**12.5**
Female	*****	3	3	6	28	30	13.3	12.7
Male	*****	3	3	6	12	42	11.2	12.9

cder_mpl1r_wp251

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	**469**	**1**	**1**	**1**	**1**	**15**	**1.2**	**1.3**
Female	371	1	1	1	1	13	1.1	0.8
Male	98	1	1	1	1	15	1.7	2.2
glasdegib	**145**	**10**	**28**	**30**	**56**	**210**	**45.3**	**34.6**
Female	68	11	28	30	52	210	42.5	35.4
Male	77	10	28	30	60	180	47.8	33.9
larotrectinib	**372**	**4**	**30**	**30**	**60**	**944**	**68.9**	**105.7**
Female	206	6	30	30	60	529	55.7	66.6
Male	166	4	30	30	60	944	85.3	138.3
amifampridine	**1,126**	**2**	**30**	**60**	**90**	**1,364**	**123.1**	**196.5**
Female	693	2	30	40	90	1,345	124.3	204.4
Male	433	4	30	60	104	1,364	121.2	183.5
gilteritinib	**2,325**	**1**	**30**	**30**	**60**	**1,335**	**64.7**	**85.5**
Female	1,190	1	30	30	65	1,335	65.8	86.2
Male	1,135	1	30	30	60	1,216	63.5	84.9
prucalopride	**53,489**	**1**	**30**	**30**	**90**	**1,273**	**74.1**	**97.4**
Female	42,837	1	30	30	90	1,273	73.5	96.7
Male	10,652	1	30	30	90	1,133	76.6	100.0
calaspargase pegol-mknl	**18**	**1**	**1**	**1**	**1**	**2**	**1.1**	**0.2**
Female	*****	1	1	1	1	1	1.0	NaN
Male	*****	1	1	1	1	2	1.1	0.2
tagraxofusp-erzs	**307**	**1**	**1**	**4**	**5**	**5**	**3.2**	**1.8**
Female	55	1	1	4	5	5	3.1	1.8
Male	252	1	1	4	5	5	3.3	1.8
ravulizumab	**11,047**	**1**	**1**	**1**	**1**	**721**	**3.1**	**21.4**

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	6,351	1	1	1	1	649	3.0	20.9
Male	4,696	1	1	1	1	721	3.4	22.1

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Sentinel

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | Total Number of Episodes | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	**11,465**	**11,445**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	17	17	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	16	16	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	262	262	2.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,914	*****	*****	*****	*****	0	*****	0	NaN	0	NaN
≥ 65 years	9,256	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
patisiran	**11,536**	**11,463**	**100.0%**	**26**	**100.0%**	*****	*****	*****	*****	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	70	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,790	1,767	15.4%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	9,676	*****	*****	*****	*****	26	59.1%	*****	*****	0	NaN
ethinyl estradiol and segesterone acetate	**1,696**	**821**	**100.0%**	**427**	**100.0%**	**420**	**100.0%**	**28**	**100.0%**	**0**	**NaN**
0-17 years	68	24	2.9%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	516	229	27.9%	140	32.8%	*****	*****	*****	*****	0	NaN
25-40 years	915	462	56.3%	222	52.0%	218	51.9%	13	46.4%	0	NaN
41-64 years	197	106	12.9%	*****	*****	50	11.9%	*****	*****	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
migalastat	**535**	**253**	**100.0%**	**160**	**100.0%**	**100**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	56	32	12.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	132	66	26.1%	42	26.3%	*****	*****	*****	*****	*****	*****
41-64 years	248	117	46.2%	76	47.5%	*****	*****	*****	*****	*****	*****

cder_mpl1r_wp251

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | Total Number of Episodes | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	99	38	15.0%	*****	*****	28	28.0%	*****	*****	*****	*****
stiripentol	**718**	**325**	**100.0%**	**219**	**100.0%**	**141**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	535	242	74.5%	165	75.3%	106	75.2%	*****	*****	*****	*****
18-24 years	151	67	20.6%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	32	16	4.9%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
cenegermin-bkbj	**2,778**	**1,665**	**100.0%**	**1,076**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	25	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	13	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	133	86	5.2%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	563	*****	*****	199	18.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	2,044	1,199	72.0%	822	76.4%	23	63.9%	0	0.0%	0	NaN
lanadelumab	**4,873**	**2,918**	**100.0%**	**1,114**	**100.0%**	**721**	**100.0%**	**87**	**100.0%**	**33**	**100.0%**
0-17 years	352	206	7.1%	83	7.5%	*****	*****	*****	*****	0	0.0%
18-24 years	469	311	10.7%	100	9.0%	*****	*****	*****	*****	0	0.0%
25-40 years	1,131	743	25.5%	233	20.9%	137	19.0%	*****	*****	*****	*****
41-64 years	1,859	1,099	37.7%	432	38.8%	275	38.1%	38	43.7%	15	45.5%
≥ 65 years	1,062	559	19.2%	266	23.9%	201	27.9%	*****	*****	*****	*****
eravacycline	**794**	**774**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	17	17	2.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	44	44	5.7%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	71	71	9.2%	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp251

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	298	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	364	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
doravirine	**12,017**	**6,271**	**100.0%**	**3,156**	**100.0%**	**2,013**	**100.0%**	**433**	**100.0%**	**144**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	16	0.5%	*****	*****	*****	*****	0	0.0%
25-40 years	1,358	834	13.3%	306	9.7%	184	9.1%	*****	*****	*****	*****
41-64 years	8,112	4,266	68.0%	2,143	67.9%	1,338	66.5%	274	63.3%	91	63.2%
≥ 65 years	2,461	1,115	17.8%	691	21.9%	480	23.8%	*****	*****	*****	*****
doravirine/lamivudine/tenofovir disoproxil fumarate	**2,009**	**1,143**	**100.0%**	**528**	**100.0%**	**272**	**100.0%**	**48**	**100.0%**	**18**	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	50	24	2.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	402	248	21.7%	105	19.9%	*****	*****	*****	*****	*****	*****
41-64 years	1,276	729	63.8%	325	61.6%	177	65.1%	*****	*****	*****	*****
≥ 65 years	281	142	12.4%	78	14.8%	47	17.3%	*****	*****	*****	*****
moxetumomab pasudotox-tdfk	**369**	**369**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	264	264	71.5%	0	NaN	0	NaN	0	NaN	0	NaN
fremanezumab-vfrm	**132,820**	**71,876**	**100.0%**	**38,500**	**100.0%**	**20,009**	**100.0%**	**2,042**	**100.0%**	**393**	**100.0%**
0-17 years	662	401	0.6%	172	0.4%	78	0.4%	*****	*****	*****	*****

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | Total Number of Episodes | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	7,226	4,077	5.7%	2,140	5.6%	929	4.6%	*****	*****	*****	*****
25-40 years	34,529	19,509	27.1%	9,724	25.3%	4,773	23.9%	444	21.7%	79	20.1%
41-64 years	74,251	39,791	55.4%	21,583	56.1%	11,456	57.3%	1,193	58.4%	228	58.0%
≥ 65 years	16,152	8,098	11.3%	4,881	12.7%	2,773	13.9%	325	15.9%	75	19.1%
duvelisib	**733**	**418**	**100.0%**	**190**	**100.0%**	**114**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	29	15.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	623	353	84.4%	161	84.7%	*****	*****	*****	*****	*****	*****
galcanezumab-gnlm	**350,640**	**199,693**	**100.0%**	**94,563**	**100.0%**	**49,433**	**100.0%**	**5,655**	**100.0%**	**1,296**	**100.0%**
0-17 years	1,299	780	0.4%	327	0.3%	168	0.3%	*****	*****	*****	*****
18-24 years	19,334	11,564	5.8%	5,157	5.5%	2,380	4.8%	*****	*****	*****	*****
25-40 years	94,750	55,778	27.9%	25,266	26.7%	12,256	24.8%	1,193	21.1%	257	19.8%
41-64 years	192,684	109,091	54.6%	51,625	54.6%	27,782	56.2%	3,379	59.8%	807	62.3%
≥ 65 years	42,573	22,480	11.3%	12,188	12.9%	6,847	13.9%	875	15.5%	183	14.1%
dacomitinib	**86**	**48**	**100.0%**	**21**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	17	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	69	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
cemiplimab-rwlc	**54,816**	**54,747**	**100.0%**	**49**	**100.0%**	**20**	**100.0%**	**0**	**NaN**	**0**	**NaN**

cder_mpl1r_wp251

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	4,514	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	50,106	50,042	91.4%	*****	*****	*****	*****	0	NaN	0	NaN
sarecycline	**17,129**	**13,675**	**100.0%**	**2,844**	**100.0%**	**594**	**100.0%**	*****	*****	*****	*****
0-17 years	8,516	6,846	50.1%	1,388	48.8%	*****	*****	*****	*****	*****	*****
18-24 years	4,299	3,444	25.2%	692	24.3%	*****	*****	*****	*****	0	0.0%
25-40 years	2,621	2,091	15.3%	441	15.5%	*****	*****	*****	*****	0	0.0%
41-64 years	1,558	1,196	8.7%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	135	98	0.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
omadacycline	**3,003**	**2,512**	**100.0%**	**356**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	80	62	2.5%	*****	*****	*****	4.7%	0	0.0%	0	0.0%
18-24 years	81	69	2.7%	*****	*****	*****	2.4%	0	0.0%	0	0.0%
25-40 years	281	242	9.6%	26	7.3%	*****	*****	*****	*****	0	0.0%
41-64 years	1,193	1,006	40.0%	136	38.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,368	1,133	45.1%	173	48.6%	*****	*****	*****	*****	0	0.0%
elapegademase-lvlr	**230**	**155**	**100.0%**	**54**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	99	72	46.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	70	47	30.3%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

cder_mpl1r_wp251

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
inotersen	**368**	**197**	**100.0%**	**89**	**100.0%**	**70**	**100.0%**	*********	**100.0%**	*********	**100.0%**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	53	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	302	153	77.7%	78	87.6%	*****	*****	*****	*****	*****	*****
talazoparib	**582**	**341**	**100.0%**	**147**	**100.0%**	*********	*********	*********	*********	**0**	**NaN**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	21	14.3%	*****	*****	*****	*****	0	NaN
41-64 years	320	191	56.0%	80	54.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	187	103	30.2%	46	31.3%	*****	*****	*****	*****	0	NaN
baloxavir marboxil	**4,641**	*********	**100.0%**	*********	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	868	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	355	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	945	945	20.4%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	1,485	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	988	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
lorlatinib	**1,567**	**840**	**100.0%**	**423**	**100.0%**	**251**	**100.0%**	**41**	**100.0%**	**12**	**100.0%**
0-17 years	53	39	4.6%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	21	11	1.3%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	120	57	6.8%	45	10.6%	*****	*****	*****	*****	0	0.0%
41-64 years	701	361	43.0%	181	42.8%	133	53.0%	*****	*****	*****	*****

cder_mpl1r_wp251

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | **1-30 Days** | | **31-90 Days** | | **91-365 Days** | | **366-730 Days** | | **731+ Days** | |
	Total Number of Episodes	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**	**Number of Episodes**	**Percent of Total Episodes**
≥ 65 years	672	372	44.3%	181	42.8%	97	38.6%	*****	*****	*****	*****
revefenacin	**17,253**	**14,948**	**100.0%**	**1,585**	**100.0%**	**640**	**100.0%**	**64**	**100.0%**	**16**	**100.0%**
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	126	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	3,439	2,670	17.9%	545	34.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	13,675	12,179	81.5%	1,012	63.8%	431	67.3%	*****	*****	*****	*****
rifamycin	**19**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
emapalumab-lzsg	**469**	**469**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	357	357	76.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	51	51	10.9%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	43	43	9.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
glasdegib	**145**	**98**	**100.0%**	**36**	**100.0%**	**11**	**100.0%**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	127	84	85.7%	*****	*****	11	100.0%	0	NaN	0	NaN
larotrectinib	**372**	**216**	**100.0%**	**103**	**100.0%**	*****	**100.0%**	*****	**100.0%**	*****	*****
0-17 years	122	61	28.2%	43	41.7%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	92	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	144	89	41.2%	39	37.9%	15	32.6%	*****	*****	0	0.0%
amifampridine	**1,126**	**533**	**100.0%**	**313**	**100.0%**	**187**	**100.0%**	**63**	**100.0%**	**30**	**100.0%**
0-17 years	12	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	37	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	72	36	6.8%	22	7.0%	*****	*****	*****	*****	*****	*****
41-64 years	372	209	39.2%	91	29.1%	49	26.2%	*****	*****	*****	*****
≥ 65 years	633	265	49.7%	184	58.8%	123	65.8%	39	61.9%	*****	*****
gilteritinib	**2,325**	**1,347**	**100.0%**	**621**	**100.0%**	**331**	**100.0%**	*****	**100.0%**	*****	**100.0%**
0-17 years	28	12	0.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	42	29	2.2%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	151	94	7.0%	33	5.3%	*****	*****	*****	*****	0	0.0%
41-64 years	648	360	26.7%	179	28.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,456	852	63.3%	396	63.8%	194	58.6%	*****	*****	*****	*****
prucalopride	**53,489**	**29,872**	**100.0%**	**14,977**	**100.0%**	**7,558**	**100.0%**	**882**	**100.0%**	**200**	**100.0%**
0-17 years	670	394	1.3%	168	1.1%	*****	*****	*****	*****	*****	*****
18-24 years	2,838	1,647	5.5%	780	5.2%	*****	*****	*****	*****	*****	*****

cder_mpl1r_wp251

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	8,721	5,005	16.8%	2,410	16.1%	1,138	15.1%	131	14.9%	37	18.5%
41-64 years	23,278	12,899	43.2%	6,583	44.0%	3,312	43.8%	403	45.7%	81	40.5%
≥ 65 years	17,982	9,927	33.2%	5,036	33.6%	2,642	35.0%	308	34.9%	69	34.5%
calaspargase pegol-mknl	**18**	**18**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tagraxofusp-erzs	**307**	**307**	**100.0%**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**	**0**	**NaN**
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	16	16	5.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	280	280	91.2%	0	NaN	0	NaN	0	NaN	0	NaN
ravulizumab	**11,047**	**10,892**	**100.0%**	**72**	**100.0%**	*****	**100.0%**	*****	**100.0%**	**0**	**NaN**
0-17 years	698	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	498	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	2,252	2,214	20.3%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	3,347	3,302	30.3%	*****	*****	28	38.4%	*****	*****	0	NaN
≥ 65 years	4,252	4,196	38.5%	*****	*****	27	37.0%	*****	*****	0	NaN

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**11,465**	**1**	**1**	**1**	**1**	**323**	**1.2**	**5.5**
0-17 years	17	1	1	1	1	1	1.0	0.0
18-24 years	16	1	1	1	1	1	1.0	0.0
25-40 years	262	1	1	1	1	1	1.0	0.0
41-64 years	1,914	1	1	1	1	84	1.4	4.3
≥ 65 years	9,256	1	1	1	1	323	1.2	5.8
patisiran	**11,536**	**1**	**1**	**1**	**1**	**651**	**2.0**	**14.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	70	1	1	1	1	273	14.1	48.4
41-64 years	1,790	1	1	1	1	336	2.8	17.2
≥ 65 years	9,676	1	1	1	1	651	1.8	13.5
ethinyl estradiol and segesterone acetate	**1,696**	**1**	**28**	**33**	**91**	**681**	**91.8**	**105.1**
0-17 years	68	1	30	79	90	625	98.7	104.7
18-24 years	516	1	28	49	116	616	99.4	107.8
25-40 years	915	1	28	30	91	681	86.8	101.7
41-64 years	197	1	28	30	93	622	92.3	112.6
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	**535**	**2**	**28**	**56**	**84**	**828**	**87.5**	**116.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	56	11	28	28	84	331	64.5	67.2
25-40 years	132	8	28	31	84	756	75.0	96.0
41-64 years	248	2	28	56	84	828	87.3	120.7
≥ 65 years	99	12	28	56	160	784	117.9	146.6

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	**718**	**1**	**30**	**40**	**90**	**1,124**	**95.5**	**138.8**
0-17 years	535	1	30	40	90	1,124	94.2	135.0
18-24 years	151	11	30	40	98	778	95.8	136.5
25-40 years	32	9	30	32	115	1,019	115.5	202.1
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**2,778**	**1**	**14**	**28**	**42**	**413**	**31.9**	**24.4**
0-17 years	25	14	14	28	42	84	30.3	18.4
18-24 years	13	1	7	7	14	49	14.8	14.3
25-40 years	133	5	14	28	42	133	31.3	21.8
41-64 years	563	2	14	28	42	413	30.6	25.9
≥ 65 years	2,044	1	14	28	42	364	32.4	24.2
lanadelumab	**4,873**	**1**	**28**	**28**	**56**	**1,497**	**71.8**	**114.7**
0-17 years	352	1	28	28	84	707	66.9	85.7
18-24 years	469	1	28	28	56	489	54.8	68.3
25-40 years	1,131	1	28	28	56	1,413	60.3	98.7
41-64 years	1,859	1	28	28	56	1,497	74.9	122.8
≥ 65 years	1,062	1	28	28	84	1,452	87.5	136.3
eravacycline	**794**	**1**	**1**	**1**	**6**	**141**	**5.4**	**10.8**
0-17 years	17	1	1	1	1	2	1.1	0.2
18-24 years	44	1	1	1	1	15	2.0	3.0
25-40 years	71	1	1	1	1	14	2.2	3.0
41-64 years	298	1	1	1	7	85	6.0	10.8
≥ 65 years	364	1	1	1	6	141	6.2	12.3

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	**12,017**	**1**	**30**	**30**	**90**	**1,565**	**94.4**	**146.8**
0-17 years	*****	30	30	189	252	560	212.2	217.6
18-24 years	*****	5	30	30	60	394	61.1	70.7
25-40 years	1,358	1	30	30	60	1,280	70.9	98.7
41-64 years	8,112	1	30	30	90	1,565	92.0	143.1
≥ 65 years	2,461	1	30	60	120	1,453	116.1	176.8
doravirine/lamivudine/tenofovir disoproxil fumarate	**2,009**	**1**	**30**	**30**	**76**	**1,378**	**80.3**	**123.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	1	30	40	90	269	63.1	53.3
25-40 years	402	2	30	30	60	892	66.5	92.4
41-64 years	1,276	1	30	30	90	1,378	82.6	127.7
≥ 65 years	281	3	30	30	90	990	92.8	145.6
moxetumomab pasudotox-tdfk	**369**	**1**	**1**	**1**	**1**	**2**	**1.0**	**0.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	264	1	1	1	1	2	1.0	0.1
fremanezumab-vfrm	**132,820**	**1**	**30**	**30**	**90**	**1,543**	**73.3**	**94.7**
0-17 years	662	1	28	30	60	1,140	64.4	93.3
18-24 years	7,226	1	30	30	84	1,175	65.0	75.3
25-40 years	34,529	1	30	30	84	1,543	68.4	87.0
41-64 years	74,251	1	30	30	90	1,478	74.6	96.6

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	16,152	1	30	30	90	1,464	81.9	108.1
duvelisib	**733**	**1**	**28**	**28**	**65**	**1,098**	**65.2**	**86.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	28	28	28	28.0	0.0
41-64 years	*****	2	28	28	56	380	59.1	63.5
≥ 65 years	623	1	28	28	84	1,098	66.5	89.9
galcanezumab-gnlm	**350,640**	**1**	**30**	**30**	**75**	**1,496**	**70.6**	**96.3**
0-17 years	1,299	1	28	30	60	1,230	67.1	98.3
18-24 years	19,334	1	28	30	60	1,434	62.4	79.3
25-40 years	94,750	1	30	30	60	1,470	65.5	86.8
41-64 years	192,684	1	30	30	84	1,496	72.4	100.2
≥ 65 years	42,573	1	30	30	90	1,476	78.0	104.5
dacomitinib	**86**	**4**	**30**	**30**	**90**	**596**	**85.7**	**111.2**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	17	30	30	30	60	596	97.4	143.5
≥ 65 years	69	4	30	30	90	549	82.9	102.8
cemiplimab-rwlc	**54,816**	**1**	**1**	**1**	**1**	**315**	**1.1**	**3.9**
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	4,514	1	1	1	1	213	1.2	4.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	50,106	1	1	1	1	315	1.1	3.8
sarecycline	**17,129**	**1**	**30**	**30**	**30**	**750**	**40.4**	**32.0**
0-17 years	8,516	1	30	30	30	750	40.0	31.2
18-24 years	4,299	1	30	30	30	660	40.6	32.7
25-40 years	2,621	1	30	30	30	390	39.5	29.0
41-64 years	1,558	1	30	30	30	405	43.3	37.8
≥ 65 years	135	5	30	30	60	320	45.7	39.2
omadacycline	**3,003**	**1**	**5**	**14**	**30**	**1,145**	**26.6**	**48.8**
0-17 years	80	1	1	30	30	240	31.5	43.0
18-24 years	81	1	7	15	30	311	27.7	45.5
25-40 years	281	1	7	14	30	540	26.8	46.0
41-64 years	1,193	1	5	14	30	1,145	25.7	51.8
≥ 65 years	1,368	1	5	14	30	640	27.0	47.1
elapegademase-lvlr	**230**	**2**	**28**	**28**	**56**	**1,243**	**54.8**	**102.3**
0-17 years	99	17	28	28	56	330	42.8	41.0
18-24 years	70	2	14	28	56	500	50.5	76.7
25-40 years	*****	4	28	28	56	1,243	81.0	180.8
41-64 years	*****	3	28	70	88	118	62.8	42.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**368**	**2**	**28**	**28**	**84**	**1,260**	**84.9**	**126.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	2	28	28	56	252	53.5	63.0
41-64 years	53	21	28	28	56	378	61.9	74.1

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	302	5	28	28	84	1,260	90.2	135.4
talazoparib	**582**	**1**	**30**	**30**	**60**	**660**	**62.7**	**69.2**
0-17 years	*****	15	15	15	15	15	15.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	30	30	60	450	54.5	65.5
41-64 years	320	4	30	30	60	444	58.9	59.5
≥ 65 years	187	8	30	30	90	660	73.1	84.0
baloxavir marboxil	**4,641**	**1**	**1**	**1**	**1**	**90**	**2.9**	**7.3**
0-17 years	868	1	1	1	1	42	1.2	2.2
18-24 years	355	1	1	1	1	90	1.5	5.1
25-40 years	945	1	1	1	1	30	1.2	1.7
41-64 years	1,485	1	1	1	1	60	1.8	4.7
≥ 65 years	988	1	1	1	10	90	8.2	12.8
lorlatinib	**1,567**	**1**	**30**	**30**	**90**	**1,397**	**82.6**	**128.5**
0-17 years	53	6	30	30	58	456	51.0	68.8
18-24 years	21	14	30	30	90	622	105.3	162.7
25-40 years	120	1	30	60	90	525	69.1	74.4
41-64 years	701	1	30	30	90	1,308	85.4	126.2
≥ 65 years	672	1	30	30	90	1,397	83.9	140.2
revefenacin	**17,253**	**1**	**1**	**1**	**30**	**1,248**	**23.5**	**57.2**
0-17 years	*****	25	25	25	25	25	25.0	NaN
18-24 years	*****	19	30	57	105	437	94.3	117.9
25-40 years	126	1	30	30	44	900	53.3	101.8
41-64 years	3,439	1	1	30	30	1,144	37.4	66.9

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	13,675	1	1	1	30	1,248	19.7	53.2
rifamycin	**19**	**3**	**3**	**6**	**27**	**42**	**12.1**	**12.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	29	30	30	29.0	1.4
41-64 years	*****	3	3	6	9	42	9.9	11.7
≥ 65 years	*****	3	3	3	27	27	11.0	13.9
emapalumab-lzsg	**469**	**1**	**1**	**1**	**1**	**15**	**1.2**	**1.3**
0-17 years	357	1	1	1	1	15	1.2	1.2
18-24 years	*****	1	1	3	7	13	4.4	4.2
25-40 years	51	1	1	1	1	1	1.0	0.0
41-64 years	43	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
glasdegib	**145**	**10**	**28**	**30**	**56**	**210**	**45.3**	**34.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	42	56	56	42.0	19.8
41-64 years	*****	10	20	30	30	60	30.6	15.8
≥ 65 years	127	11	29	30	60	210	47.3	36.1
larotrectinib	**372**	**4**	**30**	**30**	**60**	**944**	**68.9**	**105.7**
0-17 years	122	10	21	31	60	480	60.6	75.3
18-24 years	*****	30	30	45	180	300	105.0	130.8
25-40 years	*****	15	18	30	52	90	40.1	27.1
41-64 years	92	4	30	30	76	944	94.2	171.7

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	144	9	30	30	60	468	60.7	66.2
amifampridine	**1,126**	**2**	**30**	**60**	**90**	**1,364**	**123.1**	**196.5**
0-17 years	12	2	27	45	165	423	112.6	142.2
18-24 years	37	4	30	52	90	529	85.6	102.1
25-40 years	72	2	30	32	90	1,252	120.9	222.2
41-64 years	372	4	30	30	86	1,345	100.4	173.0
≥ 65 years	633	2	30	60	138	1,364	139.0	209.9
gilteritinib	**2,325**	**1**	**30**	**30**	**60**	**1,335**	**64.7**	**85.5**
0-17 years	28	28	30	60	150	300	90.3	71.9
18-24 years	42	1	30	30	60	690	93.2	156.7
25-40 years	151	1	30	30	60	488	64.1	75.7
41-64 years	648	1	30	30	81	1,335	68.1	91.5
≥ 65 years	1,456	1	30	30	60	1,216	61.9	80.9
prucalopride	**53,489**	**1**	**30**	**30**	**90**	**1,273**	**74.1**	**97.4**
0-17 years	670	1	30	30	83	748	65.9	80.9
18-24 years	2,838	1	30	30	90	1,049	69.4	91.6
25-40 years	8,721	1	30	30	90	1,140	70.7	94.6
41-64 years	23,278	1	30	30	90	1,233	74.9	97.7
≥ 65 years	17,982	1	30	30	90	1,273	75.8	99.6
calaspargase pegol-mknl	**18**	**1**	**1**	**1**	**1**	**2**	**1.1**	**0.2**
0-17 years	*****	1	1	1	1	2	1.1	0.3
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

cder_mpl1r_wp251

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
tagraxofusp-erzs	**307**	**1**	**1**	**4**	**5**	**5**	**3.2**	**1.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	2	5	5	5	3.6	1.8
25-40 years	*****	1	1	3	4	4	2.5	2.1
41-64 years	16	1	1	2	4	4	2.2	1.4
≥ 65 years	280	1	1	4	5	5	3.3	1.8
ravulizumab	**11,047**	**1**	**1**	**1**	**1**	**721**	**3.1**	**21.4**
0-17 years	698	1	1	1	1	169	2.9	12.2
18-24 years	498	1	1	1	1	448	2.8	22.3
25-40 years	2,252	1	1	1	1	649	3.8	28.6
41-64 years	3,347	1	1	1	1	560	3.0	17.8
≥ 65 years	4,252	1	1	1	1	721	3.0	20.7

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	11,465	1	13	13	13	1,071	15.9	32.5
patisiran	11,536	1	20	20	20	685	22.1	18.1
ethinyl estradiol and segesterone acetate	1,696	1	122	285	335	1,057	248.7	148.4
migalastat	535	1	3	6	14	791	20.9	63.5
stiripentol	718	1	2	5	14	434	17.8	41.7
cenegermin-bkbj	2,778	1	1	6	25	1,203	53.8	138.4
lanadelumab	4,873	1	3	7	18	1,044	18.5	47.9
eravacycline	794	1	1	3	6	827	15.5	71.7
doravirine	12,017	1	3	6	18	1,118	21.0	53.4
doravirine/lamivudine/tenofovir disoproxil fumarate	2,009	1	3	6	17	845	19.4	45.7
moxetumomab pasudotox-tdfk	369	1	1	1	23	131	9.3	14.8
fremanezumab-vfrm	132,820	1	3	7	20	1,461	23.9	63.3
duvelisib	733	1	2	6	14	494	15.6	35.8
galcanezumab-gnlm	350,640	1	3	7	19	1,452	22.0	56.6
dacomitinib	86	1	3	6	16	106	15.1	20.6
cemiplimab-rwlc	54,816	1	20	20	20	996	23.4	22.1
sarecycline	17,129	1	4	11	29	1,125	33.3	72.5
omadacycline	3,003	1	2	6	23	1,198	35.9	88.8
elapegademase-lvlr	230	1	4	9	19	600	20.2	46.6
inotersen	368	1	3	7	15	381	18.4	41.1
talazoparib	582	1	3	6	15	1,085	15.8	52.1
baloxavir marboxil	4,641	1	19	114	357	1,482	274.3	341.4
lorlatinib	1,567	1	2	6	15	1,071	24.2	82.2
revefenacin	17,253	1	14	27	37	1,268	37.5	59.2
rifamycin	19	1	3	5	24	1,119	71.1	254.3

cder_mpl1r_wp251

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	469	1	2	6	6	254	7.0	13.4
glasdegib	145	1	2	6	12	83	9.1	11.6
larotrectinib	372	1	2	5	15	336	16.2	37.4
amifampridine	1,126	1	3	6	15	1,127	17.2	62.3
gilteritinib	2,325	1	3	9	26	508	25.3	48.0
prucalopride	53,489	1	3	8	25	1,318	31.1	76.9
calaspargase pegol-mknl	18	20	26	31	46	59	35.1	12.6
tagraxofusp-erzs	307	1	4	18	24	416	24.0	39.3
ravulizumab	11,047	1	55	55	55	1,201	52.8	31.2

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**11,465**	**1**	**13**	**13**	**13**	**1,071**	**15.9**	**32.5**
Female	5,055	1	13	13	13	1,071	16.5	34.6
Male	6,410	1	13	13	13	1,000	15.5	30.8
patisiran	**11,536**	**1**	**20**	**20**	**20**	**685**	**22.1**	**18.1**
Female	3,877	1	20	20	20	685	22.7	22.6
Male	7,659	1	20	20	20	458	21.8	15.2
ethinyl estradiol and segesterone acetate	**1,696**	**1**	**122**	**285**	**335**	**1,057**	**248.7**	**148.4**
Female	1,695	1	121	285	335	1,057	248.6	148.4
Male	*****	354	354	354	354	354	354.0	NaN
migalastat	**535**	**1**	**3**	**6**	**14**	**791**	**20.9**	**63.5**
Female	262	1	2	6	15	559	20.6	55.5
Male	273	1	3	6	14	791	21.2	70.5
stiripentol	**718**	**1**	**2**	**5**	**14**	**434**	**17.8**	**41.7**
Female	442	1	2	5	13	434	17.3	41.4
Male	276	1	2	7	16	348	18.7	42.4
cenegermin-bkbj	**2,778**	**1**	**1**	**6**	**25**	**1,203**	**53.8**	**138.4**
Female	1,863	1	1	5	24	1,203	54.4	138.5
Male	915	1	1	6	28	1,097	52.7	138.2
lanadelumab	**4,873**	**1**	**3**	**7**	**18**	**1,044**	**18.5**	**47.9**
Female	3,217	1	3	7	18	772	18.7	47.4
Male	1,656	1	3	8	18	1,044	18.0	48.9
eravacycline	**794**	**1**	**1**	**3**	**6**	**827**	**15.5**	**71.7**
Female	501	1	1	2	6	827	16.6	73.6
Male	293	1	1	3	6	743	13.6	68.4

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	**12,017**	**1**	**3**	**6**	**18**	**1,118**	**21.0**	**53.4**
Female	2,773	1	3	7	20	789	23.3	51.2
Male	9,244	1	3	6	17	1,118	20.3	54.0
doravirine/lamivudine/tenofovir disoproxil fumarate	**2,009**	**1**	**3**	**6**	**17**	**845**	**19.4**	**45.7**
Female	621	1	3	6	17	803	18.0	43.2
Male	1,388	1	3	6	17	845	20.0	46.7
moxetumomab pasudotox-tdfk	**369**	**1**	**1**	**1**	**23**	**131**	**9.3**	**14.8**
Female	60	1	1	1	23	46	8.4	11.8
Male	309	1	1	1	23	131	9.5	15.4
fremanezumab-vfrm	**132,820**	**1**	**3**	**7**	**20**	**1,461**	**23.9**	**63.3**
Female	115,099	1	3	7	20	1,431	23.9	63.1
Male	17,721	1	3	7	20	1,461	23.9	64.0
duvelisib	**733**	**1**	**2**	**6**	**14**	**494**	**15.6**	**35.8**
Female	320	1	2	6	15	285	15.7	31.6
Male	413	1	3	6	14	494	15.5	38.9
galcanezumab-gnlm	**350,640**	**1**	**3**	**7**	**19**	**1,452**	**22.0**	**56.6**
Female	299,278	1	3	7	19	1,452	21.8	55.9
Male	51,362	1	3	7	20	1,273	23.4	60.6
dacomitinib	**86**	**1**	**3**	**6**	**16**	**106**	**15.1**	**20.6**
Female	48	1	2	6	15	106	13.4	19.7
Male	38	1	3	9	18	105	17.2	21.9
cemiplimab-rwlc	**54,816**	**1**	**20**	**20**	**20**	**996**	**23.4**	**22.1**
Female	13,170	1	20	20	20	996	23.7	22.6
Male	41,646	1	20	20	20	936	23.3	21.9

cder_mpl1r_wp251

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
sarecycline	**17,129**	**1**	**4**	**11**	**29**	**1,125**	**33.3**	**72.5**
Female	10,240	1	4	11	29	1,125	33.8	75.4
Male	6,889	1	5	12	30	1,104	32.5	68.2
omadacycline	**3,003**	**1**	**2**	**6**	**23**	**1,198**	**35.9**	**88.8**
Female	1,573	1	2	6	24	1,198	38.4	92.4
Male	1,430	1	2	6	20	915	33.1	84.5
elapegademase-lvlr	**230**	**1**	**4**	**9**	**19**	**600**	**20.2**	**46.6**
Female	129	1	4	9	18	600	19.9	55.8
Male	101	1	4	8	19	176	20.6	31.4
inotersen	**368**	**1**	**3**	**7**	**15**	**381**	**18.4**	**41.1**
Female	214	1	4	7	15	303	19.8	43.8
Male	154	1	3	7	17	381	16.6	37.1
talazoparib	**582**	**1**	**3**	**6**	**15**	**1,085**	**15.8**	**52.1**
Female	552	1	3	6	15	1,085	15.5	51.8
Male	30	1	3	6	14	314	19.8	56.7
baloxavir marboxil	**4,641**	**1**	**19**	**114**	**357**	**1,482**	**274.3**	**341.4**
Female	2,541	1	18	106	355	1,463	268.5	336.1
Male	2,100	1	20	133	359	1,482	281.5	347.6
lorlatinib	**1,567**	**1**	**2**	**6**	**15**	**1,071**	**24.2**	**82.2**
Female	825	1	2	5	15	1,071	28.8	102.2
Male	742	1	2	6	14	737	19.1	51.1
revefenacin	**17,253**	**1**	**14**	**27**	**37**	**1,268**	**37.5**	**59.2**
Female	9,899	1	13	27	37	1,043	37.6	60.4
Male	7,354	1	16	27	36	1,268	37.3	57.7

cder_mpl1r_wp251

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
rifamycin	**19**	**1**	**3**	**5**	**24**	**1,119**	**71.1**	**254.3**
Female	*****	1	2	5	21	29	10.5	11.2
Male	11	1	3	6	32	1,119	115.1	333.6
emapalumab-lzsg	**469**	**1**	**2**	**6**	**6**	**254**	**7.0**	**13.4**
Female	371	1	3	6	10	254	8.0	14.8
Male	98	1	2	2	3	23	3.2	3.0
glasdegib	**145**	**1**	**2**	**6**	**12**	**83**	**9.1**	**11.6**
Female	68	1	2	5	9	31	7.0	6.5
Male	77	1	3	7	12	83	10.9	14.4
larotrectinib	**372**	**1**	**2**	**5**	**15**	**336**	**16.2**	**37.4**
Female	206	1	3	6	13	336	17.8	43.4
Male	166	1	2	5	15	219	14.1	28.3
amifampridine	**1,126**	**1**	**3**	**6**	**15**	**1,127**	**17.2**	**62.3**
Female	693	1	3	6	14	1,127	17.9	67.0
Male	433	1	3	5	16	943	16.1	54.0
gilteritinib	**2,325**	**1**	**3**	**9**	**26**	**508**	**25.3**	**48.0**
Female	1,190	1	3	9	26	495	25.5	47.3
Male	1,135	1	3	8	25	508	25.1	48.8
prucalopride	**53,489**	**1**	**3**	**8**	**25**	**1,318**	**31.1**	**76.9**
Female	42,837	1	3	9	26	1,318	31.2	76.8
Male	10,652	1	3	8	25	1,181	30.8	77.3
calaspargase pegol-mknl	**18**	**20**	**26**	**31**	**46**	**59**	**35.1**	**12.6**
Female	*****	27	27	27	27	27	27.0	NaN
Male	17	20	26	34	46	59	35.6	12.8

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
tagraxofusp-erzs	**307**	**1**	**4**	**18**	**24**	**416**	**24.0**	**39.3**
Female	55	1	3	20	29	229	25.5	35.6
Male	252	1	6	17	23	416	23.6	40.2
ravulizumab	**11,047**	**1**	**55**	**55**	**55**	**1,201**	**52.8**	**31.2**
Female	6,351	1	55	55	55	1,000	53.1	31.0
Male	4,696	1	55	55	55	1,201	52.4	31.5

NaN: Not a number

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**11,465**	**1**	**13**	**13**	**13**	**1,071**	**15.9**	**32.5**
0-17 years	17	2	6	13	13	27	11.8	7.7
18-24 years	16	6	6	13	13	27	12.1	6.2
25-40 years	262	4	8	13	15	604	17.7	41.3
41-64 years	1,914	1	12	13	13	1,000	17.3	38.7
≥ 65 years	9,256	1	13	13	13	1,071	15.6	30.9
patisiran	**11,536**	**1**	**20**	**20**	**20**	**685**	**22.1**	**18.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	70	2	20	20	24	549	39.4	78.6
41-64 years	1,790	1	20	20	20	685	21.9	18.3
≥ 65 years	9,676	1	20	20	20	601	22.0	16.7
ethinyl estradiol and segesterone acetate	**1,696**	**1**	**122**	**285**	**335**	**1,057**	**248.7**	**148.4**
0-17 years	68	1	59	266	335	503	224.0	140.2
18-24 years	516	1	142	286	331	1,020	252.1	147.1
25-40 years	915	1	125	286	337	1,057	250.2	149.7
41-64 years	197	1	108	286	335	900	241.0	148.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	**535**	**1**	**3**	**6**	**14**	**791**	**20.9**	**63.5**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	56	1	3	6	28	791	32.1	106.3
25-40 years	132	1	3	7	21	615	25.3	67.8
41-64 years	248	1	2	6	12	559	16.7	54.5
≥ 65 years	99	1	2	4	14	308	19.3	43.3

cder_mpl1r_wp251

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	**718**	**1**	**2**	**5**	**14**	**434**	**17.8**	**41.7**
0-17 years	535	1	2	5	13	434	16.4	39.2
18-24 years	151	1	2	7	18	358	24.7	52.6
25-40 years	32	1	1	3	13	47	8.5	11.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**2,778**	**1**	**1**	**6**	**25**	**1,203**	**53.8**	**138.4**
0-17 years	25	1	1	5	26	389	34.0	80.0
18-24 years	13	1	3	5	7	277	26.8	75.4
25-40 years	133	1	1	5	21	665	48.9	121.4
41-64 years	563	1	2	7	30	1,093	49.5	125.5
≥ 65 years	2,044	1	1	5	23	1,203	55.7	143.6
lanadelumab	**4,873**	**1**	**3**	**7**	**18**	**1,044**	**18.5**	**47.9**
0-17 years	352	1	3	7	15	565	18.8	44.7
18-24 years	469	1	3	7	20	772	19.9	47.6
25-40 years	1,131	1	3	8	20	782	19.4	50.1
41-64 years	1,859	1	3	7	18	714	17.8	40.8
≥ 65 years	1,062	1	3	6	15	1,044	18.0	57.3
eravacycline	**794**	**1**	**1**	**3**	**6**	**827**	**15.5**	**71.7**
0-17 years	17	2	6	6	6	317	23.9	75.5
18-24 years	44	1	5	6	6	30	6.4	4.4
25-40 years	71	1	4	6	7	827	42.5	157.9
41-64 years	298	1	1	5	6	508	13.7	47.5
≥ 65 years	364	1	1	2	3	743	12.3	64.4

cder_mpl1r_wp251

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	**12,017**	**1**	**3**	**6**	**18**	**1,118**	**21.0**	**53.4**
0-17 years	*****	2	8	11	12	210	48.6	90.3
18-24 years	81	1	5	17	39	490	31.9	57.7
25-40 years	1,358	1	4	10	28	595	28.6	56.3
41-64 years	8,112	1	3	6	18	1,118	21.2	56.0
≥ 65 years	2,461	1	2	5	12	742	15.6	40.6
doravirine/lamivudine/tenofovir disoproxil fumarate	**2,009**	**1**	**3**	**6**	**17**	**845**	**19.4**	**45.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	1	2	9	19	265	23.5	50.5
25-40 years	402	1	3	8	22	845	26.5	60.8
41-64 years	1,276	1	3	6	17	803	18.6	43.2
≥ 65 years	281	1	2	5	10	226	12.1	24.0
moxetumomab pasudotox-tdfk	**369**	**1**	**1**	**1**	**23**	**131**	**9.3**	**14.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	24	24	30	36	36	30.0	8.5
41-64 years	103	1	1	1	23	131	9.6	17.3
≥ 65 years	264	1	1	1	23	119	9.1	13.7
fremanezumab-vfrm	**132,820**	**1**	**3**	**7**	**20**	**1,461**	**23.9**	**63.3**
0-17 years	662	1	3	7	19	675	21.0	47.5
18-24 years	7,226	1	3	7	21	1,461	23.6	59.5
25-40 years	34,529	1	3	7	20	1,431	23.6	62.8
41-64 years	74,251	1	3	7	21	1,337	24.4	64.4
≥ 65 years	16,152	1	3	6	19	1,329	22.7	61.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
duvelisib	**733**	**1**	**2**	**6**	**14**	**494**	**15.6**	**35.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	37	39	39	27.0	19.1
41-64 years	107	1	3	7	18	414	21.3	49.7
≥ 65 years	623	1	2	6	14	494	14.5	32.9
galcanezumab-gnlm	**350,640**	**1**	**3**	**7**	**19**	**1,452**	**22.0**	**56.6**
0-17 years	1,299	1	3	7	18	617	21.0	52.3
18-24 years	19,334	1	3	7	19	1,186	20.3	50.6
25-40 years	94,750	1	3	7	20	1,323	21.9	55.6
41-64 years	192,684	1	3	7	20	1,452	22.2	56.8
≥ 65 years	42,573	1	3	6	18	1,173	22.4	60.6
dacomitinib	**86**	**1**	**3**	**6**	**16**	**106**	**15.1**	**20.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	17	1	2	7	45	106	24.2	30.9
≥ 65 years	69	1	3	6	14	105	12.8	16.8
cemiplimab-rwlc	**54,816**	**1**	**20**	**20**	**20**	**996**	**23.4**	**22.1**
0-17 years	*****	86	86	131	175	175	130.5	62.9
18-24 years	*****	20	20	20	20	20	20.0	0.0
25-40 years	192	12	20	20	21	237	25.7	27.0
41-64 years	4,514	1	20	20	20	595	24.0	25.3
≥ 65 years	50,106	1	20	20	20	996	23.3	21.8

cder_mpl1r_wp251

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
sarecycline	**17,129**	**1**	**4**	**11**	**29**	**1,125**	**33.3**	**72.5**
0-17 years	8,516	1	4	12	30	1,044	33.1	71.6
18-24 years	4,299	1	4	11	28	1,104	33.2	74.1
25-40 years	2,621	1	4	10	28	1,125	31.9	70.6
41-64 years	1,558	1	4	12	32	783	36.3	76.0
≥ 65 years	135	1	3	6	19	555	32.3	76.2
omadacycline	**3,003**	**1**	**2**	**6**	**23**	**1,198**	**35.9**	**88.8**
0-17 years	80	1	3	6	13	138	12.0	18.6
18-24 years	81	1	6	15	46	744	53.6	111.8
25-40 years	281	1	3	7	27	447	34.9	71.4
41-64 years	1,193	1	2	6	22	1,198	37.2	92.4
≥ 65 years	1,368	1	1	5	21	893	35.3	89.6
elapegademase-lvlr	**230**	**1**	**4**	**9**	**19**	**600**	**20.2**	**46.6**
0-17 years	99	1	3	7	16	105	13.5	19.2
18-24 years	70	1	5	9	22	176	21.1	34.1
25-40 years	55	1	5	10	22	600	32.3	82.5
41-64 years	*****	2	3	8	13	14	8.0	5.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**368**	**1**	**3**	**7**	**15**	**381**	**18.4**	**41.1**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	1	3	4	7	36	9.5	11.3
41-64 years	53	1	2	6	14	189	21.5	43.2
≥ 65 years	302	1	3	7	16	381	18.3	41.6

cder_mpl1r_wp251

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	**Minimum**	**Q1**	**Median**	**Q3**	**Maximum**	**Mean**	**Standard Deviation**
talazoparib	**582**	**1**	**3**	**6**	**15**	**1,085**	**15.8**	**52.1**
0-17 years	*****	6	6	7	11	11	8.0	2.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	72	1	3	9	19	137	14.5	19.2
41-64 years	320	1	3	7	14	287	12.5	21.5
≥ 65 years	187	1	3	5	16	1,085	21.9	86.5
baloxavir marboxil	**4,641**	**1**	**19**	**114**	**357**	**1,482**	**274.3**	**341.4**
0-17 years	868	1	23	210	458	1,463	326.2	369.4
18-24 years	355	1	5	112	371	1,408	266.8	332.1
25-40 years	945	1	10	101	357	1,472	274.7	352.3
41-64 years	1,485	1	11	94	336	1,463	250.9	333.9
≥ 65 years	988	1	38	142	346	1,482	266.4	314.5
lorlatinib	**1,567**	**1**	**2**	**6**	**15**	**1,071**	**24.2**	**82.2**
0-17 years	53	1	3	9	15	341	19.4	47.8
18-24 years	21	1	2	7	16	211	20.2	45.0
25-40 years	120	1	2	6	13	287	17.1	36.6
41-64 years	701	1	2	6	13	924	17.9	51.0
≥ 65 years	672	1	2	5	16	1,071	32.6	111.6
revefenacin	**17,253**	**1**	**14**	**27**	**37**	**1,268**	**37.5**	**59.2**
0-17 years	*****	19	19	19	19	19	19.0	NaN
18-24 years	12	1	4	7	11	132	17.3	36.3
25-40 years	126	1	3	9	31	429	35.7	72.3
41-64 years	3,439	1	5	23	37	942	36.9	66.9
≥ 65 years	13,675	1	20	28	37	1,268	37.7	57.0

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
rifamycin	**19**	**1**	**3**	**5**	**24**	**1,119**	**71.1**	**254.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	4	4	4	3.5	0.7
41-64 years	14	1	3	6	24	71	14.7	19.3
≥ 65 years	*****	1	1	17	1,119	1,119	379.0	640.9
emapalumab-lzsg	**469**	**1**	**2**	**6**	**6**	**254**	**7.0**	**13.4**
0-17 years	357	1	2	6	6	254	7.0	14.4
18-24 years	*****	1	2	3	6	6	3.6	2.1
25-40 years	51	1	2	4	14	62	10.1	12.8
41-64 years	43	2	2	3	3	17	4.2	4.0
≥ 65 years	*****	1	2	5	6	23	6.4	6.7
glasdegib	**145**	**1**	**2**	**6**	**12**	**83**	**9.1**	**11.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	5	6	6	4.5	2.1
41-64 years	16	1	2	4	11	17	6.3	5.5
≥ 65 years	127	1	2	6	12	83	9.5	12.1
larotrectinib	**372**	**1**	**2**	**5**	**15**	**336**	**16.2**	**37.4**
0-17 years	122	1	3	7	17	221	18.4	36.8
18-24 years	*****	2	3	5	8	9	5.3	3.3
25-40 years	*****	1	2	6	11	178	28.6	56.7
41-64 years	92	1	3	5	11	336	15.8	41.0
≥ 65 years	144	1	2	5	14	322	14.0	34.5

cder_mpl1r_wp251

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
amifampridine	**1,126**	**1**	**3**	**6**	**15**	**1,127**	**17.2**	**62.3**
0-17 years	12	1	2	6	8	22	6.8	6.4
18-24 years	37	1	4	8	23	588	30.1	95.6
25-40 years	72	1	4	10	24	166	20.6	27.9
41-64 years	372	1	3	6	16	943	19.3	67.0
≥ 65 years	633	1	2	5	13	1,127	15.0	60.3
gilteritinib	**2,325**	**1**	**3**	**9**	**26**	**508**	**25.3**	**48.0**
0-17 years	28	1	6	16	47	508	53.0	106.9
18-24 years	42	1	4	10	35	217	29.3	43.0
25-40 years	151	1	4	12	35	248	30.6	47.0
41-64 years	648	1	3	7	24	495	22.5	41.8
≥ 65 years	1,456	1	3	9	25	460	25.3	48.8
prucalopride	**53,489**	**1**	**3**	**8**	**25**	**1,318**	**31.1**	**76.9**
0-17 years	670	1	3	9	26	1,173	31.6	80.6
18-24 years	2,838	1	3	8	23	1,207	28.5	79.2
25-40 years	8,721	1	3	8	23	1,318	28.0	73.6
41-64 years	23,278	1	3	8	25	1,245	30.9	75.8
≥ 65 years	17,982	1	3	9	27	1,188	33.4	79.4
calaspargase pegol-mknl	**18**	**20**	**26**	**31**	**46**	**59**	**35.1**	**12.6**
0-17 years	14	20	26	31	46	51	34.4	11.6
18-24 years	*****	27	27	44	59	59	43.3	16.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	20	20	20	20	20	20.0	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

| | Total Number of Gaps | Distribution of Treatment Episode Gap Durations, days | | | | | | |
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
tagraxofusp-erzs	**307**	**1**	**4**	**18**	**24**	**416**	**24.0**	**39.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	15	16	26	34	17.2	11.2
25-40 years	*****	26	26	34	41	41	33.5	10.6
41-64 years	16	2	2	22	28	37	17.9	13.6
≥ 65 years	280	1	6	17	23	416	24.5	41.0
ravulizumab	**11,047**	**1**	**55**	**55**	**55**	**1,201**	**52.8**	**31.2**
0-17 years	698	1	27	55	55	343	49.0	30.5
18-24 years	498	1	55	55	55	868	55.4	43.4
25-40 years	2,252	1	55	55	56	1,000	55.9	39.4
41-64 years	3,347	1	55	55	55	1,201	53.4	31.3
≥ 65 years	4,252	1	55	55	55	567	50.9	23.5

*NaN: Not a number

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

		Distribution of First Treatment Episode Gap Duration, days						
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	761	3	6	6	8	496	11.3	27.5
patisiran	531	1	20	20	21	549	25.9	36.3
ethinyl estradiol and segesterone acetate	1,444	1	128	285	335	1,057	251.3	150.4
migalastat	112	1	2	6	21	535	23.6	59.4
stiripentol	217	1	3	8	21	358	30.9	61.3
cenegermin-bkbj	1,850	1	1	5	19	1,203	48.9	133.1
lanadelumab	823	1	3	7	18	1,044	23.8	74.8
eravacycline	262	1	1	3	7	743	17.4	74.8
doravirine	2,936	1	3	7	19	877	26.5	69.1
doravirine/lamivudine/tenofovir disoproxil fumarate	536	1	2	6	17	845	24.4	59.4
moxetumomab pasudotox-tdfk	41	1	1	1	1	131	7.0	21.7
fremanezumab-vfrm	37,391	1	3	8	23	1,461	27.8	74.3
duvelisib	252	1	3	7	18	494	19.0	47.3
galcanezumab-gnlm	94,009	1	3	8	24	1,452	26.9	67.0
dacomitinib	34	1	4	7	32	106	21.1	27.0
cemiplimab-rwlc	5,809	1	20	20	20	679	22.8	18.1
sarecycline	7,547	1	4	11	28	1,125	33.9	78.7
omadacycline	1,176	1	2	9	35	1,198	47.6	109.6
elapegademase-lvlr	28	1	4	7	19	176	23.1	39.6
inotersen	85	1	2	6	13	381	19.0	53.6
talazoparib	200	1	3	5	11	314	14.8	34.8
baloxavir marboxil	3,817	1	18	137	377	1,482	292.6	354.5
lorlatinib	492	1	2	6	15	1,071	31.5	113.3
revefenacin	3,864	1	6	24	40	1,035	44.2	84.1
rifamycin	14	1	4	9	24	1,119	93.6	295.7

cder_mpl1r_wp251

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	29	1	2	3	4	13	3.5	2.4
glasdegib	96	1	3	6	12	83	9.9	12.8
larotrectinib	150	1	3	5	17	336	18.2	40.0
amifampridine	235	1	3	6	17	1,127	29.7	117.9
gilteritinib	924	1	4	10	29	508	29.6	57.0
prucalopride	16,546	1	4	10	32	1,318	42.9	103.0
calaspargase pegol-mknl	15	20	21	38	47	59	36.8	13.2
tagraxofusp-erzs	58	1	20	25	33	156	27.1	21.9
ravulizumab	1,635	1	13	13	55	830	30.5	38.8

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**761**	**3**	**6**	**6**	**8**	**496**	**11.3**	**27.5**
Female	326	3	6	6	11	496	11.9	29.9
Male	435	4	6	6	8	384	10.9	25.6
patisiran	**531**	**1**	**20**	**20**	**21**	**549**	**25.9**	**36.3**
Female	186	1	20	20	21	549	27.4	48.1
Male	345	1	20	20	20	285	25.1	27.9
ethinyl estradiol and segesterone acetate	**1,444**	**1**	**128**	**285**	**335**	**1,057**	**251.3**	**150.4**
Female	1,443	1	128	285	335	1,057	251.2	150.5
Male	*****	354	354	354	354	354	354.0	NaN
migalastat	**112**	**1**	**2**	**6**	**21**	**535**	**23.6**	**59.4**
Female	56	1	2	6	22	535	31.0	78.1
Male	56	1	3	6	18	204	16.3	30.2
stiripentol	**217**	**1**	**3**	**8**	**21**	**358**	**30.9**	**61.3**
Female	122	1	2	8	23	358	31.6	57.6
Male	95	1	3	8	19	348	30.0	66.1
cenegermin-bkbj	**1,850**	**1**	**1**	**5**	**19**	**1,203**	**48.9**	**133.1**
Female	1,219	1	1	5	18	1,203	49.6	134.4
Male	631	1	1	5	20	1,033	47.5	130.7
lanadelumab	**823**	**1**	**3**	**7**	**18**	**1,044**	**23.8**	**74.8**
Female	552	1	3	7	16	714	21.4	60.3
Male	271	1	4	7	20	1,044	28.7	97.9
eravacycline	**262**	**1**	**1**	**3**	**7**	**743**	**17.4**	**74.8**
Female	137	1	1	4	8	393	16.4	52.8
Male	125	1	1	2	6	743	18.4	93.4
doravirine	**2,936**	**1**	**3**	**7**	**19**	**877**	**26.5**	**69.1**

cder_mpl1r_wp251

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	722	1	3	8	23	789	27.0	61.7
Male	2,214	1	3	6	18	877	26.3	71.3
doravirine/lamivudine/tenofovir disoproxil fumarate	**536**	**1**	**2**	**6**	**17**	**845**	**24.4**	**59.4**
Female	160	1	2	6	16	207	16.8	30.2
Male	376	1	2	7	19	845	27.6	67.9
moxetumomab pasudotox-tdfk	**41**	**1**	**1**	**1**	**1**	**131**	**7.0**	**21.7**
Female	*****	1	1	1	1	1	1.0	0.0
Male	36	1	1	1	1	131	7.8	23.1
fremanezumab-vfrm	**37,391**	**1**	**3**	**8**	**23**	**1,461**	**27.8**	**74.3**
Female	32,378	1	3	8	23	1,431	27.6	73.4
Male	5,013	1	3	8	24	1,461	28.8	79.5
duvelisib	**252**	**1**	**3**	**7**	**18**	**494**	**19.0**	**47.3**
Female	108	1	3	7	16	281	17.3	33.7
Male	144	1	3	7	18	494	20.2	55.4
galcanezumab-gnlm	**94,009**	**1**	**3**	**8**	**24**	**1,452**	**26.9**	**67.0**
Female	80,097	1	3	8	24	1,452	26.4	65.4
Male	13,912	1	3	9	26	1,273	29.9	75.2
dacomitinib	**34**	**1**	**4**	**7**	**32**	**106**	**21.1**	**27.0**
Female	23	1	3	6	32	106	19.7	25.6
Male	11	1	6	7	42	105	24.1	30.7
cemiplimab-rwlc	**5,809**	**1**	**20**	**20**	**20**	**679**	**22.8**	**18.1**
Female	1,530	1	20	20	20	355	23.0	15.0
Male	4,279	1	20	20	20	679	22.8	19.1
sarecycline	**7,547**	**1**	**4**	**11**	**28**	**1,125**	**33.9**	**78.7**
Female	4,575	1	4	11	28	1,125	34.4	81.2

cder_mpl1r_wp251

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	2,972	1	5	11	29	1,044	33.1	74.7
omadacycline	**1,176**	**1**	**2**	**9**	**35**	**1,198**	**47.6**	**109.6**
Female	634	1	3	9	38	1,198	50.3	116.7
Male	542	1	2	8	34	915	44.4	100.8
elapegademase-lvlr	**28**	**1**	**4**	**7**	**19**	**176**	**23.1**	**39.6**
Female	12	2	4	6	14	105	16.1	28.6
Male	16	1	5	8	27	176	28.4	46.4
inotersen	**85**	**1**	**2**	**6**	**13**	**381**	**19.0**	**53.6**
Female	42	1	2	5	11	303	16.7	48.7
Male	43	1	3	7	19	381	21.3	58.4
talazoparib	**200**	**1**	**3**	**5**	**11**	**314**	**14.8**	**34.8**
Female	189	1	2	5	11	287	13.5	28.3
Male	11	2	3	5	23	314	37.7	92.4
baloxavir marboxil	**3,817**	**1**	**18**	**137**	**377**	**1,482**	**292.6**	**354.5**
Female	2,101	1	17	116	374	1,463	285.9	349.2
Male	1,716	1	19	159	379	1,482	300.9	360.7
lorlatinib	**492**	**1**	**2**	**6**	**15**	**1,071**	**31.5**	**113.3**
Female	267	1	2	6	15	1,071	41.8	145.1
Male	225	1	2	6	15	504	19.2	53.5
revefenacin	**3,864**	**1**	**6**	**24**	**40**	**1,035**	**44.2**	**84.1**
Female	2,261	1	6	24	40	1,035	43.9	83.6
Male	1,603	1	6	24	39	797	44.5	84.9
rifamycin	**14**	**1**	**4**	**9**	**24**	**1,119**	**93.6**	**295.7**
Female	*****	1	1	5	17	24	8.7	9.6
Male	*****	2	5	12	52	1,119	157.3	389.3

cder_mpl1r_wp251

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
emapalumab-lzsg	**29**	**1**	**2**	**3**	**4**	**13**	**3.5**	**2.4**
Female	15	2	2	2	5	6	3.2	1.7
Male	14	1	2	3	4	13	3.9	3.0
glasdegib	**96**	**1**	**3**	**6**	**12**	**83**	**9.9**	**12.8**
Female	46	1	2	6	12	31	8.1	7.2
Male	50	1	4	8	12	83	11.5	16.3
larotrectinib	**150**	**1**	**3**	**5**	**17**	**336**	**18.2**	**40.0**
Female	82	1	3	7	19	336	20.9	46.1
Male	68	1	3	5	16	219	14.8	31.2
amifampridine	**235**	**1**	**3**	**6**	**17**	**1,127**	**29.7**	**117.9**
Female	138	1	3	6	18	1,127	32.6	128.5
Male	97	1	3	5	16	943	25.5	101.4
gilteritinib	**924**	**1**	**4**	**10**	**29**	**508**	**29.6**	**57.0**
Female	462	1	4	10	30	495	31.7	62.0
Male	462	1	4	9	28	508	27.5	51.4
prucalopride	**16,546**	**1**	**4**	**10**	**32**	**1,318**	**42.9**	**103.0**
Female	13,138	1	4	10	32	1,318	42.7	102.4
Male	3,408	1	3	10	33	1,181	43.8	105.6
calaspargase pegol-mknl	**15**	**20**	**21**	**38**	**47**	**59**	**36.8**	**13.2**
Female	*****	27	27	27	27	27	27.0	NaN
Male	14	20	21	41	47	59	37.5	13.4
tagraxofusp-erzs	**58**	**1**	**20**	**25**	**33**	**156**	**27.1**	**21.9**
Female	*****	2	26	37	41	49	32.6	13.7
Male	49	1	19	23	30	156	26.0	23.1
ravulizumab	**1,635**	**1**	**13**	**13**	**55**	**830**	**30.5**	**38.8**

cder_mpl1r_wp251

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

		Distribution of First Treatment Episode Gap Duration, days						
	Total Number of Gaps	**Minimum**	**Q1**	**Median**	**Q3**	**Maximum**	**Mean**	**Standard Deviation**
Female	874	1	13	13	55	830	31.4	42.3
Male	761	1	13	13	55	390	29.5	34.2

*NaN: Not a Number

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mogamulizumab-kpkc	**761**	**3**	**6**	**6**	**8**	**496**	**11.3**	**27.5**
0-17 years	*****	3	3	8	13	13	8.0	7.1
18-24 years	*****	6	6	6	6	6	6.0	0.0
25-40 years	23	4	6	7	19	288	26.3	60.0
41-64 years	152	5	6	6	13	97	11.8	14.0
≥ 65 years	582	4	6	6	7	496	10.7	28.1
patisiran	**531**	**1**	**20**	**20**	**21**	**549**	**25.9**	**36.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	2	18	20	68	549	109.0	188.7
41-64 years	109	1	20	20	22	165	24.9	24.2
≥ 65 years	412	1	20	20	20	285	24.2	24.3
ethinyl estradiol and segesterone acetate	**1,444**	**1**	**128**	**285**	**335**	**1,057**	**251.3**	**150.4**
0-17 years	56	1	58	260	327	503	222.4	138.1
18-24 years	454	1	150	289	332	1,020	256.0	149.1
25-40 years	772	1	131	286	337	1,057	252.8	151.6
41-64 years	162	1	96	280	336	900	241.1	152.2
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
migalastat	**112**	**1**	**2**	**6**	**21**	**535**	**23.6**	**59.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	3	5	11	84	16.8	27.8
25-40 years	27	1	5	13	47	204	29.1	44.0
41-64 years	48	1	2	7	18	535	22.7	76.5
≥ 65 years	27	1	1	4	21	184	22.3	46.9

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
stiripentol	**217**	**1**	**3**	**8**	**21**	**358**	**30.9**	**61.3**
0-17 years	163	1	3	8	21	348	28.0	54.2
18-24 years	46	1	2	8	20	358	44.7	84.3
25-40 years	*****	1	2	4	19	36	10.8	12.8
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
cenegermin-bkbj	**1,850**	**1**	**1**	**5**	**19**	**1,203**	**48.9**	**133.1**
0-17 years	16	1	1	2	29	389	42.2	99.1
18-24 years	*****	1	4	6	11	17	7.4	5.7
25-40 years	86	1	1	6	14	350	25.5	54.8
41-64 years	365	1	2	6	26	1,093	48.7	128.6
≥ 65 years	1,375	1	1	4	16	1,203	50.7	138.3
lanadelumab	**823**	**1**	**3**	**7**	**18**	**1,044**	**23.8**	**74.8**
0-17 years	81	1	2	7	14	221	18.1	39.0
18-24 years	83	1	4	8	24	148	19.9	28.5
25-40 years	223	1	3	7	15	782	23.9	72.9
41-64 years	290	1	3	7	20	714	20.8	55.2
≥ 65 years	146	1	2	6	15	1,044	34.8	126.7
eravacycline	**262**	**1**	**1**	**3**	**7**	**743**	**17.4**	**74.8**
0-17 years	*****	317	317	317	317	317	317.0	NaN
18-24 years	*****	1	3	6	19	30	10.5	13.2
25-40 years	25	1	4	6	12	735	40.4	145.9
41-64 years	112	1	1	3	6	105	9.0	18.2
≥ 65 years	120	1	1	2	7	743	18.0	82.1

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
doravirine	**2,936**	**1**	**3**	**7**	**19**	**877**	**26.5**	**69.1**
0-17 years	*****	8	8	11	210	210	76.3	115.8
18-24 years	25	1	7	16	51	490	47.9	97.2
25-40 years	376	1	4	11	31	569	34.5	66.3
41-64 years	1,907	1	3	7	19	877	26.9	72.4
≥ 65 years	625	1	2	5	13	742	19.2	56.9
doravirine/lamivudine/tenofovir disoproxil fumarate	**536**	**1**	**2**	**6**	**17**	**845**	**24.4**	**59.4**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	1	2	7	12	265	43.1	88.0
25-40 years	128	1	3	8	22	845	35.6	91.5
41-64 years	327	1	2	5	17	337	20.8	43.0
≥ 65 years	67	1	3	7	10	226	16.9	37.2
moxetumomab pasudotox-tdfk	**41**	**1**	**1**	**1**	**1**	**131**	**7.0**	**21.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	36	36	36	36	36	36.0	NaN
41-64 years	*****	1	1	1	1	131	17.3	46.0
≥ 65 years	32	1	1	1	1	35	3.5	8.0
fremanezumab-vfrm	**37,391**	**1**	**3**	**8**	**23**	**1,461**	**27.8**	**74.3**
0-17 years	216	1	3	7	20	675	29.2	71.7
18-24 years	2,201	1	3	8	25	1,461	26.6	67.3
25-40 years	10,072	1	3	8	22	1,431	26.1	69.4
41-64 years	20,271	1	3	8	24	1,337	29.1	78.5
≥ 65 years	4,631	1	3	7	23	1,051	26.4	68.2

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
duvelisib	**252**	**1**	**3**	**7**	**18**	**494**	**19.0**	**47.3**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	5	5	22	39	39	22.0	24.0
41-64 years	46	1	3	7	16	414	19.8	60.8
≥ 65 years	204	1	3	6	18	494	18.7	44.1
galcanezumab-gnlm	**94,009**	**1**	**3**	**8**	**24**	**1,452**	**26.9**	**67.0**
0-17 years	433	1	3	8	22	617	28.2	66.7
18-24 years	5,404	1	3	8	23	1,186	24.3	59.0
25-40 years	26,599	1	3	8	24	1,161	25.9	63.4
41-64 years	49,801	1	3	8	25	1,452	27.3	68.3
≥ 65 years	11,772	1	3	8	25	1,173	28.7	72.3
dacomitinib	**34**	**1**	**4**	**7**	**32**	**106**	**21.1**	**27.0**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	43	62	106	38.3	38.4
≥ 65 years	27	1	4	6	28	105	16.6	22.0
cemiplimab-rwlc	**5,809**	**1**	**20**	**20**	**20**	**679**	**22.8**	**18.1**
0-17 years	*****	86	86	86	86	86	86.0	NaN
18-24 years	*****	20	20	20	20	20	20.0	NaN
25-40 years	22	13	20	21	24	47	24.0	7.7
41-64 years	481	3	20	20	21	175	23.5	12.0
≥ 65 years	5,304	1	20	20	20	679	22.7	18.6

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
sarecycline	**7,547**	**1**	**4**	**11**	**28**	**1,125**	**33.9**	**78.7**
0-17 years	3,682	1	4	12	29	1,044	33.3	76.8
18-24 years	1,972	1	4	10	26	977	33.9	80.6
25-40 years	1,260	1	4	10	27	1,125	32.4	78.1
41-64 years	592	1	5	12	33	783	38.0	80.6
≥ 65 years	41	1	6	12	89	555	72.9	124.0
omadacycline	**1,176**	**1**	**2**	**9**	**35**	**1,198**	**47.6**	**109.6**
0-17 years	15	1	3	5	19	138	17.6	34.3
18-24 years	23	1	4	12	46	744	74.7	162.1
25-40 years	92	1	5	11	41	388	39.6	68.7
41-64 years	454	1	3	10	34	1,198	52.5	119.7
≥ 65 years	592	1	2	7	35	893	44.7	105.3
elapegademase-lvlr	**28**	**1**	**4**	**7**	**19**	**176**	**23.1**	**39.6**
0-17 years	*****	4	4	11	28	105	26.6	34.3
18-24 years	*****	1	4	5	7	176	24.1	57.0
25-40 years	*****	4	7	10	18	86	19.8	27.4
41-64 years	*****	6	6	6	6	6	6.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
inotersen	**85**	**1**	**2**	**6**	**13**	**381**	**19.0**	**53.6**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	4	20	36	36	20.0	22.6
41-64 years	13	1	1	6	13	115	21.1	36.2
≥ 65 years	70	1	2	6	13	381	18.6	57.1

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
talazoparib	**200**	**1**	**3**	**5**	**11**	**314**	**14.8**	**34.8**
0-17 years	*****	11	11	11	11	11	11.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	28	1	3	6	18	137	14.5	26.3
41-64 years	103	1	3	5	11	287	14.8	33.4
≥ 65 years	68	1	2	5	12	314	15.0	40.3
baloxavir marboxil	**3,817**	**1**	**18**	**137**	**377**	**1,482**	**292.6**	**354.5**
0-17 years	779	1	24	218	531	1,463	334.3	374.0
18-24 years	316	1	6	104	383	1,408	270.1	333.5
25-40 years	832	1	10	103	376	1,413	285.4	359.6
41-64 years	1,194	1	8	106	363	1,463	275.4	352.2
≥ 65 years	696	1	38	193	357	1,482	294.4	335.8
lorlatinib	**492**	**1**	**2**	**6**	**15**	**1,071**	**31.5**	**113.3**
0-17 years	24	1	2	11	23	341	26.0	68.0
18-24 years	*****	1	1	9	20	24	10.5	11.4
25-40 years	39	1	3	6	20	287	19.6	47.0
41-64 years	224	1	2	5	13	924	18.9	70.1
≥ 65 years	201	1	2	7	16	1,071	48.9	156.7
revefenacin	**3,864**	**1**	**6**	**24**	**40**	**1,035**	**44.2**	**84.1**
0-17 years	*****	19	19	19	19	19	19.0	NaN
18-24 years	*****	4	4	8	12	16	8.6	4.3
25-40 years	41	1	4	11	33	429	48.4	98.5
41-64 years	1,075	1	4	18	41	921	43.8	82.5
≥ 65 years	2,740	1	8	25	40	1,035	44.3	84.6

cder_mpl1r_wp251

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
rifamycin	**14**	**1**	**4**	**9**	**24**	**1,119**	**93.6**	**295.7**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	4	4	4	4	4.0	NaN
41-64 years	*****	1	4	9	24	71	16.9	21.5
≥ 65 years	*****	1	1	17	1,119	1,119	379.0	640.9
emapalumab-lzsg	**29**	**1**	**2**	**3**	**4**	**13**	**3.5**	**2.4**
0-17 years	18	1	2	3	5	6	3.4	1.7
18-24 years	*****	2	2	4	6	6	4.0	2.8
25-40 years	*****	2	2	2	3	3	2.3	0.5
41-64 years	*****	3	3	8	13	13	8.0	7.1
≥ 65 years	*****	2	2	2	3	3	2.3	0.6
glasdegib	**96**	**1**	**3**	**6**	**12**	**83**	**9.9**	**12.8**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	3	3	3	3	3.0	NaN
41-64 years	*****	1	2	5	14	17	8.0	6.4
≥ 65 years	86	1	3	6	12	83	10.2	13.4
larotrectinib	**150**	**1**	**3**	**5**	**17**	**336**	**18.2**	**40.0**
0-17 years	33	1	2	4	18	219	20.1	40.6
18-24 years	*****	3	3	6	9	9	6.0	4.2
25-40 years	*****	1	2	6	42	178	34.6	62.6
41-64 years	39	1	3	9	21	336	26.7	59.5
≥ 65 years	68	1	2	5	16	92	10.7	14.7

cder_mpl1r_wp251

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
amifampridine	**235**	**1**	**3**	**6**	**17**	**1,127**	**29.7**	**117.9**
0-17 years	*****	1	6	6	6	22	8.2	8.0
18-24 years	*****	1	3	15	36	588	97.6	216.6
25-40 years	19	1	10	17	46	111	27.3	27.6
41-64 years	74	1	3	6	17	943	30.0	115.3
≥ 65 years	130	1	3	6	14	1,127	27.0	123.0
gilteritinib	**924**	**1**	**4**	**10**	**29**	**508**	**29.6**	**57.0**
0-17 years	12	4	10	20	38	508	61.7	141.3
18-24 years	15	1	3	10	62	118	33.9	39.9
25-40 years	69	1	6	13	40	248	38.5	55.0
41-64 years	239	1	4	8	28	495	28.8	55.3
≥ 65 years	589	1	4	9	27	460	28.2	55.3
prucalopride	**16,546**	**1**	**4**	**10**	**32**	**1,318**	**42.9**	**103.0**
0-17 years	202	1	4	10	32	1,173	46.8	121.1
18-24 years	890	1	4	11	33	1,207	43.8	112.0
25-40 years	2,728	1	3	10	28	1,318	39.1	101.2
41-64 years	7,088	1	3	10	32	1,245	41.1	99.2
≥ 65 years	5,638	1	4	11	35	1,188	46.7	106.3
calaspargase pegol-mknl	**15**	**20**	**21**	**38**	**47**	**59**	**36.8**	**13.2**
0-17 years	11	20	21	38	47	51	36.5	12.4
18-24 years	*****	27	27	44	59	59	43.3	16.0
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	20	20	20	20	20	20.0	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
tagraxofusp-erzs	**58**	**1**	**20**	**25**	**33**	**156**	**27.1**	**21.9**
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	26	26	30	34	34	30.0	5.7
25-40 years	*****	26	26	34	41	41	33.5	10.6
41-64 years	*****	2	19	25	27	37	22.0	12.9
≥ 65 years	49	1	20	23	32	156	27.2	23.5
ravulizumab	**1,635**	**1**	**13**	**13**	**55**	**830**	**30.5**	**38.8**
0-17 years	107	1	13	14	54	315	31.9	38.1
18-24 years	81	12	13	14	55	116	32.0	25.7
25-40 years	323	1	13	15	55	830	36.8	54.8
41-64 years	428	1	13	14	55	398	34.2	36.9
≥ 65 years	696	1	13	13	21	524	25.0	30.9

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

| | | Censoring Reason | | | | | | | | | | | |
| | | End of Exposure Episode[2] | | Occurrence of User-Defined Censoring Criteria[3] | | Evidence of Death[4] | | Disenrollment[5] | | End of Data[6] | | End of Study Period[7] | |
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
mogamulizumab-kpkc	12,281	12,280	100.0%	0	0.0%	*****	0.0%	*****	0.0%	*****	0.0%	*****	0.0%
patisiran	12,106	*****	100.0%	0	0.0%	*****	0.0%	21	0.2%	15	0.1%	15	0.1%
ethinyl estradiol and segesterone acetate	13,768	13,768	100.0%	0	0.0%	0	0.0%	4,483	32.6%	2,161	15.7%	2,161	15.7%
migalastat	705	702	99.6%	0	0.0%	*****	*****	128	18.2%	*****	*****	69	9.8%
stiripentol	1,120	1,119	99.9%	0	0.0%	*****	*****	252	22.5%	*****	*****	205	18.3%
cenegermin-bkbj	8,299	8,262	99.6%	0	0.0%	43	0.5%	420	5.1%	345	4.2%	345	4.2%
lanadelumab	5,982	5,967	99.7%	0	0.0%	15	0.3%	691	11.6%	441	7.4%	441	7.4%
eravacycline	1,517	1,511	99.6%	0	0.0%	12	0.8%	19	1.3%	12	0.8%	12	0.8%
doravirine	16,829	16,663	99.0%	0	0.0%	181	1.1%	3,164	18.8%	2,247	13.4%	2,247	13.4%
doravirine/lamivudine/tenofovir disoproxil fumarate	3,004	2,996	99.7%	0	0.0%	*****	*****	620	20.6%	*****	*****	470	15.6%
moxetumomab pasudotox-tdfk	418	418	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
fremanezumab-vfrm	192,410	192,288	99.9%	0	0.0%	135	0.1%	24,201	12.6%	14,426	7.5%	14,426	7.5%
duvelisib	1,216	1,147	94.3%	0	0.0%	72	5.9%	66	5.4%	47	3.9%	47	3.9%
galcanezumab-gnlm	496,084	495,757	99.9%	0	0.0%	355	0.1%	63,757	12.9%	39,446	8.0%	39,446	8.0%
dacomitinib	156	147	94.2%	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
cemiplimab-rwlc	61,461	61,456	100.0%	0	0.0%	*****	0.0%	35	0.1%	*****	*****	27	0.0%
sarecycline	31,451	31,451	100.0%	0	0.0%	0	0.0%	1,605	5.1%	774	2.5%	774	2.5%
omadacycline	6,973	6,936	99.5%	0	0.0%	44	0.6%	292	4.2%	231	3.3%	231	3.3%
elapegademase-lvlr	262	262	100.0%	0	0.0%	0	0.0%	24	9.2%	20	7.6%	20	7.6%

cder_mpl1r_wp251

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1,2018 to May 31, 2023[1]

		Censoring Reason											
	Total Number of Episodes	End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
inotersen	483	479	99.2%	0	0.0%	*****	*****	23	4.8%	*****	*****	13	2.7%
talazoparib	954	937	98.2%	0	0.0%	22	2.3%	77	8.1%	43	4.5%	43	4.5%
baloxavir marboxil	114,747	114,711	100.0%	0	0.0%	38	0.0%	652	0.6%	513	0.4%	513	0.4%
lorlatinib	2,622	2,500	95.3%	0	0.0%	134	5.1%	406	15.5%	263	10.0%	263	10.0%
revefenacin	25,449	25,200	99.0%	0	0.0%	273	1.1%	1,354	5.3%	886	3.5%	886	3.5%
rifamycin	87	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
emapalumab-lzsg	506	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
glasdegib	470	364	77.4%	0	0.0%	114	24.3%	23	4.9%	*****	*****	*****	*****
larotrectinib	712	676	94.9%	0	0.0%	39	5.5%	111	15.6%	76	10.7%	76	10.7%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1,2018 to May 31, 2023[1]

		End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
amifampridine	1,528	1,490	97.5%	0	0.0%	40	2.6%	264	17.3%	202	13.2%	202	13.2%
gilteritinib	4,113	3,780	91.9%	0	0.0%	365	8.9%	397	9.7%	251	6.1%	251	6.1%
prucalopride	86,613	86,359	99.7%	0	0.0%	278	0.3%	11,089	12.8%	7,942	9.2%	7,942	9.2%
calaspargase pegol-mknl	50	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
tagraxofusp-erzs	395	395	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
ravulizumab	12,906	12,904	100.0%	0	0.0%	*****	*****	118	0.9%	*****	*****	101	0.8%

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[4]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[5]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[6]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[7]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Mogamulizumab-Kpkc		Patisiran		Ethinyl Estradiol and Segesterone Acetate		Migalastat	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	877	223,835,743	609	223,836,011	14,941	223,821,679	218	223,836,402
Claim recorded during specified age range	877	0	609	0	14,941	0	218	0
Episode defining index claim recorded during the query period	877	0	609	0	14,941	0	218	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	816	61	570	39	12,072	2,869	170	48
Met inclusion and exclusion criteria	816	0	570	0	12,072	0	170	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	816	0	570	0	12,072	0	170	0
Final cohort								
Number of members	816	N/A	570	N/A	12,072	N/A	170	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Stiripentol		Cenegermin-Bkbj		Lanadelumab		Eravacycline	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	449	223,836,171	5,859	223,830,761	1,275	223,835,345	826	223,835,794
Claim recorded during specified age range	449	0	5,859	0	1,275	0	826	0
Episode defining index claim recorded during the query period	449	0	5,859	0	1,275	0	826	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	402	47	5,521	338	1,109	166	723	103
Met inclusion and exclusion criteria	402	0	5,521	0	1,109	0	723	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	402	0	5,521	0	1,109	0	723	0
Final cohort								
Number of members	402	N/A	5,521	N/A	1,109	N/A	723	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Doravirine		Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate		Moxetumomab Pasudotox-Tdfk		Fremanezumab-Vfrm	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	5,731	223,830,889	1,212	223,835,408	*****	*****	69,269	223,767,351
Claim recorded during specified age range	5,731	0	1,212	0	*****	0	69,269	0
Episode defining index claim recorded during the query period	5,731	0	1,212	0	*****	0	69,269	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	4,812	919	995	217	49	*****	59,590	9,679
Met inclusion and exclusion criteria	4,812	0	995	0	49	0	59,590	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	4,812	0	995	0	49	0	59,590	0
Final cohort								
Number of members	4,812	N/A	995	N/A	49	N/A	59,590	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Duvelisib		Galcanezumab-Gnlm		Dacomitinib		Cemiplimab-Rwlc	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	517	223,836,103	169,290	223,667,330	81	223,836,539	7,058	223,829,562
Claim recorded during specified age range	517	0	169,290	0	81	0	7,058	0
Episode defining index claim recorded during the query period	517	0	169,290	0	81	0	7,058	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	483	34	145,444	23,846	70	11	6,645	413
Met inclusion and exclusion criteria	483	0	145,444	0	70	0	6,645	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	483	0	145,444	0	70	0	6,645	0
Final cohort								
Number of members	483	N/A	145,444	N/A	70	N/A	6,645	N/A

N/A: Not Applicable

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Sarecycline		Omadacycline		Elapegademase-Lvlr		Inotersen	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	15,875	223,820,745	4,384	223,832,236	*****	*****	*****	*****
Claim recorded during specified age range	15,875	0	4,384	0	*****	0	*****	0
Episode defining index claim recorded during the query period	15,875	0	4,384	0	*****	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	14,322	1,553	3,970	414	*****	*****	*****	*****
Met inclusion and exclusion criteria	14,322	0	3,970	0	*****	0	*****	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	14,322	0	3,970	0	32	0	115	0
Final cohort								
Number of members	14,322	N/A	3,970	N/A	32	N/A	115	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Talazoparib		Baloxavir Marboxil		Lorlatinib		Revefenacin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	426	223,836,194	127,460	223,709,160	1,213	223,835,407	9,577	223,827,043
Claim recorded during specified age range	426	0	127,460	0	1,213	0	9,577	0
Episode defining index claim recorded during the query period	426	0	127,460	0	1,213	0	9,577	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	372	54	110,106	17,354	1,055	158	8,196	1,381
Met inclusion and exclusion criteria	372	0	110,106	0	1,055	0	8,196	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	372	0	110,106	0	1,055	0	8,196	0
Final cohort								
Number of members	372	N/A	110,106	N/A	1,055	N/A	8,196	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Rifamycin		Emapalumab-Lzsg		Glasdegib		Larotrectinib	
	Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	99	223,836,521	42	223,836,578	335	223,836,285	408	223,836,212
Claim recorded during specified age range	99	0	42	0	335	0	408	0
Episode defining index claim recorded during the query period	99	0	42	0	335	0	408	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	68	31	*****	*****	*****	*****	340	68
Met inclusion and exclusion criteria	68	0	*****	0	*****	0	340	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	68	0	37	0	325	0	340	0
Final cohort								
Number of members	68	N/A	37	N/A	325	N/A	340	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Amifampridine		Gilteritinib		Prucalopride		Calaspargase Pegol-Mknl	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
Members with a valid index event								
Had any cohort-defining claim during the query period	471	223,836,149	2,031	223,834,589	37,120	223,799,500	42	223,836,578
Claim recorded during specified age range	471	0	2,031	0	37,120	0	42	0
Episode defining index claim recorded during the query period	471	0	2,031	0	37,120	0	42	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	402	69	1,788	243	33,124	3,996	*****	*****
Met inclusion and exclusion criteria	402	0	1,788	0	33,124	0	*****	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	402	0	1,788	0	33,124	0	32	0
Final cohort								
Number of members	402	N/A	1,788	N/A	33,124	N/A	32	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

	Tagraxofusp-Erzs		Ravulizumab	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
Members with a valid index event				
Had any cohort-defining claim during the query period	95	223,836,525	2,021	223,834,599
Claim recorded during specified age range	95	0	2,021	0
Episode defining index claim recorded during the query period	95	0	2,021	0
Members with required pre-index history				
Had sufficient pre-index continuous enrollment	*****	*****	1,859	162
Met inclusion and exclusion criteria	*****	0	1,859	0
Members with required post-index follow-up				
Had sufficient post-index continuous enrollment	88	0	1,859	0
Final cohort				
Number of members	88	N/A	1,859	N/A

N/A: Not Applicable

 *****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1a. Patient Entry into Study by Month for Mogamulizumab-Kpkc in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 8, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1c. Patient Entry into Study by Month for Ethinyl Estradiol and Segesterone Acetate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1d. Patient Entry into Study by Month for Migalastat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 10, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1e. Patient Entry into Study by Month for Stiripentol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 20, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on August 22, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Figure 1g. Patient Entry into Study by Month for Lanadelumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 23, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on August 27, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1i. Patient Entry into Study by Month for Doravirine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 30, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1j. Patient Entry into Study by Month for Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on August 30, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1k. Patient Entry into Study by Month for Moxetumomab Pasudotox-Tdfk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on September 13, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1l. Patient Entry into Study by Month for Fremanezumab-Vfrm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on September 14, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

Figure 1m. Patient Entry into Study by Month for Duvelisib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on September 24, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1n. Patient Entry into Study by Month for Galcanezumab-Gnlm in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

---

*The FDA approval date for this drug was on September 27, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1o. Patient Entry into Study by Month for Dacomitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on September 27, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on September 28, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1q. Patient Entry into Study by Month for Sarecycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 1, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

Figure 1r. Patient Entry into Study by Month for Omadacycline in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 2, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1s. Patient Entry into Study by Month for Elapegademase-Lvlr in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 5, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1t. Patient Entry into Study by Month for Inotersen in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 5, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1u. Patient Entry into Study by Month for Talazoparib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 16, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1v. Patient Entry into Study by Month for Baloxavir Marboxil in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on October 24, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*The FDA approval date for this drug was on November 2, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1x. Patient Entry into Study by Month for Revefenacin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on November 9, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1y. Patient Entry into Study by Month for Rifamycin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on November 16, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1z. Patient Entry into Study by Month for Emapalumab-Lzsg in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on November 20, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1aa. Patient Entry into Study by Month for Glasdegib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on November 21, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on November 26, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on November 28, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1ad. Patient Entry into Study by Month for Gilteritinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on November 28, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on December 14, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*The FDA approval date for this drug was on December 20, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

Figure 1ag. Patient Entry into Study by Month for Tagraxofusp-Erzs in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

*The FDA approval date for this drug was on December 21, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.*

*The FDA approval date for this drug was on December 21, 2018, as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 20, 2023)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2004	11/30/2022
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	12/31/2022
DP04	01/01/2006	02/28/2023
DP05	01/01/2000	05/31/2023
DP06	01/01/2000	04/30/2023
DP07	01/01/2000	08/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	10/31/2022
DP10	01/01/2007	01/31/2023
DP11	01/01/2014	12/31/2020
DP12	01/01/2008	04/30/2023
DP13	01/01/2010	12/31/2022

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Mogamulizumab-Kpkc	
mogamulizumab-kpkc	Poteligeo
Patisiran	
patisiran sodium, lipid complex	Onpattro
Ethinyl Estradiol and Segesterone Acetate	
ethinyl estradiol and segesterone acetate	Annovera
Migalastat	
migalastat HCl	Galafold
Stiripentol	
stiripentol	Diacomit
Cenegermin-Bkbj	
cenegermin-bkbj	Oxervate
Lanadelumab	
lanadelumab-flyo	Takhzyro
Eravacycline	
eravacycline di-hydrochloride	Xerava
Doravirine	
doravirine	Pifeltro
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate	
doravirine, lamivudine, tenofovir disoproxil fumarate	Delstrigo
Moxetumomab Pasudotox-Tdfk	
moxetumomab pasudotox-tdfk	Lumoxiti
Fremanezumab-Vfrm	
fremanezumab-vfrm	Ajovy Autoinjector
fremanezumab-vfrm	Ajovy Syringe
Duvelisib	
duvelisib	Copiktra
Galcanezumab-Gnlm	
galcanezumab-gnlm	Emgality
galcanezumab-gnlm	Emgality Pen
galcanezumab-gnlm	Emgality Syringe
Dacomitinib	
dacomitinib	Vizimpro
Cemiplimab-Rwlc	
cemiplimab-rwlc	Libtayo
Sarecycline	
sarecycline HCl	Seysara
Omadacycline	
omadacycline tosylate	Nuzyra

cder_mpl1r_wp251

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
omadacycline tosylate	Nuzyra (7 Day with Load Dose)
omadacycline tosylate	Nuzyra (7 Day)
Elapegademase-Lvlr	
elapegademase-lvlr	Revcovi
inotersen	
Inotersen sodium	Tegsedi
Talazoparib	
talazoparib	Talzenna
talazoparib tosylate	Talzenna
Baloxavir Marboxil	
baloxavir marboxil	Xofluza
Lorlatinib	
lorlatinib	Lorbrena
Revefenacin	
revefenacin	Yupelri
Rifamycin	
rifamycin sodium	Aemcolo
Emapalumab-Lzsg	
emapalumab-lzsg	Gamifant
Glasdegib	
glasdegib maleate	Daurismo
Larotrectinib	
larotrectinib sulfate	Vitrakvi
Amifampridine	
amifampridine	Ruzurgi
amifampridine phosphate	Firdapse
Gilteritinib	
gilteritinib fumarate	Xospata
Prucalopride	
prucalopride succinate	Motegrity
Calaspargase Pegol-Mknl	
calaspargase pegol-mknl	Asparlas
Tagraxofusp-Rrzs	
tagraxofusp-erzs	Elzonris
Ravulizumab	
ravulizumab-cwvz	Ultomiris

Code	Description	Code Category	Code Type
Mogamulizumab-Kpkc			
C9038	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
J9204	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
Patisiran			
C9036	Injection, patisiran, 0.1 mg	Procedure	HCPCS
J0222	Injection, patisiran, 0.1 mg	Procedure	HCPCS
Ethinyl Estradiol and Segesterone Acetate			
J7294	Segesterone acetate and ethinyl estradiol 0.15 mg	Procedure	HCPCS
Lanadelumab			
J0593	Injection, lanadelumab-flyo, 1 mg	Procedure	HCPCS
Eravacycline			
J0122	Injection, eravacycline, 1 mg	Procedure	HCPCS
Moxetumomab Pasudotox-Tdfk			
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
Fremanezumab-Vfrm			
C9040	Injection, fremanezumab-vfrm, 1 mg	Procedure	HCPCS
J3031	Injection, fremanezumab-vfrm, 1 mg	Procedure	HCPCS
Cemiplimab-Rwlc			
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
Omadacycline			
C9051	Injection, omadacycline, 1 mg	Procedure	HCPCS
J0121	Injection, omadacycline, 1 mg	Procedure	HCPCS
XW033B6	INTRO OMADACYCLINE PRPH VN PRC NT 6	Procedure	ICD-10-PCS
XW043B6	INTRO OMADACYCLNE CNTRL VN PRC NT 6	Procedure	ICD-10-PCS
Revefenacin			
J7677	Revefenacin inhalation solution, noncompounded, administered through DME, 1 mcg	Procedure	HCPCS
Emapalumab-Lzsg			
66658050101	emapalumab-lzsg	Diagnosis	ICD-10-CM
66658050501	emapalumab-lzsg	Diagnosis	ICD-10-CM
66658051001	emapalumab-lzsg	Diagnosis	ICD-10-CM
72171050501	emapalumab-lzsg	Diagnosis	ICD-10-CM
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
J9210	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
Gilteritinib			
XW0DXV5	INT GILTERITINB MTH PHRX EXT NW G5	Procedure	ICD-10-PCS
Calaspargase Pegol-Mknl			
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
Tagraxofusp-Erzs			
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
XW033Q5	INT TAGRAXOFSPERZS PERI VN PC NW G5	Procedure	ICD-10-PCS

cder_mpl1r_wp251

Code	Description	Code Category	Code Type
XW043Q5	INT TAGRAXOFSPERZS CTRL VN PC NW G5	Procedure	ICD-10-PCS
Ravulizumab			
C9052	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS
J1303	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Breast Cancer			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal Cancer			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depression			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp251

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Lung Cancer			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthrosis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthrosis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthrosis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthrosis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthrosis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthrosis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthrosis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthrosis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthrosis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthrosis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthrosis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthrosis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthrosis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthrosis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthrosis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthrosis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthrosis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthrosis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthrosis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthrosis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM

cder_mpl1r_wp251

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
715.95	Osteoarthrosis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthrosis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthrosis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthrosis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4

cder_mpl1r_wp251

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool version 12.1.2 to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2018 in the Sentinel Distributed Database (SDD). This query is Part 2 of 2 of the NME 2018 queries representing NMEs from Aug 2018 - Dec 2018.

Query period:	01/01/2018 - Most recent available data
Coverage requirement:	Medical and Drug Coverage
Pre-index enrollment requirement:	183 days
Post-index requirement:	0 days
Enrollment gap:	45 days
Age groups:	0-17, 18-24, 25-40, 41-64, 65+ years
Stratifications:	Age group, Sex
	Calendar Month (for Figures only)
Restrictions:	Male and Female
Distribution of index-defining codes:	No
Envelope macro:	Reclassify encounters during inpatient stay as inpatient
Freeze data:	No

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	mogamulizumab-kpkc	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

cder_mpl1r_wp251

Appendix F. Specifications Defining Parameters for this Request

2	patisiran	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	ethinyl estradiol and segesterone acetate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	migalastat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	stiripentol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

cder_mpl1r_wp251

6	cenegermin-bkbj	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	lanadelumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	eravacycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	doravirine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

10	doravirine-lamiv-tenofov	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	moxetumomab pasudotox-tdfk	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	fremanezumab-vfrm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	duvelisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

14	galcanezumab-gnlm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	dacomitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	cemiplimab-rwlc	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	sarecycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

18	omadacycline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	elapegademase-lvlr	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	inotersen	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	talazoparib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

cder_mpl1r_wp251

Appendix F. Specifications Defining Parameters for this Request

22	baloxavir marboxil	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	lorlatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	revefenacin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	rifamycin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

26	emapalumab-lzsg	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
27	glasdegib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
28	larotrectinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
29	amifampridine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

30	gilteritinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
31	prucalopride	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
32	calaspargase pegol-mknl	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
33	tagraxofusp-erzs	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

34	ravulizumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.
N/A: Not Applicable

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Covariates

Characteristic	Characteristic Number	Care setting/ Principal diagnosis[1]	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
Chronic Conditions Data Warehouse (Selection of conditions, care settings and no. of instances from both 27 and 30 CCW lists, approved for 2019 part 1)							
Acute Myocardial Infarction	1	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	3	IPP, IPS or	-183	-1	N/A	1	N/A
	4	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	5	3 or 4	-183	-1	N/A	N/A	N/A
Diabetes	6	IP*, IS* or	-183	-1	N/A	1	N/A
	7	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	8	6 or 7	-183	-1	N/A	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	N/A	1	N/A
Hyperlipidemia	10	IP*, IS* or	-183	-1	N/A	1	N/A
	11	AV*, ED*, OA*	-183	-1	N/A	2	N/A

Covariates

Characteristic	Characteristic Number	Care setting/ Principal diagnosis[1]	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
	12	10 or 11	-183	-1	N/A	N/A	N/A
	13	IP*, IS* or	-183	-1	N/A	1	N/A
Hypertension	14	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	15	13 or 14	-183	-1	N/A	N/A	N/A
Depression	16	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	N/A	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	N/A	1	N/A
	20	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	21	19 or 20	-183	-1	N/A	N/A	N/A
	22	IP*, IS* or	-183	-1	N/A	1	N/A
Breast Cancer	23	AV*, ED* OA*	-183	-1	N/A	2	N/A

cder_mpl1r_wp251

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

			Covariates				
Characteristic	**Characteristic Number**	**Care setting/ Principal diagnosis[1]**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensing**	**Number of instances the covariate should be found in evaluation period**	**Forced supply to attach to dispensing**
	24	22 or 23	-183	-1	N/A	N/A	N/A
	25	IP*, IS* or	-183	-1	N/A	1	N/A
Colorectal Cancer	26	AV*, ED* OA*	-183	-1	N/A	2	N/A
	27	25 or 26	-183	-1	N/A	N/A	N/A
	28	IP*, IS* or	-183	-1	N/A	1	N/A
Prostate Cancer	29	AV*, ED* OA*	-183	-1	N/A	2	N/A
	30	28 or 29	-183	-1	N/A	N/A	N/A
	31	IP*, IS* or	-183	-1	N/A	1	N/A
Lung Cancer	32	AV*, ED* OA*	-183	-1	N/A	2	N/A
	33	31 or 32	-183	-1	N/A	N/A	N/A
	34	IP*, IS* or	-183	-1	N/A	1	N/A
Endometrial Cancer	35	AV*, ED* OA*	-183	-1	N/A	2	N/A

cder_mpl1r_wp251

					Covariates	
Characteristic	Characteristic Number	Care setting/ Principal diagnosis[1]	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
	36	34 or 35	-183	-1	N/A	N/A	N/A
Acquired Hypothyroidism	37	IP*, IS*, or	-183	-1	N/A	1	N/A
	38	AV*, ED* OA*	-183	-1	N/A	2	N/A
	39	37 or 38	-183	-1	N/A	N/A	N/A
Anemia	40	Any	-183	-1	N/A	1	N/A
Asthma	41	IP*, IS*, or	-183	-1	N/A	1	N/A
	42	AV*, ED* OA*	-183	-1	N/A	2	N/A
	43	41 or 42	-183	-1	N/A	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*, or	-183	-1	N/A	1	N/A
	45	AV*, ED* OA*	-183	-1	N/A	2	N/A
	46	44 or 45	-183	-1	N/A	N/A	N/A
	47	IP*, IS*, or	-183	-1	N/A	1	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

			Covariates				
Characteristic	**Characteristic Number**	**Care setting/ Principal diagnosis[1]**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensing**	**Number of instances the covariate should be found in evaluation period**	**Forced supply to attach to dispensing**
Chronic Kidney Disease	48	AV*, ED* OA*	-183	-1	N/A	2	N/A
	49	47 or 48	-183	-1	N/A	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*, or	-183	-1	N/A	1	N/A
	51	AV*, ED* OA*	-183	-1	N/A	2	N/A
	52	50 or 51	-183	-1	N/A	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	N/A	1	N/A
Osteoporosis	54	IP*, IS*, or	-183	-1	N/A	1	N/A
	55	AV*, ED* OA*	-183	-1	N/A	2	N/A
	56	54 or 55	-183	-1	N/A	N/A	N/A

Other

Obesity: diagnosed or identified by weight management procedures	57	Any	-183	-1	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	58	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A

cder_mpl1r_wp251

Covariates

Characteristic	Characteristic Number	Care setting/ Principal diagnosis[1]	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
Overweight	59	Any	-183	-1	N/A	1	N/A
Smoking: diagnosed or identified by smoking cessation procedures	60	Any	-183	-1	N/A	1	N/A
Smoking: identified by smoking-related prescriptions	61	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	62	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	63	Any	-183	-1	N/A	1	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

		Covariates					
Characteristic	**Characteristic Number**	**Care setting/ Principal diagnosis**[1]	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensing**	**Number of instances the covariate should be found in evaluation period**	**Forced supply to attach to dispensing**
History of Cardiac Arrest	64	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	65	Any	-183	-1	N/A	1	N/A

*The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

N/A: Not Applicable

NaN: Not a Number

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Query start date
1 Jan 2018

Cohort entry date[2]
First dispensing of NME
Day 0

Query end date
End of data

Enrollment requirement
Drug and Medical Coverage

Pre-index: [-183,-1]

Allowed coverage gap

45 days

Exposure Episode 1
(NME days supply)

Exposure Episode 2 or more
(NME days supply)

Episode length

None (0 days)

Episode gap

None (0 days)

Episode extension

Baseline Characteristics[3]

I

II: (-183, -1)

Follow-Up

(0, censoring[4])

[1] Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.
[2] 26 scenarios defined on initiation of NMEs approved in 2019 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.
[3] Baseline characteristics:
    Window I: Age, Sex, Race, Hispanic Ethnicity, Year
    Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking
[4] Censoring: earliest of death, disenrollment, data partner data end date, query end date

cder_mpl1r_wp251